;Category;Title;Auteur;Lien;Number of pages;Content;Date
0;biologie;Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19);Dae-Gyun Ahn and al;https://www.groupedeveillecovid.fr/blog/2020/04/21/current-status-of-epidemiology-diagnosis-therapeutics-and-vaccines-for-novel-coronavirus-disease-2019-covid-19/;12;"324Ahn et al.J. Microbiol. Biotechnol.'˛˛ ˜,˜ ,,˘ˇ&/˛˛˙  ˙!˘7˘ˇ˘ˇ-+H/>˚""$))˚Hˇˇ.//˛˛˙!˛˙2/2˛'˙˜˚""˚˜˙˛˜˙˝˜$˛+,*+.--2˚!˙˙˙4˘ˇ0#˙˛˜˚!˙#˙˚$4'˛˛˙ ""˚%-˚#,-78/˛˜=˙%3I?84&4?˛˛˙8I,.7ˇˇ/')#˙%˚ ,!,˝˙< A""˚˙  ,˚˙#˙ ˙,!˙˜˘ˇ˘ˇA,/˛˛˙#˙˚ ,=˝˙,%˚,3I?84,/,?˛˛˙I,.7ˇˇA!˙ ""O/˛˛˙  ˙!ˇ6>˘ˇ˘ˇ-&8P""""˙#˙/˙%˜˜"" (AA<<<A""˛˜""˙#/˛˛˙  ˙!˘7:˙˘ˇ˘ˇ7ˇ!>/)#$""#/'#)#˙%˚˝˜˜"" (AA<<<A˜#$B!/˛˛˙  ˘7˘ˇ˘ˇ˚!˜:˙  ˘ˇ'˛˛,˙˚˛%˜%,7˘>˙˚P""""˙#/'#)#˙%˚˜˜"" (AA<<<˙˚˜O""˙#˙/˛˛˙  ˘˘ˇ˘ˇ76˝""#˜)4˚˙˚$M4˙'˙#˜/')#%˚˝˜˜"" (AA<<<!˙˜O#A,""#)'˙˚$,!˙'˙#""/˛˛˙  ˙!˘7˘ˇ˘ˇ7.$:˛""#˜%/#)%˜""(AA<<<˙O˝˘/˛˛˙  ˘˘ˇ˘ˇ7*2˙8H23H>33˚˚#˙,-˜˙!˙'˙%=%˛#˙#""˙˚˛˙#˜˙˛˜%˚#˜$7&&7,&ˇˇ&7+22˘ˇ6=˙""˚˝!$˙=:˚""˙-,767-ˆ>˛˙#=2!#˙8˘ˇˇ.4%%˙˚#%#˙O)!˛!˜˙)!˝!˛˛8!8>(˝""#%˜˙%˛˜˛˙#˚˙˛˙""˜#""""˘&˘*,˘&6.77H˚1343˘- ˝˛$!!˚˛˙##˛˚)˜˙""˚'˜˚#˜˜<˜:˛˙˚#˙,- #˙9'%˙˛˜#˛.6.6,7&=2>H/!$,!˙""˙!˙˙˙˝˜'˚!!#""""&,7+&ˇH>/4HH>˘ˇ7>1?˚ )$!$,!˜˙! ˜˚˜""˚  %˙˛˜,#""""&-&223˙ˆE˘ˇ˘ˇ˝˙˛!˙""˙!˙˜˝˙˜˛˙˜˚$˝˙ˇ˘ˇ&˘= ˙3=32˙3˘/!˙""˙!˙˜2/˛%˙˛˝˙!˜˙!  ""˚˚&""""˘ˇ7,˘&6H=3>3˘ˇˇˆ˙˙˚˜˙˜%/˛ ˙˜˜˛#!""˙ ˙'˛˙!˚˛˚.+67,.+&.4%%$2˘ˇ7˚'˚˝˜˚˙ !˝'˙6ˇˇˇˇˇ6&*ˇ˘ˇ˙˝˜)˚˙1  ˛˜˙!<˜˙<""˚)#˙)˜˛˘-ˇ,˘&+˙˙˚˝/##˝H˚!˙##˛/=&&˘! ˙˚˙˛˙""%˚˛'˚˘˘&0.˘ˇ,.˘&-%˝$˚˛H˙˚˙1ˆ˙˙˚˙˚1˜2˘ˇˇ*˛'˚+˙˝""#˜ ˙'˙˚˛˜˚˙ ""˚˜˚$ !˚˙˛˚'˚˚˙˛˙""˜˚˛˙#˚˜˚˛)-&77,-&&6&7=˚˙ H˙""˜ ˙ ˙˚'˙ ˚%%˙#˛""!˝˛ ˙  ˙˚""8˝7++&,7+&&4˙#ˆ˙#%P2˚I&&˘˝""˙""˜! ˙;˚˙˛˙""˜˚˙˜˛'˚=ˆ0?˛-,.˘ˇ>?˙'22˙>/˘ˇˇ6/˜˙'˙˚˙˘ %#˚˙˛˙""%˜˙2/˛˚'˚.*ˇ,.*.?2>224˙11˙˚ 4>##˙˘ˇ4˙""˜!$#""˙""˜ #˚%˜˙˙˝˙˚˛'˚ ,0>˛*,˘*.˘H˚˙˝""2#˜9˙˚˚#˙˚ˆ&&*# %˛˙#˚˚˙˛˙""%˛'˚ I3.6!˘66-64>#˙</EEH˘˝˛'HJ ""1˙""˚˜˙ ˙ I,˛˙˜$#˙!˛˜˜˜˚˙˛˙""!˙˜˙˚˝!˙˝#,˙ ˜˙˚ ""˚˚˙˛˙""˜˚,!˙ ˜˚9$-˘ˇ˘,-˘ˆH%˙'˚ ˝˜˝)˚$˜%#$'˛˘˙)˙**66,**";21 avril 2020 
0;biologie;Into the Eye of the Cytokine Storm;Jennifer R. Tisoncik et al;https://www.groupedeveillecovid.fr/blog/2020/04/10/into-the-eye-of-the-cytokine-storm/;17;ThomasR.Martin,M.D.,isEmeritusProfessorofMedicineandaformermemberoftheDivi-sionofPulmonaryandCriticalCareMedicineattheUniversityofWashington.HereceivedtheM.D.degreefromtheUniversityofPenn-sylvaniaandthencompletedtrainingininter-nalmedicineandpulmonaryandcriticalcaremedicineattheUniversityofWashingtoninSe-attle.Hehashadalongstandinginterestinmechanismsofhostdefense,in˜ammation,andinjuryinthelungsandhasservedastheDirec-toroftheUniversityofWashingtonSpecializedCenterinAcuteLungInjuryResearch.InJune2011,hebecametheDirectorofClinicalSciencesintheRespiratoryFranchiseatNovartisPharmaceuticalsinEastHanover,NJ.MichaelG.KatzehasaPh.D.inmicrobiologyfromHahnemannUniversity,PA.Heiscur-rentlyaProfessorofMicrobiologyattheUni-versityofWashington,whereheservesasAs-sociateDirectorattheWashingtonNationalPrimateResearchCenterandisHeadoftheCenter™sDivisionofFunctionalGenomicsandInfectiousDisease,Co-DirectorofthePaci˚cNorthwestRegionalCenterofExcel-lence,DirectoroftheCenterforSystemsandTranslationalResearchonInfectiousDisease(STRIDE),ProgramDirectorofanNIAIDcontracttousesystemsbiol-ogyapproachestodevelopcomputationalmodelsofthehostresponsetorespiratoryvirusinfection,andProgramDirectorofaNIDAP30CenterfocusedonusinggenomicandproteomictechnologiestostudyhepatitisCvirus(HCV)andHCV-associatedliverdisease.Hisresearchinterestsarefocusedonapplyinggenomicandproteomictechnologiestothestudyofvirus-hostinteractionsandtheinnateimmuneresponse.Tisonciketal.32mmbr.asm.orgMicrobiologyandMolecularBiologyReviews;10 avril 2020 
0;biologie;Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection;Bermejo-Martin and al;https://www.groupedeveillecovid.fr/blog/2020/04/10/lymphopenic-community-acquired-pneumonia-as-signature-of-severe-covid-19-infection/;2;"2 Letter to the Editor / Journal of Infection xxx (xxxx) xxx ARTICLE IN PRESS JID: YJINF [m5G; March 12, 2020;11:30 ] Ethics committee approval Not applicable References 1. Tang Julian W, Tambyah Paul A, Hui David SC. Emergence of a novel coron- avirus causing respiratory illness from Wuhan, China. J Infect 2020; 80 (3):350–71. doi: 10.1016/j.jinf.2020.01.014 . 2. Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020; 0 (0). doi: 10.1016/S0140-6736(20)30183-5 . 3. Xiaobo Yang , Yuan Yu , Jiqian Xu , Huaqing Shu , Jia’an Xia , Hong Liu , et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet 2020 . 4. Dawei Wang, Bo Hu, Chang Hu, Fangfang Zhu, Xing Liu, Jing Zhang, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020. doi: 10.1001/jama.2020.1585 . 5. Cameron Mark J, Longsi Ran, Luoling Xu, Ali Danesh, Bermejo-Martin Jesus F, Cameron Cheryl M. et al. interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol 2007; 81 (16):8692–706. doi: 10.1128/ JVI.00527-07 . 6. Nelson Lee, David Hui, Alan Wu, Paul Chan, Peter Cameron, Joynt Gavin M. et al. a major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348 (20):1986–94. doi: 10.1056/NEJMoa030685 . 7. Raúl Méndez, Rosario Menéndez, Isabel Amara-Elori, Laura Feced, Alba Piró, Paula Ramírez, et al. Lymphopenic community-acquired pneumonia is associ- ated with a dysregulated immune response and increased severity and mortal- ity. J Infect 2019; 78 (6):423–31. doi: 10.1016/j.jinf.2019.04.006 . 8. Nanshan Chen, Min Zhou, Xuan Dong, Jieming Qu, Fengyun Gong, Yang Han, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020. doi: 10.1016/S0140- 6736(20)30211- 7 . 9. Bermejo-Martin Jesus F, Marta Martín-Fernandez, Cristina López-Mestanza, Pa- tricia Duque, Raquel Almansa. Shared features of endothelial dysfunction be- tween sepsis and its preceding risk factors (Aging and chronic disease). J Clin Med 2018; 7 (11). doi: 10.3390/jcm7110400 . 10. Rosario Menéndez, Raúl Méndez, Raquel Almansa, Alicia Ortega, Ricardo Alonso, Marta Suescun, et al. Simultaneous depression of immunological synapse and endothelial injury is associated with organ dysfunction in community-acquired pneumonia. J Clin Med 2019; 8 (9). doi: 10.3390/jcm8091404 . Jesús F Bermejo-Martin , Raquel Almansa Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007 Salamanca, Spain Hospital Universitario Río Hortega de Valladolid. Calle Dulzaina, 2, 47012 Valladolid, Spain Centro de Investigación Biomedica En Red-Enfermedades Respiratorias, Instituto de Salud Carlos III, Av . de Monforte de Lemos, 5, 28029, Madrid, Spain Rosario Menéndez Centro de Investigación Biomedica En Red-Enfermedades Respiratorias, Instituto de Salud Carlos III, Av . de Monforte de Lemos, 5, 28029, Madrid, Spain Pulmonology Service, University and Polytechnic Hospital La Fe, Avinguda de Fernando Abril Martorell, 106, 46026 València, Spain Raúl Mendez Pulmonology Service, University and Polytechnic Hospital La Fe, Avinguda de Fernando Abril Martorell, 106, 46026 València, Spain David J Kelvin Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada Division of Immunity Shantou University Medical College, 22 Xinling Rd, Jinping, Shantou, Guangdong, China Antoni Torres Centro de Investigación Biomedica En Red-Enfermedades Respiratorias, Instituto de Salud Carlos III, Av . de Monforte de Lemos, 5, 28029, Madrid, Spain Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona - Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB) - SGR 911- Carrer de Villarroel, 170, 08036 Barcelona, Spain Corresponding author: Jesús F Bermejo-Martin, Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca (IBSAL), Paseo de San Vicente, 58-182, 37007 Salamanca, Spain. E-mail address: jfbermejo@saludcastillayleon.es (J.F. Bermejo-Martin) Accepted 28 February 2020 ";10 avril 2020 
0;biologie;Functional exhaustion of antiviral lymphocytes in COVID-19 patients;Zheng et al;https://www.groupedeveillecovid.fr/blog/2020/04/10/functional-exhaustion-of-antiviral-lymphocytes-in-covid-19-patients/;3;ADDITIONALINFORMATIONTheonlineversionofthisarticle(https://doi.org/10.1038/s41423-020-0402-2)containssupplementarymaterial.Competinginterests:Theauthorsdeclarenocompetinginterests.REFERENCES1.Zhu,N.etal.AnovelcoronavirusfrompatientswithpneumoniainChina,2019.N.Engl.J.Med.382,727Œ733(2020).2.Zhang,C.etal.NKG2AisaNKcellexhaustioncheckpointforHCVpersistence.Nat.Commun.10,1507(2019).3.Zhou,P.etal.Apneumoniaoutbreakassociatedwithanewcoronavirusofprobablebatorigin.Nature579,270Œ273(2020).4.Chen,N.etal.Epidemiologicalandclinicalcharacteristicsof99casesof2019novelcoronaviruspneumoniainWuhan,China:adescriptivestudy.Lancet395,507Œ513(2020).5.Li,F.etal.BlockingthenaturalkillercellinhibitoryreceptorNKG2AincreasesactivityofhumannaturalkillercellsandclearshepatitisBvirusinfectioninmice.Gastroenterology144,392Œ401(2013).6.Andre,P.etal.Anti-NKG2AmAbisacheckpointinhibitorthatpromotesanti-tumorimmunitybyunleashingbothTandNKcells.Cell175,1731Œ1743(2018).7.Barathan,M.etal.ViralpersistenceandchronicityinhepatitisCvirusinfection:roleofT-cellapoptosis,senescenceandexhaustion.Cells7,165(2018).8.Barber,D.L.etal.RestoringfunctioninexhaustedCD8Tcellsduringchronicviralinfection.Nature439,682Œ687(2006).9.Zhang,Q.etal.BlockadeofthecheckpointreceptorTIGITpreventsNKcellexhaustionandelicitspotentanti-tumorimmunity.Nat.Immunol.19,723Œ732(2018).10.Haanen,J.B.&Cerundolo,V.NKG2A,anewkidontheimmunecheckpointblock.Cell175,1720Œ1722(2018).OpenAccessThisarticleislicensedunderaCreativeCommonsAttribution4.0InternationalLicense,whichpermitsuse,sharing,adaptation,distributionandreproductioninanymediumorformat,aslongasyougiveappropriatecredittotheoriginalauthor(s)andthesource,providealinktotheCreativeCommonslicense,andindicateifchangesweremade.Theimagesorotherthirdpartymaterialinthisarticleareincludedinthearticle™sCreativeCommonslicense,unlessindicatedotherwiseinacreditlinetothematerial.Ifmaterialisnotincludedinthearticle™sCreativeCommonslicenseandyourintendeduseisnotpermittedbystatutoryregulationorexceedsthepermitteduse,youwillneedtoobtainpermissiondirectlyfromthecopyrightholder.Toviewacopyofthislicense,visithttp://creativecommons.org/licenses/by/4.0/.©TheAuthor(s)2020FunctionalexhaustionofantivirallymphocytesinCOVID-19patientsMZhengetal.3Cellular&MolecularImmunology_#####################_;10 avril 2020 
0;biologie;Hematologic parameters in patients with COVID-19 infection;Fan et al;https://www.groupedeveillecovid.fr/blog/2020/04/10/hematologic-parameters-in-patients-with-covid-19-infection/;8;"  <100 100-150 >150 0 (0.0) 15 (25.9) 43 (74.1) 0 (0.0) 3 (33.3) 6 (66.7) 0 (0.0) 18 (26.9) 49 (73.1) Peak ANC (x109/L) 3.5  (2.6  4.4)  11.6  (9.3  13.8)  <0.001 3.8  (2.7  5.0)  Peak ANC (x109/L) <0.5 0.5-1.0 >1   0 (0.0) 0 (0.0) 58 (100.0)   0 (0.0) 0 (0.0) 9 (100.0)    0 (0.0) 0 (0.0) 67 (100.0) Peak LDH (U/L)3 451  (367  629)  1081  (752  1460)  <0.001 470  (386  684)  Peak LDH (U/L)3 <=550 >550   35 (66.0) 18 (34.0)   0 (0.0) 9 (100.0) <0.001   35 (56.5) 27 (43.6) a) Abbreviations used in table: Hemoglobin (Hb); white blood cell (WBC); absolute lymphocyte count (ALC); absolute monocyte count (AMC); absolute neutrophil count (ANC); lactate dehydrogenase (LDH) b)  c) For continuous variables, median and IQR (Interquartile range) have been presented due to the non-normality of the data. Correspondingly, Mann-Whitney tests were used to assess if differences between ICU and non-ICU groups were statistically significant. d) For categorical variables, -ICU groups due to the small expected cell counts when blood profiles were categorised.  e) Nadir and peak of the hematologic parameters are obtained by following up with the patients from the point of admission to their latest available blood test value as at 28 February 2020. 1 In total, 69 patients were admitted to NCID. 67 patients had at least one complete blood count (CBC) performed during inpatient stay; 65 patients had CBC performed on day of admission. 2 There were 30 patients who had LDH (reference range 270-550 U/L) performed at admission. 3 There were 62 patients who had LDH (reference range 270-550 U/L) performed during inpatient stay. ";10 avril 2020 
0;biologie;Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia;Fan Wang et al;https://www.groupedeveillecovid.fr/blog/2020/04/10/characteristics-of-peripheral-lymphocyte-subset-alteration-in-covid-19-pneumonia/;20;"Accepted Manuscript   19. Cannon MJ, Stott EJ, Taylor G, Askonas BA. Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. Immunology 1987; 62:133-8. 20. Munoz JL, McCarthy CA, Clark ME, Hall CB. Respiratory syncytial virus infection in C57BL/6 mice: clearance of virus from the lungs with virus-specific cytotoxic T cells. J Virol 1991; 65:4494-7. 21. Schmidt ME, Varga SM. The CD8 T Cell Response to Respiratory Virus Infections. Front Immunol 2018; 9:678.  Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiaa150/5813618 by Universite de Strasbourg France user on 08 April 2020";10 avril 2020 
0;biologie;Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy;Angela Ceribelli and al;https://www.groupedeveillecovid.fr/blog/2020/04/09/recommendations-for-coronavirus-infection-in-rheumatic-diseases-treated-with-biologic-therapy/;4;"MinistryofHealthmustbeappliedtoeveryone,inparticularbyrheumaticpatientsundergoingimmunosuppressivetherapies.Patientsarethereforestronglyencouragedtoavoidsocialcontactandmaintainisolation.ChronictherapieswillbeguaranteedforrheumaticpatientsalsointheseweeksofCoViD-19outbreakinwhichtheroutineout-patientclinicsareclosed,astheNationalHealthSystemhasauthorizedpeopletomoveforveryspecicreasonssuchashealthissuesandtheneedforbiologictherapieswhichareavailableonlyinsomehospitals.AstocilizumabandbaricitinibmaystarttobeusedtotreatCoViD-19severepneumoniacases,theiravailabilitymustbeguaranteedforthetreatmentofrheumaticpatientswhoareusingthesecompounds.Ifarheumaticpatientdevelopssymptomsofanyinfection,itisimportanttofollowtheguidelinessuggestedbytherheumatologycommunityandimmunosuppressivetherapyshouldbepausedforthedurationoftheinfection.Theoneexceptionishydroxychloroquine,whichmayhavetherapeuticpotentialforCoViD-19infectionandshouldthereforenotbestoppedinpatientswhohavebeentakingitforarheumaticdisease.Asmentionedabove,itispossiblethatIL-6blockadeandtheuseofJAKinhibitorscouldhavebenecialeectsonseverelungdisease,butwedon'tyetknowenoughtorecommendcontinuingtheseagents,sincetheycouldadverselyaectviralclearance.MuchmorestudyofthekineticsofSARS-CoV2inthelung,andtherelationoftheimmunere-sponsetotheonsetofCRS,isthereforeneededtoclarifyre-commendationsforpatientsontheseagents.TheepidemiologicalscenarioisrapidlychangingdailyandwestillhavenoknowledgeabouttheinfectionrateandcourseofCoViD-19inrheumatologicconditions.Therefore,anationalorinternationalreg-istryisstronglyencouragedtounderstandtheimpactoftheinfectiononspecicrheumaticdiseasesortreatmentsandtheriskfactorsforpooroutcomes.TheItalianSocietyofRheumatologyhasestablishedsucharegistryinMarch2020anddataarebeingcollected.Althoughourobservationshavenoepidemiologicalgrounds,wearequitesur-prisedbythelimitednumberofrheumaticpatientscontactingusbe-causeofaCoViD-19infection.Furthermore,aninternationalregistrysupportedbyAmericaCollegeofRheumatology,EuropeanLeagueAgainstRheumatismandotherrheumatologicsocietiesworldwideisbeinglaunched.Inthemeantime,itisimportantthatpatientsarereassuredandconsultationsmadeavailableusingmediathatexcludeaperson-to-personrelationshiptominimizetheriskofinfection.References[1]R.Lu,X.Zhao,J.Li,P.Niu,B.Yang,H.Wu,etal.,Genomiccharacterisationandepidemiologyof2019novelcoronavirus:implicationsforvirusoriginsandreceptorbinding,Lancet(London,England)395(10224)(2020)565Œ574Epub2020/01/30.[2]X.Xu,C.Yu,J.Qu,L.Zhang,S.Jiang,D.Huang,etal.,Imagingandclinicalfeaturesofpatientswith2019novelcoronavirusSARS-CoV-2,Eur.J.Nucl.Med.Mol.Imag.(2020),https://doi.org/10.1007/s00259-020-4735-9.[3]Q.Han,Q.Lin,S.Jin,L.You,Recentinsightsinto2019-nCoV:abriefbutcom-prehensivereview,J.Infect.S0163Œ4453(20)(2020)30087-6.[4]Z.Wu,J.M.McGoogan,Characteristicsofandimportantlessonsfromthecor-onavirusdisease2019(COVID-19)outbreakinChina:summaryofareportof72314casesfromtheChinesecenterfordiseasecontrolandprevention,J.Am.Med.Assoc.(2020),https://doi.org/10.1001/jama.2020.648.[5]H.A.Rothan,S.N.Byrareddy,Theepidemiologyandpathogenesisofcoronavirusdisease(COVID-19)outbreak,J.Autoimmun.(2020)102433.[6]J.Chen,K.Subbarao,TheimmunobiologyofSARS*,Annu.Rev.Immunol.25(2007)443Œ472.[7]Y.Zheng,J.Shang,Y.Yang,C.Liu,Y.Wan,Q.Geng,etal.,Lysosomalproteasesareadeterminantofcoronavirustropism,J.Virol.92(24)(2018)e01504Œe01518.[8]J.Gao,Z.Tian,YangX.Breakthrough,ChloroquinephosphatehasshownapparentecacyintreatmentofCOVID-19associatedpneumoniainclinicalstudies,BiosciTrends(2020),https://doi.org/10.5582/bst.2020.01047.[9]X.Yao,F.Ye,M.Zhang,C.Cui,B.Huang,P.Niu,etal.,Invitroantiviralactivityandprojectionofoptimizeddosingdesignofhydroxychloroquineforthetreatmentofsevereacuterespiratorysyndromecoronavirus2(SARS-CoV-2),Clin.Infect.Dis.(2020)ciaa237.[10]R.Channappanavar,S.Perlman,Pathogenichumancoronavirusinfections:causesandconsequencesofcytokinestormandimmunopathology,Semin.Immunopathol.39(5)(2017)529Œ539Epub2017/05/02.[11]T.Yoshikawa,T.Hill,K.Li,C.J.Peters,C.-T.K.Tseng,Severeacuterespiratorysyndrome(SARS)coronavirus-inducedlungepithelialcytokinesexacerbateSARSpathogenesisbymodulatingintrinsicfunctionsofmonocyte-derivedmacrophagesanddendriticcells,J.Virol.83(7)(2009)3039Œ3048Epub2008/11/12.[12]R.Q.Le,L.Li,W.Yuan,S.S.Shord,L.Nie,B.A.Habtemariam,etal.,FDAapprovalsummary:tocilizumabfortreatmentofchimericantigenreceptorTcell-inducedsevereorlife-threateningcytokinereleasesyndrome,Oncol.23(8)(2018)943Œ947Epub2018/04/05.[13]M.XuXh,T.Li,W.Sun,D.Wang,B.Fu,Y.Zhou,X.Zheng,Y.Yang,X.Li,X.Zhang,A.Pan,H.Wei,EectiveTreatmentofSevereCOVID-19PatientswithTocilizumab,ChinaXiv,2020;20200300026.[14]Y.Yang,F.Peng,R.Wang,K.Guan,T.Jiang,G.Xu,etal.,Thedeadlycor-onaviruses:the2003SARSpandemicandthe2020novelcoronavirusepidemicinChina,J.Autoimmun.(2020)102434.[15]P.Richardson,I.Grin,C.Tucker,D.Smith,O.Oechsle,A.Phelan,etal.,Baricitinibaspotentialtreatmentfor2019-nCoVacuterespiratorydisease,Lancet(London,England)395(10223)(2020)e30Œe31Epub2020/02/04.[16]R.Channappanavar,A.R.Fehr,R.Vijay,M.Mack,J.Zhao,D.K.Meyerholz,etal.,DysregulatedtypeIinterferonandinammatorymonocyte-macrophageresponsescauselethalpneumoniainSARS-CoV-infectedmice,CellHostMicrobe19(2)(2016)181Œ193.[17]J.Zheng,S.Perlman,ImmuneresponsesininuenzaAvirusandhumancor-onavirusinfections:anongoingbattlebetweenthevirusandhost,Curr.Opin.Virol.28(2018)43Œ52.[18]M.J.Cameron,L.Ran,L.Xu,A.Danesh,J.F.Bermejo-Martin,C.M.Cameron,etal.,Interferon-mediatedimmunopathologicaleventsareassociatedwithatypicalinnateandadaptiveimmuneresponsesinpatientswithsevereacuterespiratorysyndrome,J.Virol.81(16)(2007)8692Œ8706.[19]C.A.Vaine,R.J.Soberman,TheCD200-CD200R1inhibitorysignalingpathway:immuneregulationandhost-pathogeninteractions,Adv.Immunol.121(2014)191Œ211.[20]G.Karnam,T.P.Rygiel,M.Raaben,G.C.M.Grinwis,F.E.Coenjaerts,M.E.Ressing,etal.,CD200receptorcontrolssex-specicTLR7responsestoviralinfection,e1002710-e,PLoSPathog.8(5)(2012)Epub2012/05/17.[21]K.Hayakawa,L.-D.D.Pham,J.H.Seo,N.Miyamoto,T.Maki,Y.Terasaki,etal.,CD200restrainsmacrophageattackonoligodendrocyteprecursorsviatoll-likere-ceptor4downregulation,J.Cerebr.BloodFlowMetabol.36(4)(2016)781Œ793Epub2015/09/30.[22]R.E.Seeds,S.Mukhopadhyay,I.M.Jones,S.Gordon,J.L.Miller,TheroleofmyeloidreceptorsonmurineplasmacytoiddendriticcellsininductionoftypeIinterferon,Int.Immunopharm.11(7)(2011)794Œ801Epub2011/01/31.[23]M.Jani,A.Barton,K.Hyrich,Predictionofinfectionriskinrheumatoidarthritispatientstreatedwithbiologics:areweanyclosertoriskstratication?Curr.Opin.Rheumatol.31(3)(2019)285Œ292.A.Ceribelli,etal.";9 avril 2020 
0;biologie;Interleukin-6 Use in COVID-19 Pneumonia Related Macrophage Activation Syndrome;Kassem Sharif, Charlie Bridgewood;https://www.groupedeveillecovid.fr/blog/2020/04/07/interleukin-6-use-in-covid-19-pneumonia-related-macrophage-activation-syndrome/;26;Table 2.   Therapy Considerations Based on COVID-19 MAS-like Picture    Primary HLH Features Secondary HLH Pattern Immune State Viral induced immunodeficiency   Normal Immunity Viraemia Persistent Viral Shedding more likely   Initial Viraemia  With clonally expanded T-cells that appear-5-7 days post infection. Progression Rate Unclear  Unclear Resolution Rate Slower resolution May quickly improve on viral load elimination?  CRP Elevated ++ Elevated+++ Ferritin Elevated++ Elevated ++  (possible rapid rise) Anti-Viral Therapy Consider Anti-viral therapy ? Corticosteroids Caution (increase viraemia) consider if viraemia cleared? Anti-IL-6R and biologics Less likely to benefit  (may cause harm More likely benefit Frequency Very Common Less Common            View publication statsView publication stats;7 avril 2020 
0;biologie;Updated approaches against SARS -CoV – 2;Haiou Li and al;https://www.groupedeveillecovid.fr/blog/2020/04/06/updated-approaches-against-sars-cov-2/;25; on April 5, 2020 at Universite de Strasbourghttp://aac.asm.org/Downloaded from ;6 avril 2020 
0;biologie;Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection.;Zhang B et al;https://www.groupedeveillecovid.fr/blog/2020/04/05/treatment-with-convalescent-plasma-for-critically-ill-patients-with-sars-cov-2-infection/;12;;5 avril 2020 
0;bloc-operatoire;Early experience in an international group of hand surgery;Pr Philippe LIVERNEAUX et al;https://www.groupedeveillecovid.fr/blog/2020/04/10/early-experience-in-an-international-group-of-hand-surgery/;8;"Given the infection of a hand surgeon in Wuhan [2] and ourstudy’s ﬁndings, an international consensus is needed on themeasures to be taken by hand surgeons during a viral pandemic.Human and animal rightsThe authors declare that the work described has not involvedexperimentation on humans or animals.Informed consent and patient detailsThe authors declare that the work described does not involve patients orvolunteers.Disclosure of interestThe authors declare that they have no competing interest.FundingThis work did not receive any grant from funding agencies in the public,commercial, or not-for-proﬁt sectors.Author contributionsAll authors attest that they meet the current International Committee ofMedical Journal Editors (ICMJE) criteria for Authorship.References[1] Liang ZC, Wang W, Murphy D, Hui JHP. Novel Coronavirus and orthopaedicsurgery: early experiences from Singapore. J Bone Joint Surg Am 2020;00.http://dx.doi.org/10.2106/JBJS.20.00236 [e1(1-5)d], (in press).[2] Wang K, Wang Q, Chen Z. A case of hand surgeon infection of COVID-19 due toexposure to treating a suspect patient. Chinese J Hand Surg 2020;36. http://dx.doi.org/10.3760/cma.j.cn311653-20200304-00096 (2020-03-08), Avail-able from URL: http://rs.yiigle.com/yufabiao/1184341.htm.[3] Tang JB, Giddins G. Why and how to report surgeons’ levels of expertise. J HandSurg Eur 2016;41:365–6.[4] Centers for Disease Control and Prevention. Coronavirus Disease 2019(COVID-19) Situation Summary. Available from URL: https://www.cdc.gov/coronavirus/2019-ncov/summary.html. (accessed March 2020).[5] Ti LK, Ang LS, Foong TW, Ng BSW. What we do when a COVID-19 patient needsan operation: operating room preparation and guidance. Can J Anaesth 2020.http://dx.doi.org/10.1007/s12630-020-01617-4 [Epub ahead of print] PubMedPMID: 32144591.[6] Wong J, Goh QY, Tan Z, Lie SA, Tay YC, Ng SY, et al. Preparing for a COVID-19pandemic: a review of operating room outbreak response measures in a largetertiary hospital in Singapore. Can J Anaesth 2020. http://dx.doi.org/10.1007/s12630-020-01620-9 [Epub ahead of print] Review. PubMed PMID: 32162212.[7] World Health Organisation. Announces COVID-19 outbreak a pandemic.Available from URL: http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic.[8] World Health Organisation 2020c. Statement on the second meeting of theInternational Health Regulations (2005) Emergency Committee regarding theoutbreak of novel Coronavirus (2019-nCoV). Available from URL: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov). Accessed 30 January 2020.[9] World Health Organization. Coronavirus disease 2019 (COVID 19) SituationReport- 24 March 2020. Available from URL: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200324-sitrep-64-covid-19.pdf?sfvrsn=703b2c40_2. (accessed March 2020).[10] Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl JMed 2020. http://dx.doi.org/10.1056/NEJMp2003539 [Epub ahead of print]PubMed PMID: 32160451.[11] World Health Organisation. Infection prevention and control during healthcare when COVID-19 is suspected. Interim Guidance – 19 March 2020. Avail-able from URL: https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125.F. Ducournau et al. / Hand Surgery and Rehabilitation xxx (2020) xxx–xxx8G ModelHANSUR-1121; No. of Pages 8Please cite this article in press as: Ducournau F, et al. COVID-19: Initial experience of an international group of hand surgeons. Hand SurgRehab (2020), https://doi.org/10.1016/j.hansur.2020.04.001";10 avril 2020 
0;bloc-operatoire;Surgery in COVID-19 patients: operational directives;Federico Coccolini and al;https://www.groupedeveillecovid.fr/blog/2020/04/10/surgery-in-covid-19-patients-operational-directives/;7;"9.DoremalenND,BushmakerT,MorrisDH,HolbrookMG,GambleA,WilliamsonBN,etal.AerosolandsurfacestabilityofSARS-CoV-2ascomparedwithSARS-CoV-1.NewEnglJMed.2020;[Epubaheadofprint].Publisher™sNoteSpringerNatureremainsneutralwithregardtojurisdictionalclaimsinpublishedmapsandinstitutionalaffiliations.Coccolinietal.WorldJournalofEmergencySurgery          (2020) 15:25 Page7of7";10 avril 2020 
0;bloc-operatoire;Perioperative COVID-19 Defense: An Evidence-Based Approach for Optimization of Infection Control and Operating Room Management;Franklin Dexter et al;https://www.groupedeveillecovid.fr/blog/2020/04/01/perioperative-covid-19-defense-an-evidence-based-approach-for-optimization-of-infection-control-and-operating-room-management/;21;" 21 35. Dexter F, Bayman EO, Epstein RH. Statistical modeling of average and variability of time to extubation for meta-analysis comparing desflurane to sevoflurane. Anesth Analg 2010;110:570-580. DOI: https://doi.org/10.1213/ane.0b013e3181b5dcb7 36. Agoliati A, Dexter F, Lok J, Masursky D, Sarwar MF, Stuart SB, Bayman EO, Epstein RH. Meta-analysis of average and variability of time to extubation comparing isoflurane with desflurane or isoflurane with sevoflurane. Anesth Analg 2010;110:1433-1439. DOI: https://doi.org/10.1213/ane.0b013e3181d58052 37. Tiwari V, Dexter F, Rothman BS, Ehrenfeld JM, Epstein RH. Explanation for the near constant mean time remaining in surgical cases exceeding their estimated duration, necessary for appropriate display on electronic white boards. Anesth Analg 2013;117:487-493. DOI: https://doi.org/10.1213/ane.0b013e3182977 ";1 avril 2020 
0;bloc-operatoire;Preparing for a COVID-19 pandemic: a review of operating room outbreak response measures in a large tertiary hospital in Singapore;Jolin Wong and Al;https://www.groupedeveillecovid.fr/blog/2020/03/26/preparing-for-a-covid-19-pandemic-a-review-of-operating-room-outbreak-response-measures-in-a-large-tertiary-hospital-in-singapore/;14;"54.ChangD,XuH,RebazaA,SharmaL,DelaCruzCS.Protectinghealth-careworkersfromsubclinicalcoronavirusinfection.LancetRespirMed2020;DOI:https://doi.org/10.1016/S2213-2600(20)30066-7.55.LiJP,LamDS,ChenY,TingDS.Novelcoronavirusdisease2019(COVID-19):theimportanceofrecognisingpossibleearlyocularmanifestationandusingprotectiveeyewear.BrJOphthalmol2020;104:297-8.56.CentersforDiseaseControlandPrevention.Recommendedguidanceforextendeduseandlimitedreuseofn95˚lteringfacepiecerespiratorsinhealthcaresettings-NIOSHWorkplaceSafetyandHealthTopic.AvailablefromURL:https://www.cdc.gov/niosh/topics/hcwcontrols/recommendedguidanceextuse.html(accessedMarch2020).57.RadonovichLJJr,ChengJ,ShenalBV,HodgsonM,BenderBS.Respiratortoleranceinhealthcareworkers.JAMA2009;301:36-8.58.RebmannT,CarricoR,WangJ.Physiologicandothereffectsandcompliancewithlong-termrespiratoruseamongmedicalintensivecareunitnurses.AmJInfectControl2013;41:1218-23.59.FisherEM,ShafferRE.Considerationsforrecommendingextendeduseandlimitedreuseof˚lteringfacepiecerespiratorsinhealthcaresettings.JOccupEnvironHyg2014;11:D115-28.60.RebmannT,AlexanderS,BartleyJ,etal.APICpositionpaper:extendingtheuseand/orreusingrespiratoryprotectioninhealthcaresettingsduringdisasters.Washington,DC:APIC;2009.61.PhanLT,MaitaD,MortizDC,etal.Personalprotectiveequipmentdof˚ngpracticesofhealthcareworkers.JOccupEnvironHyg2019;16:575-81.62.JohnA,TomasME,CadnumJL,etal.Arehealthcarepersonneltrainedincorrectuseofpersonalprotectiveequipment?AmJInfectControl2016;44:840-2.63.BoardonHealthSciencesPolicy.InstituteofMedicine.De˚ningPAPRsandCurrentStandards.DC:NationalAcademiesPress(US);2015.64.RobergeRJ.EvaluationoftherationaleforconcurrentuseofN95˚lteringfacepiecerespiratorswithloose-˚ttingpoweredair-purifyingrespiratorsduringaerosol-generatingmedicalprocedures.AmJInfectControl2008;36:135-41.65.CoatesMJ,JundiAS,JamesMR.Chemicalprotectiveclothing;astudyintotheabilityofstafftoperformlifesavingprocedures.JAccidEmergMed2000;17:115-8.66.LairdIS,GoldsmithR,PackRJ,VitalisA.Theeffectonheartrateandfacialskintemperatureofwearingrespiratoryprotectionatwork.AnnOccupHyg2002;46:143-8.67.NicolleL.SARSsafetyandscience/Lascienceetlesmesuresdese´curite´contreleSRAS.CanJAnesth2003;DOI:https://doi.org/10.1007/BF03018360.68.KampfG,TodtD,PfaenderS,SteinmannE.Persistenceofcoronavirusesoninanimatesurfacesandtheirinactivationwithbiocidalagents.JHospInfect2020;DOI:https://doi.org/10.1016/j.jhin.2020.01.022.69.SongX,VossebeinL,ZilleA.Ef˚cacyofdisinfectant-impregnatedwipesusedforsurfacedisinfectioninhospitals:areview.AntimicrobResistInfectControl2019;DOI:https://doi.org/10.1186/s13756-019-0595-2.70.PottageT,RichardsonC,ParksS,WalkerJT,BennettAM.Evaluationofhydrogenperoxidegaseousdisinfectionsystemstodecontaminateviruses.JHospInfect2010;74:55-61.71.GoyalSM,ChanderY,YezliS,OtterJA.Evaluatingthevirucidalef˚cacyofhydrogenperoxidevapour.JHospInfect2014;86:255-9.72.KimDK,KangDH.UVCLEDirradiationeffectivelyinactivatesaerosolizedviruses,bacteria,andfungiinachamber-typeairdisinfectionsystem.ApplEnvironMicrobiol2018;DOI:https://doi.org/10.1128/AEM.00944-18.Publisher™sNoteSpringerNatureremainsneutralwithregardtojurisdictionalclaimsinpublishedmapsandinstitutionalaf˚liations.123J.Wongetal.";26 mars 2020 
0;bloc-operatoire;What we do when a COVID-19 patient needs an operation: operating room preparation and guidance;Lian Kah Ti and Al;https://www.groupedeveillecovid.fr/blog/2020/03/26/what-we-do-when-a-covid-19-patient-needs-an-operation-operating-room-preparation-and-guidance/;3;"2.GovernmentofSingapore.Coronavirusdisease2019:casesinSingapore.AvailablefromURL:https://www.gov.sg/article/covid-19-cases-in-singapore(accessedMarch2020).3.WorldHealthOrganization.Coronavirusdisease(COVID-2019)situationreports.AvailablefromURL:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports(accessedMarch2020).4.PengPW,HoPL,HotaSS.Outbreakofanewcoronavirus:whatanaesthetistsshouldknow.BrJAnesth2020;DOI:https://doi.org/10.1016/j.bja.2020.02.008.5.WangD,HuB,HuC,etal.Clinicalcharacteristicsof138hospitalizedpatientswith2019novelcoronavirusŒinfectedpneumoniainWuhan,China.JAMA2019;DOI:https://doi.org/10.1001/jama.2020.1585.PublisherÕsNoteSpringerNatureremainsneutralwithregardtojurisdictionalclaimsinpublishedmapsandinstitutionalaf˚liations.123WhatwedowhenaCOVID-19patientneedsanoperation";26 mars 2020 
0;clinique;"The COVID-19 pandemic: diverse contexts; different epidemics—how and why?";Wim Van Damme and al;https://www.groupedeveillecovid.fr/blog/2020/08/10/the-covid-19-pandemic-diverse-contexts-different-epidemics-how-and-why-2/;16;"16BMJ Global Health 103 Khafaie MA, Rahim F. Cross- Country comparison of case fatality rates of COVID-19/SARS- COV-2. Osong Public Health Res Perspect 2020;11:74Œ80. 104 Cyranoski D. Mystery deepens over animal source of coronavirus. Nature 2020;579:18Œ19. 105 Asadi S, Wexler AS, Cappa CD, et˜al. Aerosol emission and superemission during human speech increase with voice loudness. Sci Rep 2019;9:2348. 106 Wei WE, Li Z, Chiew CJ, et˜al. Presymptomatic transmission of SARS- CoV-2 Š Singapore, January 23ŒMarch 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:411Œ5. 107 van Doremalen N, Bushmaker T, Morris DH, et˜al. Aerosol and surface stability of SARS- CoV-2 as compared with SARS- CoV-1. N Engl J Med 2020;382:1564Œ7. 108 Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential FecalŒOral transmission. Gastroenterology 2020;158:30281- X:pii: S0016Œ1519. Mar 3. 109 Xu Y, Li X, Zhu B, et˜al. Characteristics of pediatric SARS- CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med 2020;26:502Œ5. 110 Medema G, Heijnen L, Elsinga G, et˜al. Presence of SARS- Coronavirus-2 in sewage. medRxiv 2020. 111 Ahmed W, Angel N, Edson J, et˜al. First con˜rmed detection of SARS- CoV-2 in untreated wastewater in Australia: a proof of concept for the wastewater surveillance of COVID-19 in the community. Sci Total Environ 2020;728:138764. 112 Lodder W, de Roda Husman AM. SARS- CoV-2 in wastewater: potential health risk, but also data source. Lancet Gastroenterol Hepatol 2020;5:533Œ4. 113 Cheng H- Y, Jian S- W, Liu D- P, et˜al. High transmissibility of COVID-19 near symptom onset. medRxiv 2020. 114 Ferretti L, Wymant C, Kendall M, et˜al. Quantifying SARS- CoV-2 transmission suggests epidemic control with digital contact tracing. Science 2020;368:eabb6936. 115 He X, Lau EHY, Wu P, et˜al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020;26:672Œ5. 116 Araujo MB, Naimi B. Spread of SARS- CoV-2 coronavirus likely to be constrained by climate. medRxiv 2020. 117 Sajadi MM, Habibzadeh P, Vintzileos A, et˜al. Temperature, humidity and latitude analysis to predict potential spread and seasonality for COVID-19, 2020. Available: https:// ssrn. com/ abstract= 3550308 [Accessed 15 Apr 2020]. 118 Luo W, Majumder MS, Liu D, et˜al. The role of absolute humidity on transmission rates of the COVID-19 outbreak. medRxiv 2020. 119 Martelletti L, Martelletti P. Air pollution and the novel Covid-19 disease: a putative disease risk factor. SN Compr Clin Med 2020:1Œ5. 120 Guo L, Ren L, Yang S, et˜al. Pro˜ling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 2020;24. 121 Bao L, Deng W, Gao H, et˜al. Reinfection could not occur in SARS- CoV-2 infected rhesus macaques. bioRxiv 2020. 122 Yuan J, Kou S, Liang Y, et˜al. Pcr assays turned positive in 25 discharged COVID-19 patients. Clin Infect Dis 2020. 123 Lan L, Xu D, Ye G, et˜al. Positive RT- PCR test results in patients recovered from COVID-19. JAMA 2020;323:1502. 124 Bobrovitz N, Arora RK, Yan T, et˜al. Lessons from a rapid systematic review of early SARS- CoV-2 serosurveys. medRxiv 2020. 125 Okba NMA, Müller MA, Li W, et˜al. Severe acute respiratory syndrome coronavirus 2- speci˜c antibody responses in coronavirus disease patients. Emerg Infect Dis 2020;26:1478Œ88. 126 Gorse GJ, Patel GB, Vitale JN, et˜al. Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum. CVI 2010;17:1875Œ80. 127 Theel ES, Slev P, Wheeler S, et˜al. The role of antibody testing for SARS- CoV-2: is there one? J Clin Microbiol 2020:00797Œ20. 128 World Health Organization. ""Immunity passports"" in the context of COVID-19, 2020. Available: https://www. who. int/ news- room/ commentaries/ detail/ immunity- passports- in- the- context- of- covid- 19 [Accessed 30 May 2020]. 129 Britton T, Trapman P, Ball FG. The disease- induced herd immunity level for Covid-19 is substantially lower than the classical herd immunity level. medRxiv 2020. 130 Gomes MGM, Corder RM, King JG, et˜al. Individual variation in susceptibility or exposure to SARS- CoV-2 lowers the herd immunity threshold. medRxiv 2020. doi:10.1101/2020.04.27.20081893. [Epub ahead of print: 02 May 2020]. 131 Kwok KO, Lai F, Wei WI, et˜al. Herd immunity Œ estimating the level required to halt the COVID-19 epidemics in affected countries. Journal of Infection 2020;80:e32Œ3. 132 Rambaut A. Phylogenetic analysis of nCoV-2019 genomes, 2020. Available: http:// virological. org/ t/ phylodynamic- analysis- 176- genomes- 6- mar- 2020/ 356 [Accessed 15 Apr 2020]. 133 Bar- On YM, Flamholz A, Phillips R, et˜al. SARS- CoV-2 (COVID-19) by the numbers. eLife 2020;9:e57309. 134 Wang C, Liu Z, Chen Z, et˜al. The establishment of reference sequence for SARS- CoV-2 and variation analysis. J Med Virol 2020;92:667Œ74. 135 Achenbach J. The coronavirus isn™t mutating quickly, suggesting a vaccine would offer lasting protection. The Washington Post 2020 25 March, 2020. Available: https://www. washingtonpost. com/ health/ the- coronavirus- isnt- mutating- quickly- suggesting- a- vaccine- would- offer- lasting- protection/ 2020/ 03/ 24/ 406522d6- 6dfd- 11ea- b148- e4ce3fbd85b5_ story. html [Accessed 15 May 2020]. 136  Nextstrain. com. Genomic epidemiology of novel coronavirus, 2020. Available: https:// nextstrain. org/ ncov? r= location [Accessed 30 May 2020]. 137 Larremore DB, Bubar KM, Grad YH. Implications of test characteristics and population seroprevalence on ‚immune passport™ strategies, 2020. Available: http:// nrs. harvard. edu/ urn- 3: HUL. InstRepos: 42664007 [Accessed 30 May 2020]. 138 Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020;109:1088Œ95. 139 Viner RM, Mytton OT, Bonell C, et˜al. Susceptibility to and transmission of COVID-19 amongst children and adolescents compared with adults: a systematic review and meta- analysis. medRxiv 2020. 140 Bai Y, Yao L, Wei T, et˜al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323:1406Œ7. 141 Rothe C, Schunk M, Sothmann P, et˜al. Transmission of 2019- nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020;382:970Œ1.";10 août 2020 
0;clinique;Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes;Takahashi and al;https://www.groupedeveillecovid.fr/blog/2020/06/18/sex-differences-in-immune-responses-to-sars-cov-2-that-underlie-disease-outcomes/;30;"Fig. 4 Differential immune phenotypes related to COVID-19 disease progression between sexes. Patients in Cohort A are divided into stabilized group and deteriorated group, depending on the comparison between maximum clinical score after sampling and the score at the sampling (M_stablized ; M_deteriorated : F_stablized : F_aggravated= 11:6:16:6). a,indicate the detection limit, and median values are indicated for each group. b,-son between stabilized and deteriorated group. c, d, Pearson correlation heatmaps of the indicated parameters are shown for each sex. For viral load levels and max- C1. e, Correlation between for each correlation and for each sex are shown on top of each plot. Data are mean ± SEM and unpaired t-test was used to compare the differences between stabilized group and deteriorated group about each sex in a, b, c. For the age panel in a and correlation plots for age and T cells (e . CC-BY-NC-ND 4.0 International licenseIt is made available under a  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted June 9, 2020. .https://doi.org/10.1101/2020.06.06.20123414doi: medRxiv preprint ";18 juin 2020 
0;clinique;Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes;Takahashi and al;https://www.groupedeveillecovid.fr/blog/2020/06/18/sex-differences-in-immune-responses-to-sars-cov-2-that-underlie-disease-outcomes/;30;"Fig. 4 Differential immune phenotypes related to COVID-19 disease progression between sexes. Patients in Cohort A are divided into stabilized group and deteriorated group, depending on the comparison between maximum clinical score after sampling and the score at the sampling (M_stablized ; M_deteriorated : F_stablized : F_aggravated= 11:6:16:6). a,indicate the detection limit, and median values are indicated for each group. b,-son between stabilized and deteriorated group. c, d, Pearson correlation heatmaps of the indicated parameters are shown for each sex. For viral load levels and max- C1. e, Correlation between for each correlation and for each sex are shown on top of each plot. Data are mean ± SEM and unpaired t-test was used to compare the differences between stabilized group and deteriorated group about each sex in a, b, c. For the age panel in a and correlation plots for age and T cells (e . CC-BY-NC-ND 4.0 International licenseIt is made available under a  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted June 9, 2020. .https://doi.org/10.1101/2020.06.06.20123414doi: medRxiv preprint ";18 juin 2020 
0;clinique;The SARS-CoV-2 epidemic in Zimbabwe: Quo vadis?;Clinical Infectious Diseases;https://www.groupedeveillecovid.fr/blog/2020/05/18/the-sars-cov-2-epidemic-in-zimbabwe-quo-vadis/;13;"Accepted Manuscript 13  19. Berthé A, Berthé-Sanou L, Somda S, et al. The key actors maintaining elders in functional autonomy in Bobo-Dioulasso (Burkina Faso). BMC Public Health 2014; 14(1): 689. 20. Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. The Lancet HIV. 21. UNAIDS. Country Factsheet: Zimbabwe. 2018; https://www.unaids.org/en/regionscountries/countries/zimbabwe  (Accessed 27 April 2020). 22. Dyer O. Covid-ke hold. BMJ 2020; 369: m1439. 23. The World Bank. COVID-19 (Coronavirus) Drives Sub-Saharan Africa Toward First Recession in 25 Years. 2020; https://www.worldbank.org/en/news/press-release/2020/04/09/covid-19-coronavirus-drives-sub-saharan-africa-toward-first-recession-in-25-years (Accessed 18 April 2020). 24. Medina L, Schneider F. Shadow Economies Around the World: What did we learn over the last 20 years? IMF Working paper 2018; https://www.imf.org/en/Publications/WP/Issues/2018/01/25/Shadow-Economies-Around-the-World-What-Did-We-Learn-Over-the-Last-20-Years-45583  (Accessed 27 April 2020). 25. Baker T, Schell CO, Petersen DB, et al. Essential care of critical illness must not be forgotten in the COVID-19 pandemic. The Lancet 2020; 395(10232): 1253-4.   Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciaa552/5835837 by guest on 16 May 2020";18 mai 2020 
0;clinique;An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study;Lucio Verdoni and al;https://www.groupedeveillecovid.fr/blog/2020/05/14/an-outbreak-of-severe-kawasaki-like-disease-at-the-italian-epicentre-of-the-sars-cov-2-epidemic-an-observational-cohort-study/;8;"8 www.thelancet.com   Published online May 13, 2020   https://doi.org/10.1016/S0140-6736(20)31103-XAcknowledgmentsWe thank Giulia Quattrocchi and Angela Amoroso for their help retrieving patients™ data from ˜led notes.References1 Ministero della Salute. Nuovo coronavirus: cosa c™è da sapere. http://www.salute.gov.it/portale/nuovocoronavirus/ (accessed April 15, 2020).2 Flaxman S, Mishra S, Gandy A, et al. Estimating the number of infections and the impact of nonpharmaceutical interventions on COVID-19 in 11 European countries. https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/covid-19/report-13-europe-npi-impact/ (accessed March 30, 2020).3 Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727Œ33.4 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497Œ506.5 Yonker LM, Shen K, Kinane TB. Lessons unfolding from pediatric cases of COVID-19 disease caused by SARS-CoV-2 infection. Pediatr Pulmonol 2020; 55: 1085Œ86.6 Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020; published online March 16. DOI:10.1542/peds.2020-0702.7 Nicastro E, Mazza A, Gervasoni A, Di Giorgio A, D™Antiga L. A pediatric emergency department protocol to avoid intra-hospital dispersal of SARS-CoV-2 during the outbreak in Bergamo, Italy. J Pediatr 2020; published online April 21. DOI:10.1016/j.jpeds.2020.04.026.8 Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020; 158: 1831Œ33.9 Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol 2020; published online April 15. DOI:10.1002/art.41285.10 D™Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl 2020; published online March 20. DOI:10.1002/lt.25756.11 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033Œ34.12 Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54: 271Œ76.13 Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996; 94: 1379Œ85.14 Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009; 123: e783Œ89.15 Wang W, Gong F, Zhu W, Fu S, Zhang Q. Macrophage activation syndrome in Kawasaki disease: more common than we thought? Semin Arthritis Rheum 2015; 44: 405Œ10.16 Rowley AH. Is Kawasaki disease an infectious disorder? Int J Rheum Dis 2018; 21: 20Œ25.17 McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scienti˜c statement for health professionals from the American Heart Association. Circulation 2017; 135: e927Œ99.18 Ravelli A, Minoia F, Davì S, et al. 2016 Classi˜cation criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 2016; 75: 481Œ89.19 García-Pavón S, Yamazaki-Nakashimada MA, Báez M, Borjas-Aguilar KL, Murata C. Kawasaki disease complicated with macrophage activation syndrome: a systematic review. J Pediatr Hematol Oncol 2017; 39: 445Œ51.20 Kobayashi T, Saji T, Otani T, et al. E˘cacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379: 1613Œ20.21 Shulman ST, Rowley AH. Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol 2015; 11: 475Œ82.22 Nakamura Y. Kawasaki disease: epidemiology and the lessons from it. Int J Rheum Dis 2018; 21: 16Œ19.23 Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J Epidemiol 2012; 22: 216Œ21.24 Yim D, Curtis N, Cheung M, Burgner D. Update on Kawasaki disease: epidemiology, aetiology and pathogenesis. J Paediatr Child Health 2013; 49: 704Œ08.25 Makino N, Nakamura Y, Yashiro M, et al. Descriptive epidemiology of Kawasaki disease in Japan, 2011Œ2012: from the results of the 22nd nationwide survey. J Epidemiol 2015; 25: 239Œ45.26 Onouchi Y. The genetics of Kawasaki disease. Int J Rheum Dis 2018; 21: 26Œ30.27 Holman RC, Belay ED, Christensen KY, Folkema AM, Steiner CA, Schonberger LB. Hospitalizations for Kawasaki syndrome among children in the United States, 1997Œ2007. Pediatr Infect Dis J 2010; 29: 483Œ88.28 Marchesi A, Tarissi de Jacobis I, Rigante D, et al. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - de˜nition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. Ital J Pediatr 2018; 44: 102.29 Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005; 191: 499Œ502.30 McIntosh K. Coronaviruses in the limelight. J Infect Dis 2005; 191: 489Œ91.31 Ebihara T, Endo R, Ma X, Ishiguro N, Kikuta H. Lack of association between New Haven coronavirus and Kawasaki disease. J Infect Dis 2005; 192: 351Œ52.32 Esper F, Shapiro ED, Landry ML, Kahn JS. Reply to van der Hoek and Berkhout, Ebihara et al., and Belay et al. J Infect Dis 2005; 192: 35333 Turnier JL, Anderson MS, Heizer HR, Jone PN, Glodé MP, Dominguez SR. Concurrent respiratory viruses and Kawasaki disease. Pediatrics 2015; 136: e609Œ14.34 Shirato K, Imada Y, Kawase M, Nakagaki K, Matsuyama S, Taguchi F. Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease. J Med Virol 2014; 86: 2146Œ53.35 McGonagle D, Sharif K, O™Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020; published online April 3. DOI:10.1016/j.autrev.2020.102537.36 Molloy EJ, Bearer CF. COVID-19 in children and altered in˛ammatory responses. Pediatr Res 2020; published online April 3. DOI:10.1038/s41390-020-0881-y.37 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054Œ62.";14 mai 2020 
0;clinique;Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19;Wenhua Liang and al;https://www.groupedeveillecovid.fr/blog/2020/05/14/development-and-validation-of-a-clinical-risk-score-to-predict-the-occurrence-of-critical-illness-in-hospitalized-patients-with-covid-19/;9;"Jia-manTang,MD,Wei-liGu,MD,Jin-linWang,MD(GuangzhouInstituteofRespiratoryHealth).Acknowledgement:SpecialthankstoLingSang,MD,supportingWuhanJinyintanHospital;Yuan-daXu,MD,supportingWuhanUnionHospital;Ai-lanChenMD,supportingWuhanHankouHospital;Guo-qiangChen,MD,andHai-yanGuo,MD,FoshanHospital;andJunGuo,MD,DayeHospital;andtheChinaMedicalTreatmentExpertGroupforCOVID-19forprovidingvalidationdata.SeefurtheracknowledgementsintheeAppendixintheSupplement.REFERENCE1.ZhouF,YuT,DuR,etal.ClinicalcourseandriskfactorsformortalityofadultinpatientswithCOVID-19inWuhan,China:aretrospectivecohortstudy.Lancet.2020;395(10229):1054-1062.doi:10.1016/S0140-6736(20)30566-32.WuZ,McGooganJM.Characteristicsofandimportantlessonsfromthecoronavirusdisease2019(COVID-19)outbreakinChina:summaryofareportof72314casesfromtheChineseCenterforDiseaseControlandPrevention.JAMA.2020;(Feb):24.doi:10.1001/jama.2020.26483.WuC,ChenX,CaiY,etal.Riskfactorsassociatedwithacuterespiratorydistresssyndromeanddeathinpatientswithcoronavirusdisease2019pneumoniainWuhan,China.JAMAInternMed.2020;(Mar):13.doi:10.1001/jamainternmed.2020.09944.GuanWJ,NiZY,HuY,etal;ChinaMedicalTreatmentExpertGroupforCovid-19.Clinicalcharacteristicsofcoronavirusdisease2019inChina.NEnglJMed.2020;(Feb):28.doi:10.1056/NEJMoa20020325.MetlayJP,WatererGW,LongAC,etal.Diagnosisandtreatmentofadultswithcommunity-acquiredpneumonia.anofficialclinicalpracticeguidelineoftheAmericanThoracicSocietyandInfectiousDiseasesSocietyofAmerica.AmJRespirCritCareMed.2019;200(7):e45-e67.doi:10.1164/rccm.201908-1581ST6.GaoHN,LuHZ,CaoB,etal.Clinicalfindingsin111casesofinfluenzaA(H7N9)virusinfection.NEnglJMed.2013;368(24):2277-2285.doi:10.1056/NEJMoa13055847.IasonosA,SchragD,RajGV,PanageasKS.Howtobuildandinterpretanomogramforcancerprognosis.JClinOncol.2008;26(8):1364-1370.doi:10.1200/JCO.2007.12.97918.NeillAM,MartinIR,WeirR,etal.Communityacquiredpneumonia:aetiologyandusefulnessofseveritycriteriaonadmission.Thorax.1996;51(10):1010-1016.doi:10.1136/thx.51.10.10109.XuJ,LongJS.Confidenceintervalsforpredictedoutcomesinregressionmodelsforcategoricaloutcomes.StataJournal.2005;5(4):537-559.doi:10.1177/1536867X050050040510.LiangW,GuanW,ChenR,etal.CancerpatientsinSARS-CoV-2infection:anationwideanalysisinChina.LancetOncol.2020;21(3):335-337.doi:10.1016/S1470-2045(20)30096-6RiskScoreforDevelopmentofCriticalIllnessinPatientsWithCOVID-19OriginalInvestigationResearchjamainternalmedicine.com(Reprinted)JAMAInternalMedicinePublishedonlineMay12,2020E9©2020AmericanMedicalAssociation.Allrightsreserved.";14 mai 2020 
0;clinique;Methodological challenges of analysing COVID-19 data during the pandemic;Martin Wolkewitz and Livia Puljak;https://www.groupedeveillecovid.fr/blog/2020/04/30/methodological-challenges-of-analysing-covid-19-data-during-the-pandemic/;4;"12.delRioC,MalaniPN.2019novelcoronavirusŠimportantinformationforclinicians.JAMA.2020.https://doi.org/10.1001/jama.2020.1490.13.SheahanTP,SimsAC,LeistSR,etal.Comparativetherapeuticefficacyofremdesivirandcombinationlopinavir,ritonavir,andinterferonbetaagainstMERS-CoV.NatCommun.2020;11.https://doi.org/10.1038/s41467-019-13940-6.14.RussellCD,MillarJE,BaillieJK.Clinicalevidencedoesnotsupportcorticosteroidtreatmentfor2019-nCoVlunginjury.Lancet.2020;395(10223):473Œ5.https://doi.org/10.1016/S0140-6736(20)30317-2.15.ShangL,ZhaoJ,HuY,DuR,CaoB.Ontheuseofcorticosteroidsfor2019-nCoVpneumonia.Lancet.2020;395(10225):683Œ4.https://doi.org/10.1016/S0140-6736(20)30361-5.16.BouadmaL,LescureF-X,LucetJ-C,YazdanpanahY,TimsitJ-F.SevereSARS-CoV-2infections:practicalconsiderationsandmanagementstrategyforintensivists.IntensiveCareMed.February2020.https://doi.org/10.1007/s00134-020-05967-x.17.YangX,YuY,XuJ,etal.ClinicalcourseandoutcomesofcriticallyillpatientswithSARS-CoV-2pneumoniainWuhan,China:asingle-centered,retrospective,observationalstudy.LancetRespirMed.2020.https://doi.org/10.1016/S2213-2600(20)30079-5.18.XuX-W,WuX-X,JiangX-G,etal.Clinicalfindingsinagroupofpatientsinfectedwiththe2019novelcoronavirus(SARS-Cov-2)outsideofWuhan,China:retrospectivecaseseries.BMJ.2020;1:m606.https://doi.org/10.1136/bmj.m606.19.ChenN,ZhouM,DongX,etal.Epidemiologicalandclinicalcharacteristicsof99casesof2019novelcoronaviruspneumoniainWuhan,China:adescriptivestudy.Lancet.2020;395(10223):507Œ13.https://doi.org/10.1016/S0140-6736(20)30211-7.20.YoungBE,OngSWX,KalimuddinS,etal.EpidemiologicfeaturesandclinicalcourseofpatientsinfectedwithSARS-CoV-2inSingapore.JAMA.2020.https://doi.org/10.1001/jama.2020.3204.21.HuangC,WangY,LiX,etal.Clinicalfeaturesofpatientsinfectedwith2019novelcoronavirusinWuhan,China.Lancet.2020.https://doi.org/10.1016/S0140-6736(20)30183-5.22.WangD,HuB,HuC,etal.Clinicalcharacteristicsof138hospitalizedpatientswith2019novelcoronavirusŒinfectedpneumoniainWuhan,China.JAMA.2020.https://doi.org/10.1001/jama.2020.1585.23.GuanW,NiZ,HuY,etal.Clinicalcharacteristicsofcoronavirusdisease2019inChina.NewEnglJMed.2020.https://doi.org/10.1056/NEJMoa2002032.24.ArabiYM,ShalhoubS,MandourahY,etal.RibavirinandinterferontherapyforcriticallyillpatientswithMiddleEastrespiratorysyndrome:amulticenterobservationalstudy.ClinInfectDis.https://doi.org/10.1093/cid/ciz544.25.ArabiYM,MandourahY,Al-HameedF,etal.CorticosteroidtherapyforcriticallyillpatientswithMiddleEastrespiratorysyndrome.AmJRespirCritCareMed.2018;197(6):757Œ67.https://doi.org/10.1164/rccm.201706-1172OC.26.DelaneyJW,PintoR,LongJ,etal.Theinfluenceofcorticosteroidtreatmentontheoutcomeofinfluenzaa(H1N1pdm09)-relatedcriticalillness.CritCare.2016;20.https://doi.org/10.1186/s13054-016-1230-8.27.MuthuriSG,VenkatesanS,MylesPR,etal.EffectivenessofneuraminidaseinhibitorsinreducingmortalityinpatientsadmittedtohospitalwithinfluenzaaH1N1pdm09virusinfection:ameta-analysisofindividualparticipantdata.LancetRespirMed.2014;2(5):395Œ404.28.CaoB,WangY,WenD,etal.AtrialofLopinavirŒritonavirinadultshospitalizedwithsevereCovid-19.NewEnglJMed.2020.https://doi.org/10.1056/NEJMoa2001282.29.Globalresearchoncoronavirusdisease(COVID-19).https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov.Accessed4Mar2020.30.RunjicE,BehmenD,PieperD,etal.FollowingCochranereviewprotocolstocompletion10yearslater:aretrospectivecohortstudyandauthorsurvey.JClinEpidemiol.2019;111:41Œ8.https://doi.org/10.1016/j.jclinepi.2019.03.006.31.RunjicE,RombeyT,PieperD,PuljakL.HalfofsystematicreviewsaboutpainregisteredinPROSPEROwerenotpublishedandthemajorityhadinaccuratestatus.JClinEpidemiol.2019;116:114Œ21.https://doi.org/10.1016/j.jclinepi.2019.08.010.32.GarrittyC,StevensA,HamelC,GolfamM,HuttonB,WolfeD.Knowledgesynthesisinevidence-basedmedicine.SeminNuclMed.2019;49(2):136Œ44.https://doi.org/10.1053/j.semnuclmed.2018.11.006.33.SigfridL,MooreC,SalamAP,etal.Arapidresearchneedsappraisalmethodologytoidentifyevidencegapstoinformclinicalresearchprioritiesinresponsetooutbreaks-resultsfromtheLassafeverpilot.BMCMed.2019;17(1):107.https://doi.org/10.1186/s12916-019-1338-1.34.KellySE,MoherD,CliffordTJ.Qualityofconductandreportinginrapidreviews:anexplorationofcompliancewithPRISMAandAMSTARguidelines.SystRev.2016;5:79.https://doi.org/10.1186/s13643-016-0258-9.35.ModjarradK,MoorthyVS,MillettP,GsellP-S,RothC,KienyM-P.Developingglobalnormsforsharingdataandresultsduringpublichealthemergencies.PLoSMed.2016;13(1):e1001935.https://doi.org/10.1371/journal.pmed.1001935.Publisher™sNoteSpringerNatureremainsneutralwithregardtojurisdictionalclaimsinpublishedmapsandinstitutionalaffiliations.WolkewitzandPuljakBMCMedicalResearchMethodology          (2020) 20:81 Page4of4";30 avril 2020 
0;clinique;Internet Searches for Unproven COVID-19 Therapies in the United States;Michael Liu and al;https://www.groupedeveillecovid.fr/blog/2020/04/30/internet-searches-for-unproven-covid-19-therapies-in-the-united-states/;3;"CorrespondingAuthor:JohnW.Ayers,PhD,MA,DivisionofInfectiousDiseasesandGlobalHealth,DepartmentofMedicine,SchoolofMedicine,UniversityofCalifornia,SanDiego,9500GilmanDr,333CRSF,LaJolla,CA92093(ayers.john.w@gmail.com).PublishedOnline:April29,2020.doi:10.1001/jamainternmed.2020.1764AuthorContributions:DrAyershadfullaccesstoallofthedatainthestudyandtakesresponsibilityfortheintegrityofthedataandtheaccuracyofthedataanalysis.Studyconceptanddesign:Liu,Dredze,Ayers.Acquisition,analysis,orinterpretationofdata:Allauthors.Draftingofthemanuscript:Liu,Caputi,Dredze,Ayers.Criticalrevisionofthemanuscriptforimportantintellectualcontent:Allauthors.Statisticalanalysis:Liu,Caputi.Administrative,technical,ormaterialsupport:Liu,Caputi,Dredze.Studysupervision:Dredze,Kesselheim.Other:Ayers.ConflictofInterestDisclosures:DrAyersreportsreceivinggrantsfromtheBurroughsWellcomeFundandtheUniversityofCaliforniaOfficeofthePresident,aswellasnonfinancialsupportfromtheDivisionofInfectiousDiseasesandGlobalHealthoftheUniversityofCalifornia,SanDiego;healsoownsequityinDirectingMedicine,HealthWatcher,andGoodAnalytics,whicharecompaniesthatadviseontheuseofdigitaldataforpublichealthsurveillance.MrCaputireportsreceivingpersonalfeesfromGoodAnalytics.DrDredzereportsholdingequityinGoodAnalyticsandhasreceivedconsultingfeesfromDirectingMedicine;hehasalsoreceivedpaymentsfromSickweather,whichusessocialmediaforinfectiousdiseasemonitoring,andBloombergLP.DrKesselheimreportsreceivinggrantsfromArnoldVenturesandtheHarvard-MITCenterofRegulatoryScience.Nootherdisclosuresarereported.Disclaimer:Thecontentofthisarticleissolelytheresponsibilityoftheauthorsanddoesnotnecessarilyreflectthepositionorpolicyoftheiremployersandcollaboratinginstitutions.1.LiuJ,CaoR,XuM,etal.Hydroxychloroquine,alesstoxicderivativeofchloroquine,iseffectiveininhibitingSARS-CoV-2infectioninvitro.CellDiscov.2020;6(1):16.doi:10.1038/s41421-020-0156-02.WhiteNJ.Cardiotoxicityofantimalarialdrugs.LancetInfectDis.2007;7(8):549-558.doi:10.1016/S1473-3099(07)70187-13.VigdorN.Manfatallypoisonshimselfwhileself-medicatingforcoronavirus,doctorsays.NewYorkTimes.March24,2020.AccessedApril17,2020.https://www.nytimes.com/2020/03/24/us/chloroquine-poisoning-coronavirus.html.4.AyersJW,AlthouseBM,DredzeM.Couldbehavioralmedicineleadthewebdatarevolution?JAMA.2014;311(14):1399-1400.doi:10.1001/jama.2014.15055.HyndmanRJ,KhandakarY.Automatictimeseriesforecasting:theforecastpackageforR.JStatSoftw.2008.doi:10.18637/jss.v027.i036.YazdanyJ,KimAHJ.UseofhydroxychloroquineandchloroquineduringtheCOVID-19pandemic:whateveryclinicianshouldknow.AnnInternMed.PublishedonlineMarch31,2020.doi:10.7326/M20-1334Lettersjamainternalmedicine.com(Reprinted)JAMAInternalMedicinePublishedonlineApril29,2020E3©2020AmericanMedicalAssociation.Allrightsreserved.";30 avril 2020 
0;clinique;Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis;Israel Júnior Borges do Nascimento and al;https://www.groupedeveillecovid.fr/blog/2020/04/29/novel-coronavirus-infection-covid-19-in-humans-a-scoping-review-and-meta-analysis/;14;"J.Clin.Med.2020,9,94114of1484.Cao,Y.;Li,L.;Feng,Z.;Wan,S.;Huang,P.;Sun,X.;Wen,F.;Huang,X.;Ning,G.;Wang,W.Comparativegeneticanalysisofthenovelcoronavirus(SARS-CoV-2/SARS-CoV-2)receptorACE2indierentpopulations.CellDiscov.2020,6,1Œ4.[CrossRef]85.Ji,Y.;Ma,Z.;Peppelenbosch,M.P.;Pan,Q.PotentialassociationbetweenCOVID-19mortalityandhealth-careresourceavailability.LancetGlob.Health2020,8,PE480.[CrossRef]86.Djulbegovic,B.;Guyatt,G.H.Progressinevidence-basedmedicine:Aquartercenturyon.Lancet2017,390,415Œ423.[CrossRef]©2020bytheauthors.LicenseeMDPI,Basel,Switzerland.ThisarticleisanopenaccessarticledistributedunderthetermsandconditionsoftheCreativeCommonsAttribution(CCBY)license(http://creativecommons.org/licenses/by/4.0/).";29 avril 2020 
0;clinique;The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control;Yosra A. Helmy and al;https://www.groupedeveillecovid.fr/blog/2020/04/29/the-covid-19-pandemic-a-comprehensive-review-of-taxonomy-genetics-epidemiology-diagnosis-treatment-and-control/;29;"J.Clin.Med.2020,9,122529of29128.Daszak,P.;Olival,K.J.;Li,H.Astrategytopreventfuturepandemicssimilartothe2019-nCoVoutbreak.Biosaf.Health2020,2,6Œ8.[CrossRef]129.Fawzy,M.;Helmy,Y.A.TheonehealthapproachisnecessaryforthecontrolofRiftValleyfeverinfectionsinEgypt:Acomprehensivereview.Viruses2019,11,139.[CrossRef][PubMed]©2020bytheauthors.LicenseeMDPI,Basel,Switzerland.ThisarticleisanopenaccessarticledistributedunderthetermsandconditionsoftheCreativeCommonsAttribution(CCBY)license(http://creativecommons.org/licenses/by/4.0/).";29 avril 2020 
0;clinique;Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence;Poissy and al;https://www.groupedeveillecovid.fr/blog/2020/04/28/pulmonary-embolism-in-covid-19-patients-awareness-of-an-increased-prevalence/;6;"10.1161/CIRCULATIONAHA.120.047430  6  Table. Number of CT Pulmonary Angiography performed for suspicion of PE, Number and main characteristics of Pulmonary Embolism (PE) Events in Intensive Care Unit from COVID-19 pandemic period by comparison to the same period in 2019 and to influenza patients in 2019   Study period  2019, February 27th to March 31th (all ICU patients*, n=196) 2019, 1st January to 31th December (Influenza ICU patients (PCR+), n=40) 2020, February 27th to March 31th (COVID-19 ICU patients, (PCR+), n=107) Number of chest CT scans, n (%)  50 (25.5) 20 (50.0) 36 (33.6) Number of CTPA, n (%) 30 (15.3) 17 (42.5) 34 (31.8) Number of CTPA performed for a PE diagnosis, n (%) 20 (10.2) 8 (20.0) 34 (31.8) Number of PE cases (%) 12 (6.1) 3 (7.5) 22 (20.6)** Bilateral, n (%) 8 (66.6) 0 *** 8 (40.0) § Proximal, n (%) 2 (16.6) 0 *** 2 (10.0) § Segmental, n (%) 6 (50.0) 0 *** 11 (55.0) §  ARDS, n (%) 14 (7.1) 15 (37.5) 67 (62.6) Intubation, n (%) 84 (42.9) 17 (42.5) 67 (62.6) Doppler ultrasound, n (%) 12 (6.1) 2 (5.0) 8 (7.5) DVT, n (%) 9 (4.6) 1 (2.5) 5 (4.7) Patients with Pulmonary Embolism    Age, years, median (range) 66 (30 to 72) 71 (57 to 72) 57 (29 to 80) Men, n (%) 8 (66.7) 2 (66.7) 13 (59.1) Body mass index, median (range) 29 (18 to 42) 26 (16 to 52) §§ 30 (22 to 53) SOFA at admission, median (range) 8 (1 to 16) 2 (1 to 9) 4 (0 to 14) SAPS II at admission, median (range) 53 (23 to 69) 41 (34 to 65) 40 (18 to 78) ARDS, n (%) 5 (41.7)  2 (66.7) 17 (77.3) Intubation, n (%) 8 (66.7)  3 (100.0) 17 (77.3)  DVT associated to PE, n (%) 7 (58.3) 1 (33.4)  3 (13.6) * Reasons for hospitalization in this group were : acute respiratory failure (34%), sepsis/septic shock (19%), strokes and other neurological disorders (10%), non septic shock (6%), cardiac arrest (6%), intoxications (6%), metabolism disorders (4%), post-operative conditions (5%), microangiopathies (1.5%), acute kidney injury (1.5%) and others (7%: pancreatitis, self-hanging injury, severe trauma, gas embolism). ** corresponding to an absolute increase of 14.4% (95%CI, 6.1 to 22.8%) against control group of ICU patients admitted from February 27th to March 31th 2019 and 13.1% (95%CI, 1.9 to 24.3%) against and control group of Influenza ICU patients admitted January 1th to December 31th 2019.*** The 3 PE identified in Influenzae patients were unilateral and subsegmental § 2 missing values. §§1 missing value Abbreviations: BMI=body mass index; CT=computed tomography; CTPA= CT pulmonary angiography; ICU=intensive care unit; PCR= Polymerase Chain Reaction; PE=pulmonary embolism; SAPSII= Simplified Acute Physiology Score, The SAPS II score provides an estimate of the risk of death without having to specify a primary diagnosis. It includes physiological variables, type of admission and underlying disease variables. Point score between 0 and 163 predicts mortality between 0% and 100%.; SOFA=Sequential Organ Failure Assessment, is a mortality prediction score that is based on the degree of dysfunction of six organ systems. The score is calculated on admission and every 24 hours, ranging from 0 (normal) to 4 (high degree of dysfunction/failure) for each organ failure. ARDS=Acute Respiratory Distress Syndrome ";28 avril 2020 
0;covid-et-grossesse;Detection of SARS-CoV-2 in human breastmilk;Rüdiger Groß and al;https://www.groupedeveillecovid.fr/blog/2020/05/23/detection-of-sars-cov-2-in-human-breastmilk/;2;"2 www.thelancet.com   Published online May 21, 2020   https://doi.org/10.1016/S0140-6736(20)31181-81 Lackey KA, Pace RM, Williams JE, et al. SARS-CoV-2 and human milk: what is the evidence? medRxiv 2020; published online April 20. DOI:10.1101/2020.04.07.20056812 (preprint).2 Yang N, Che S, Zhang J, et al. Breastfeeding of infants born to mothers with COVID-19: a rapid review. medRxiv 2020; published April 19. DOI:10.1101/2020.04.13.20064378 (preprint).3 Chen L, Li Q, Zheng D, Jiang H, et al. Clinical characteristics of pregnant women with Covid-19 in Wuhan, China. N Engl J Med 2020; published April 17. DOI:10.1056/NEJMc2009226.4 Chu DKW, Pan Y, Cheng SMS, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 2020; 66: 549Œ55.and sterilisation of milk pumps and tubes). However, whether New-born 2 was infected by breastfeeding or other modes of transmission remains unclear. Fur ther studies of milk samples from lactating women and possible virus transmission via breastfeeding are needed to develop recommendations on whether mothers with COVID-19 should breastfeed.We declare no competing interests. RG, CC, and JAM contributed equally. This work was supported by the EU™s Horizon 2020 research and innovation programme (Fight-nCoV, 101003555 to JM) and the German Research Foundation (CRC 1279 to SS, FK, and JM; and MU 4485/1-1 to JAM)Rüdiger Groß, Carina Conzelmann, Janis A Müller, Ste˛en Stenger, Karin Steinhart, Frank Kirchho˛, *Jan Münchjan.muench@uni-ulm.deInstitute of Molecular Virology (RG, CC, JAM, FK, JM) and Institute for Microbiology and Hygiene (SS), Ulm University Medical Center, Ulm 89081, Germany; and Administrative District Heidenheim, Public Health O˙ce, Heidenheim, Germany (KS)Day 12Day 13Day 14 (morning)Day 14 (evening)Day 10 (left breast)Day 10 (right breast)Day 12Day 13Day 14 (morning)Day 14 (evening)Day 25Day 12Day 13Day 14 (morning)Day 14 (evening)Day 10 (left breast)Day 10 (right breast)Day 12Day 13Day 14 (morning)Day 14 (evening)Day 253456log10 RNA copies/mL˜40353025Ct valueNORF˜bMother 1Mother 2Mother 1Mother 2Whole milkSkimmed milkFigure ˚: Detection of SARS-CoV-2 in breastmilk from an infected motherSARS-CoV-2 RNA was isolated from whole and skimmed breastmilk obtained at di˝erent timepoints and analysed by RT-qPCR, using primer sets targeting SARS-CoV-2 N and ORF˜b genes. Samples and viral RNA standard were run in duplicates, and isolation and RT-qPCR were repeated in two independent assays. RNA in breastmilk from Mother 2 on day 25 was only isolated once and only analysed by RT-qPCR for SARS-CoV-2 N. Symbols at baseline indicate no ampli˜cation (or Ct>36·5 and no ampli˜cation in one replicate). Blue dashed line denotes quanti˜cation threshold for N (160 copies per reaction; Ct 34·2) and red dotted line for ORF˜b (32 copies per reaction; Ct 35·9). Values below these lines but above baseline indicate ampli˜cation in both replicates, but no reliable quanti˜cation. Values shown represent mean (SD) from duplicates. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. Ct=cycle threshold.";23 mai 2020 
0;covid-et-grossesse;Clinical Characteristics of Pregnant Women with Covid 19 in Wuhan , China;L.Chen et al;https://www.groupedeveillecovid.fr/blog/2020/04/23/clinical-characteristics-of-pregnant-women-with-covid-19-in-wuhan-china/;3;"Correspondencen engl j med   nejm.org 3during the postpartum period are likely to relate to pathophysiological changes (e.g., increased cir-culating blood volume) that occur in this period.Lian Chen, M.D. Qin Li, Ph.D. Danni Zheng, M.Med.Sc. Hai Jiang, M.Med.Sc. Yuan Wei, M.D.Peking University Third Hospital Beijing, ChinaLi Zou, M.D., Ph.D.Union Hospital Wuhan, ChinaLing Feng, M.D., Ph.D.Tongji Hospital Wuhan, ChinaGuoping Xiong, M.D., Ph.D.Central Hospital of Wuhan Wuhan, ChinaGuoqiang Sun, M.Med.Maternal and Child Hospital of Hubei Province Wuhan, ChinaHaibo Wang, M.B., B.S., M.P.H.First Affiliated Hospital of Sun Yat-sen University Guangzhou, ChinaYangyu Zhao, M.D., Ph.D. Jie Qiao, M.D., Ph.D.Peking University Third Hospital Beijing, China zhaoyangyu@bjmu.edu.cn jie.qiao@263.netDrs. Chen and Li, Ms. Zheng, and Mr. Jiang and Drs. Zhao and Qiao contributed equally to this letter.Supported by grants (72042013, 81521002, and 81730038) from the National Natural Science Foundation of China. The foundation had no role in the study design, the data analysis, the drafting of this letter, or the decision to submit it for publication.Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.This letter was published on April 17, 2020, at NEJM.org.1. World Health Organization. Coronavirus (COVID-19). 2020 (https://who .sprinklr .com).2. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infec-tion in nine pregnant women: a retrospective review of medical records. Lancet 2020; 395: 809-15.3. Yu N, Li W, Kang Q, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wu-han, China: a retrospective, single-centre, descriptive study. Lancet Infect Dis 2020 March 24 (Epub ahead of print).4. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. DOI:  10.1056/NEJMoa2002032.5. Creanga AA, Kamimoto L, Newsome K, et al. Seasonal and 2009 pandemic influenza A (H1N1) virus infection during preg-nancy: a population-based study of hospitalized cases. Am J Ob-stet Gynecol 2011; 204: Suppl 1: S38-S45.DOI:˜10.1056/NEJMc2009226Correspondence Copyright © 2020 Massachusetts Medical Society.";23 avril 2020 
0;covid-et-grossesse;Universal Screening for SARS-CoV-2 in Women Admitted for Delivery;Sutton D et al;https://www.groupedeveillecovid.fr/blog/2020/04/16/universal-screening-for-sars-cov-2-in-women-admitted-for-delivery/;2;The new england journal of medicinen engl j med   nejm.org 2bed assignments, inform neonatal care, and guide the use of personal protective equipment. Access to such clinical data provides an important op-portunity to protect mothers, babies, and health care teams during these challenging times.Desmond Sutton, M.D. Karin Fuchs, M.D., M.H.A. Mary D™Alton, M.D. Dena Goffman, M.D.Columbia University Irving Medical Center New York, NY dg2018@  cumc . columbia . eduDisclosure forms provided by the authors are available with the full text of this letter at NEJM.org.This letter was published on April 13, 2020, at NEJM.org.1. Breslin N, Baptiste C, Miller R, et al. COVID-19 in pregnan-cy: early lessons. Am J Obstet Gynecol MFM (in press).2. Breslin N, Baptiste C, Gyamfi-Bannerman C, et al. COVID-19 infection among asymptomatic and symptomatic pregnant wom-en: two weeks of confirmed presentations to an affiliated pair of New York City hospitals. Am J Obstet Gynecol MFM (in press).3. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2020 February 26 (Epub ahead of print).DOI:˜10.1056/NEJMc2009316Correspondence Copyright © 2020 Massachusetts Medical Society.;16 avril 2020 
0;covid-et-grossesse;Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children;Zaigham M et Andersson O;https://www.groupedeveillecovid.fr/blog/2020/04/13/clinical-and-ct-imaging-features-of-the-covid-19-pneumonia-focus-on-pregnant-women-and-children/;7;"H. Liu, F. Liu and J. Li et al. / Journal of Infection xxx (xxxx) xxx 7 ARTICLE IN PRESS JID: YJINF [m5G; March 21, 2020;1:51 ] COVID-19 pneumonia were non-speciﬁc, while the exposure his- tory and clinical symptoms could be more helpful for the screen- ing. Contributors HL, FL, DW, and WL conceived the study conception and design. HL and FL contributed to the literature search. HL, FL, JL, and TZ performed the acquisition of data. HL and JL conducted the analysis and interpretation of data. HL and FL contributed to the ﬁgures. HL, FL and JL drafted the manuscript. DW and WL contributed to critical revision of the manuscript. Declaration of Competing Interest We declare no competing interests. References 1. Zhu N , Zhang D , Wang W , Li X , Yang B , Song J , et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382 (8):727–33 . 2. Huang C , Wang Y , Li X , Ren L , Zhao J , Hu Y , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet 2020; 395 (10223):497–506 . 3. Chen N , Zhou M , Dong X , Qu J , Gong F , Han Y , et al. Epidemiological and clini- cal characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223):507–13 . 4. The International Committee on Taxonomy of Viruses (ICTV) Coronaviridae Study Group. Naming the 2019 Coronavirus. https://talk.ictvonline.org/ . 5. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneu- monia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. 2020;395(10223):514-523. 6. Phan LT , Nguyen TV , Luong QC , Nguyen TV , Nguyen HT , Le HQ , et al. Importa- tion and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med 2020; 382 (9):872–4 . 7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 Feb 7 Epub ahead of print. doi: 10.1001/jama.2020. 1585 . 8. National Health Commission of China. “Report of the latest situation of novel coronavirus pneumonia in China as of February 18, 2020”. http://www.nhc.gov. cn/xcs/yqtb/202002/8f2cfd17f4c040d89c69a4b29e99748c.shtml . 9. Yang Y , Lu Q , Liu M , Wang Y , Zhang A , Jalali N , et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv. 2020; 2020 02.10.20021675 . 10. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020 Jan 29 Epub ahead of print. doi: 10.1056/NEJMoa2001316 . 11. Guan WJ , Ni ZY , Hu Y , Liang WH , Ou CQ , He JX , et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020; 2020 02.06.20020974 . 12. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical 2019- nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology 2020 Feb 12 200343. Epub ahead of print. doi: 10.1148/radiol.2020200343 . 13. Huang P , Liu T , Huang L , Liu H , Lei M , Xu W , et al. Use of Chest CT in Com- bination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion. Radiology 2020; 295 (1):22–3 . 14. National Health Commission of China. “Diagnosis and Treatment for COVID-19 Pneumonia (Fifth Trial Version)”. http://www.nhc.gov.cn/ . 15. Mor G , Cardenas I , Abrahams V , Guller S . Inﬂammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci 2011; 1221 :80–7 . 16. Chen H , Guo J , Wang C , Luo F , Yu X , Zhang W , et al. Clinical characteris- tics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet 2020; 395 (10226):809–15 . 17. Zhu H , Wang L , Fang C , Peng S , Zhang L , Chang G , et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Translational Pediatrics 2020; 9 (1):51–60 . 18. World Health Organization. Technical-guidance for 2019-nCoV RT-PCR. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical- guidance/laboratory-guidance 19. Chung M , Bernheim A , Mei X , Zhang N , Huang M , Zeng X , et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology 2020; 295 (1):202–7 . 20. Song F , Shi N , Shan F , Zhang Z , Shen J , Lu H , et al. Emerging Coronavirus 2019-nCoV Pneumonia. Radiology 2020; 295 (1):210–17 . 21. Chang YC , Yu CJ , Chang SC , Galvin JR , Liu HM , Hsiao CH , et al. Pulmonary seque- lae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. Radiology 2005; 236 (3):1067–75 . 22. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology 2020 Feb 26 200642. Epub ahead of print. doi: 10.1148/ radiol.2020200642 . 23. Toma P , Bartoloni A , Salerno S , Granata C , Cannata V , Magistrelli A , et al. Pro- tecting sensitive patient groups from imaging using ionizing radiation: effects during pregnancy, in fetal life and childhood. Radiol Med 2019; 124 (8):736–44 . 24. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological ﬁndings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases 2020 Feb 24 pii: S1473-3099(20)30086-4. Epub ahead of print. doi: 10.1016/S1473- 3099(20)30086- 4 . 25. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological ﬁndings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020 Feb 18 pii: S2213-260 0(20)30 076-X. Epub ahead of print. doi: 10.1016/ S2213-260 0(20)30 076-X . 26. Gourgoulianis KI , Karantanas AH , Diminikou G , Molyvdas PA . Benign postpar- tum pleural effusion. Eur Respir J 1995; 8 (10):1748–50 . 27. Koo HJ , Lim S , Choe J , Choi SH , Sung H , Do KH . Radiographic and CT Features of Viral Pneumonia. Radiographics 2018; 38 (3):719–39 . 28. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneu- monia. Radiology 2020 Feb 13 200370. Epub ahead of print. doi: 10.1148/radiol. 2020200370 . Please cite this article as: H. Liu, F. Liu and J. Li et al., Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children, Journal of Infection, https://doi.org/10.1016/j.jinf.2020.03.007 ";13 avril 2020 
0;covid-et-grossesse;Maternal and Perinatal Outcomes with COVID-19: a systematic review of 108 pregnancies;Zaigham M et Andersson O;https://www.groupedeveillecovid.fr/blog/2020/04/12/maternal-and-perinatal-outcomes-with-covid-19-a-systematic-review-of-108-pregnancies/;19; This article is protected by copyright. All rights reserved Neonatal mortality 1c 0 d 0 0 f 0 1/87 (1%) Intrauterine fetal death 1c 0 d 0 0 f 0 1/87 (1%) Vertical transmission 1c N/A 0 e 0 f 0 1/75 (1%) a Data unavailable in 24 cases              N/A denotes data not available b Data unavailable in 28 cases c Data unavailable from 8 women still pregnant at the end of the study22) d Data unavailable from 10 women still pregnant at the end of the study e Data unavailable in 6 neonates f Data unavailable from 4 women still pregnant at the end of the study ;12 avril 2020 
0;covid-et-grossesse;Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia;Huaping Zhu, Lin Wang, Chengzhi Fang, Sicong Peng, Lianhong Zhang, Guiping Chang, Shiwen Xia, Wenhao Zhou;https://www.groupedeveillecovid.fr/blog/2020/03/30/clinical-analysis-of-10-neonates-born-to-mothers-with-2019-ncov-pneumonia/;10;"60Zhu et al. Neonates born to mothers with 2019-nCoV pneumonia  Transl Pediatr 2020;9(1):51-60 | http://dx.doi.org/10.21037/tp.2020.02.06Lancet 2020. [Epub ahead of print].Traditional Chinese Medicine. Diagnosis and Treatment Protocol for 2019-nCoV (Fourth Trial Edition). 2020. Available online: http://www.nhc.gov.cn/yzygj/s7653p/202001/4294563ed35b43209b31739bd0785e67.shtml4. Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv 2020. doi: 10.1101/2020.01.30.927806.5. Gagneur A, Dirson E, Audebert S, et al. Materno-fetal transmission of human coronaviruses: a prospective pilot study. Eur J Clin Microbiol Infect Dis 2008;27:863-6.6. Ng PC, Leung CW, Chiu WK, et al. SARS in newborns and children. Biol Neonate 2004;85:293-8.7. Robertson CA, Lowther SA, Birch T, et al. SARS and pregnancy: a case report. Emerg Infect Dis 2004;10:345-8.8. Stockman LJ, Lowther SA, Coy K, et al. SARS during pregnancy, United States. Emerg Infect Dis 2004;10:1689-90.9. Alserehi H, Wali G, Alshukairi A, et al. Impact of Middle East Respiratory Syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome. BMC Infect Dis 2016;16:105.10. Chan JF, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020;9:221-36.11. Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression nCov. bioRxiv 2020. doi: 10.1101/2020.01.26.919985.12. Working Group for the Prevention and Control of Neonatal 2019-nCoV Infection in the Perinatal Period of the Editorial Committee of Chinese Journal of Contemporary Pediatrics. Perinatal and neonatal management plan for prevention and control of 2019 novel coronavirus infection (1st Edition). Chinese Journal of Contemporary Pediatrics 2020;22:87-90. 13. Wang J, Xu H, Mu C, et al. A study on mother-to-fetus/case reports and a review of literature. Clin Respir J 2018;12:2539-45.Cite this article as: Zhu H, Wang L, Fang C, Peng S, Zhang L,  Chang G, Xia S, Zhou W. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr 2020;9(1):51-60. doi: 10.21037/tp.2020.02.06";30 mars 2020 
0;covid-et-grossesse;Infection par le SARS-CoV-2 chez les femmes enceintes. Etat des connaissances et proposition de pris en charge.;V Peyronnet et al;https://www.groupedeveillecovid.fr/blog/2020/03/27/infection-sars-cov-2-chez-femmes-enceintes-etat-connaissances-proposition-de-pris-charge/;23;"Page 22 of 22Journal Pre-proof22  40.  Stockman LJ, Lowther SA, Coy K, Saw J, Parashar UD. SARS during pregnancy. Emerg Infect Dis. 2004 Sep;10(9):1689-90. 41.  Alserehi H, Wali G, Alshukairi A, Alraddadi B. Impact of Middle East Respiratory Syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome. BMC Infect Dis. 2016 ;16(1): 105. 42.  Royal College of Obstericians and Gynaecologists. Coronavirus (COVID-19) infection and pregnancy  RCOG. Version 1: Published Monday 9 March, 2020. Available from: https://www.rcog.org.uk/globalassets/documents/guidelines/coronavirus-covid-19-virus-infection-in-pregnancy-2020-03-09.pdf (Accessed 15 March 2020) 43.  Poon LC, Yang H, Lee JCS, Copel JA, Leung TY, Zhang Y, et al. ISUOG Interim Guidance on 2019 novel coronavirus infection during pregnancy and puerperium: information for healthcare professionals. Ultrasound Obstet Gynecol. 2020 Mar 11;  doi: 10.1002/uog.22013  ";27 mars 2020 
0;covid-et-grossesse;PROPOSITIONS DE LA SOCIÉTÉ FRANÇAISE DE NÉONATALOGIE & DE LA SOCIÉTÉ FRANÇAISE DE PÉDIATRIE CONCERNANT LES NOUVEAU-NÉS DANS LE CONTEXTE D’ÉPIDÉMIE à COVID-19;null;https://www.groupedeveillecovid.fr/blog/2020/03/27/propositions-de-societe-francaise-de-neonatalogie-de-societe-francaise-de-pediatrie-concernant-nouveau-nes-contexte-depidemie-a-covid-19/;3;  CONSIGNES à DIFFUSER AUPRÈS DES FAMILLES dont la mère est asymptomatique et non connue comme porteuse du COVID-19 :  Comment protéger ma famille , mais aussi via    comme pour la nouveau-né, mais aussi après. Ne mettez pas à la bouche la tétine de votre enfant. Le port de masque t est recommandé. Les visites de la fratrie doivent être évitées. Les personnes avec toux doivent différer leur visite.   o Limiter vos déplacements, éviter les rassemblements o Limiter vos visites o    Geste 1 : Se laver les mains régulièrement.  Geste 2 : Se couvrir le nez et la bouche quand on tousse ou éternue.   Geste 3 : Se saluer sans se serrer la main, éviter les embrassades.  Geste 4 : Se moucher dans un mouchoir à usage unique, le jeter et se relaver les mains.  Geste 5 : Porter un masque uniquement si vous présentez des symptômes respiratoires.      Nous recommandons en outre de rester attentif aux informations provenant des autorités nationales de santé publique et des agences régionales de santé.  Aidez-vous des informations affichées dans la maternité. ;27 mars 2020 
0;covid-et-grossesse;An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal3 Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes;David A. Schwartz;https://www.groupedeveillecovid.fr/blog/2020/03/27/an-analysis-of-38-pregnant-women-with-covid-19-their-newborn-infants-and-maternal3-fetal-transmission-of-sars-cov-2-maternal-coronavirus-infections-and-pregnancy-outcomes-2/;25; Table 4. Characteristics of an additional 17 pregnant women with COVID-19 and their infants   Case and 1st author Case 1 Wang16 Cases 1 to 16 Zhang et al.17 Maternal age (years)  35 Varies from 24 to 34 years with mean of 29.3 ± 2.9  Gestational age at delivery  31 w Varies from 35 weeks 5 days up to 41 weeks with mean of 38.7 ± 1.4 Comorbid events Fetal distress Gestational diabetes (3), PROM (3), preterm delivery (3), uterine scarring (2), B-Lynch/compression suture procedure (2), severe preeclampsia (1),  fetal distress (1), fetal asphyxia (1), meconium staining (1), COVID-19 pneumonia (1) Maternal rt-PCR for SARS-CoV-2  Positive   Positive in all 16 women Symptom- to-delivery interval 13 days before delivery   Not stated C-section or vaginal C-s  C-s in all 16 women Birthweight 1830 g Varies from 2300 to 3750 grams with mean of 3139 g ± 437 Apgars at 1 & 5 mins 9, 10  Not stated Neonatal outcome Normal Bacterial pneumonia in 3 neonates, 1 preterm infant Neonatal rt-PCR for SARS-CoV-2   Neg  Viral testing results available for 10 of 16 neonates, all of whom were negative for infection  Abbreviations: PROM  premature rupture of membranes ;27 mars 2020 
0;covid-et-encologie;Managing patients with cancer during the COVID-19 pandemic: frontline experience from Wuhan;Mei and al;https://www.groupedeveillecovid.fr/blog/2020/05/06/managing-patients-with-cancer-during-the-covid-19-pandemic-frontline-experience-from-wuhan/;3;636 www.thelancet.com/oncology   Vol 21   May 2020chemotherapy protocol should be adjusted, the dose reduced, or both. The fatality rate was six (46·2%) of 13 patients with blood cancer and two (10·0%) of 20 patients with solid tumours in our centre. Patients with blood cancer were more predisposed to SARS-CoV-2 infection than were patients with solid tumours (in hospitalised patients, the rate of SARS-CoV-2 infection was ten [6·1%] of 165 patients with blood tumours and 14 [1·4%] of 1021 patients with solid tumours). The higher fatality rate in patients with blood cancer might be ascribed to aggressive chemotherapeutic protocols, agranulocytosis, and impaired immunity. Given the risk of infection and shortage of blood products, these patients should avoid intense chemotherapy or haematopoietic stem cell transplantation. Among the 33 patients with cancer with COVID-19 (˚gure 1), eight treated by targeted therapies (kinase inhibitors and proteasome inhibitors) and two receiving immune checkpoint inhibitors had more favourable outcomes than those treated with chemotherapy. With patients who are at home or visiting online clinics, chemotherapy-free alternatives involving oral or targeted drugsŠwhich do not require in-hospital administrationŠshould be given whenever possible. One patient tried to die by suicide after he became infected with SARS-CoV-2 following stem cell transplantation. Although his blood virus tests turned negative after an initial positive result, the long isolation and the pain due to graft-versus-host disease psychologically a˛ected the patient. Therefore, psychological intervention is extremely important for patients with COVID-19 who have experienced other issues, physically and mentally, apart from their primary disease.It is worth mentioning that telemedicine has an impor-tant role in the diagnosis and treatment of patients with cancer in home care. Our online clinic services cover video consultations, text-picture counselling, and medicine deliv-ery, among others. This approach substantially reduced people congregating in hospital. Patients with newly diag-nosed cancer or those on anti-tumour therapy should use internet or telephone services as the ˚rst choice to contact their doctors, refraining from going directly to hospital, to avoid infection. Doctors should comprehensively evaluate the condition of patients to give the most e˛ective or optimal treatments. Patients and their family members should be made aware that cooperating with their doctor and being compliant with the treatment prescribed will lead to the best outcomes. During this epidemic, we attended more than 80 000 patients online, including 2688 patients with cancer. By comparing the numbers of the patients who sought medical help online, we found that each of 24 oncologists who provided these services, on average, attended 19 patients online and 97 clinic visitors during the ˚rst 2 weeks before Jan 20. Conversely, during the 2 weeks after Jan 20, the number of online patients rose to 42 whereas the number of clinic visitors dropped to 36 (˚gure 2). We believe, in the future, telemedicine will be an important practicing mode for oncologists or other clinicians during pandemics.Between January and March, 2020, we witnessed the infection and deaths of a large number of people because of lack of protection, shortage of beds, and inadequate isolation. We should learn from our mistakes and stay alert. A well established public health system is essential for continuity of care during a massive epidemic. To prevent the epidemic from returning, we should be well informed about COVID-19, do early screening, protect our medical workers, properly equip our hospitals for both routine service and future crises and expand our services to internet platforms. As oncologists, we hope that society extends its compassion towards patients with cancer during the COVID-19 pandemic.Heng Mei, Xiaorong Dong, Yadan Wang, Liang Tang, *Yu Hu˜˚˛˝˙ˆˇTwo weeks after January 20Two weeks before January 20˜˚˛˝˙Figure ˚: Average number of online and clinic visitors per week per oncologistYu HuYu Hu;6 mai 2020 
0;covid-et-encologie;SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China;Jing Yu and al;https://www.groupedeveillecovid.fr/blog/2020/04/01/sars-cov-2-transmission-in-patients-with-cancer-at-a-tertiary-care-hospital-in-wuhan-china-2/;3;"www.thelancet.com/oncology   Vol 21   March 2020 337ƒJoint ˚rst authors⁄Joint senior authorsDepartment of Thoracic Oncology and Surgery (WLi, WW, JL, KX, CL, QA, WLu, HL, JH) and Department of Respiratory Disease (WG, RC, SL), China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First A˛liated Hospital of Guangzhou Medical University, Guangzhou 510120, China1 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; published online Jan 29. https://doi.org/10.1016/S0140-6736(20)30211-7.2 Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020; published online Jan 24. https://doi.org/10.1016/S0140-6736(20)30185-9.3 Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; published online Feb 3. DOI:10.1038/s41586-020-2012-7.4 Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A ˚rst step in understanding SARS pathogenesis. J Pathol 2004; 203: 631Œ37.5 Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol 2009; 10: 589Œ97.6 Li JY, Duan XF, Wang LP, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res 2014; 2014: 286170.7 Longbottom ER, Torrance HD, Owen HC, et al. Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways. Ann Surg 2016; 264: 370Œ77.8 Sica A, Massarotti M. Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun 2017; 85: 117Œ25.9 Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi 2019; 41: 19Œ28 (in Chinese).Should patients who are incarcerated on death row receive palliative cancer care?In modern society, it is accepted that individuals have the right to die with dignity. Since 1976, in the USA, people who are incarcerated have a limited constitutional right to health care, consistent with the Eighth Amendment. At present, there are more than 2600 incarcerated men and women in the USA who have been sentenced to death, most of whom have less than a high school diploma or High School Equivalency Certi˚cate (GED), and are disproportionately of minority racial or ethnic backgrounds (42% African-American representation on death row vs 13% African-American representation in the US census).1 The combination of poor health status, social determinants of health, and paucity of adequate care provided in correctional facilities is driving a public health emergency, which is endangering the North American incarcerated population. We can expect the prevalence and burden of chronic illness to rise concomitantly with the growth of the ageing population in US prisons.2 Data suggest that cancer is the leading cause of illness-related deaths in US state prisons.2 In the absence of reform, the mass incarceration trends observed over the past three decades will substantially widen disparities, adversely a˜ecting access to health care. As the US prison population ages, and with it the subpopulation of individuals sentenced to death, the burden of cancer can be expected to increase. This increase will be accompanied by the inevitable debate over the appropriate health care, both legally and morally, for those with end-stage cancer. This dilemma is bound to have a downstream e˜ect on patients with cancer who have been sentenced to death and can a˜ect the quality of palliative care provided in correctional facilities. In the community, a multidisciplinary team would manage the medical, mental health, and social service needs of a patient who chooses palliative care for a terminal diagnosis. But what of the patient who is sentenced to die by judicial execution? That any such person should receive a bene˚t of any sort, including the traditional last meal, is met with public protest and outrage. Such consternation will probably increase despite the fact that denying palliative care results in unnecessary su˜ering for the patient at no bene˚t to public safety.It is well established that professional ethics forbids health-care sta˜ from participating in any aspect of capital punishment. However, what of the incarcerated patient with cancer who is dying under the care of a physician with direct or indirect duties to the jurisdiction charged with judicial execution? What are the duties of the physician expected to provide palliative care to the incarcerated if the patient desires it? We argue that they are no di˜erent than those incumbent upon the physician and health-care sta˜ in the community. The accepted framework of medicoŒethical principles requires that oncology practitioners consider pain relief and other principles of palliative Burger/Phanie/Science Photo Library ";1 avril 2020 
0;covid-et-encologie;Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China;Liang W and al;https://www.groupedeveillecovid.fr/blog/2020/04/01/cancer-patients-in-sars-cov-2-infection-a-nationwide-analysis-in-china-3/;3;"www.thelancet.com/oncology   Vol 21   March 2020 337ƒJoint ˚rst authors⁄Joint senior authorsDepartment of Thoracic Oncology and Surgery (WLi, WW, JL, KX, CL, QA, WLu, HL, JH) and Department of Respiratory Disease (WG, RC, SL), China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First A˛liated Hospital of Guangzhou Medical University, Guangzhou 510120, China1 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; published online Jan 29. https://doi.org/10.1016/S0140-6736(20)30211-7.2 Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020; published online Jan 24. https://doi.org/10.1016/S0140-6736(20)30185-9.3 Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; published online Feb 3. DOI:10.1038/s41586-020-2012-7.4 Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A ˚rst step in understanding SARS pathogenesis. J Pathol 2004; 203: 631Œ37.5 Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol 2009; 10: 589Œ97.6 Li JY, Duan XF, Wang LP, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res 2014; 2014: 286170.7 Longbottom ER, Torrance HD, Owen HC, et al. Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways. Ann Surg 2016; 264: 370Œ77.8 Sica A, Massarotti M. Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun 2017; 85: 117Œ25.9 Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi 2019; 41: 19Œ28 (in Chinese).Should patients who are incarcerated on death row receive palliative cancer care?In modern society, it is accepted that individuals have the right to die with dignity. Since 1976, in the USA, people who are incarcerated have a limited constitutional right to health care, consistent with the Eighth Amendment. At present, there are more than 2600 incarcerated men and women in the USA who have been sentenced to death, most of whom have less than a high school diploma or High School Equivalency Certi˚cate (GED), and are disproportionately of minority racial or ethnic backgrounds (42% African-American representation on death row vs 13% African-American representation in the US census).1 The combination of poor health status, social determinants of health, and paucity of adequate care provided in correctional facilities is driving a public health emergency, which is endangering the North American incarcerated population. We can expect the prevalence and burden of chronic illness to rise concomitantly with the growth of the ageing population in US prisons.2 Data suggest that cancer is the leading cause of illness-related deaths in US state prisons.2 In the absence of reform, the mass incarceration trends observed over the past three decades will substantially widen disparities, adversely a˜ecting access to health care. As the US prison population ages, and with it the subpopulation of individuals sentenced to death, the burden of cancer can be expected to increase. This increase will be accompanied by the inevitable debate over the appropriate health care, both legally and morally, for those with end-stage cancer. This dilemma is bound to have a downstream e˜ect on patients with cancer who have been sentenced to death and can a˜ect the quality of palliative care provided in correctional facilities. In the community, a multidisciplinary team would manage the medical, mental health, and social service needs of a patient who chooses palliative care for a terminal diagnosis. But what of the patient who is sentenced to die by judicial execution? That any such person should receive a bene˚t of any sort, including the traditional last meal, is met with public protest and outrage. Such consternation will probably increase despite the fact that denying palliative care results in unnecessary su˜ering for the patient at no bene˚t to public safety.It is well established that professional ethics forbids health-care sta˜ from participating in any aspect of capital punishment. However, what of the incarcerated patient with cancer who is dying under the care of a physician with direct or indirect duties to the jurisdiction charged with judicial execution? What are the duties of the physician expected to provide palliative care to the incarcerated if the patient desires it? We argue that they are no di˜erent than those incumbent upon the physician and health-care sta˜ in the community. The accepted framework of medicoŒethical principles requires that oncology practitioners consider pain relief and other principles of palliative Burger/Phanie/Science Photo Library ";1 avril 2020 
0;covid-et-encologie;SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China;J Yu et al;https://www.groupedeveillecovid.fr/blog/2020/03/30/sars-cov-2-transmission-in-patients-with-cancer-at-a-tertiary-care-hospital-in-wuhan-china/;3;"thedataanalysis.DrsYuandOuyangcontributedequallyasco–firstauthors.DrsChuaandXiecontributedequallyasco–seniorauthors.Studyconceptanddesign:Allauthors.Acquisition,analysis,orinterpretationofdata:Allauthors.Draftingofthemanuscript:Yu,Chua.Criticalrevisionofthemanuscriptforimportantintellectualcontent:Yu,Ouyang,Xie.Statisticalanalysis:Yu,Chua.Administrative,technical,ormaterialsupport:Allauthors.Studysupervision:Yu,Chua,Xie.Funding/Support:DrChuaissupportedbytheNationalMedicalResearchCouncilClinician-ScientistAward(CSA/0027/2018).RoleoftheFunder/Sponsor:TheNationalMedicalResearchCouncilhadnoroleinthedesignandconductofthestudy;collection,management,analysis,andinterpretationofthedata;preparation,review,orapprovalofthemanuscript;anddecisiontosubmitthemanuscriptforpublication.ConflictofInterestDisclosures:Noconflictsarereported.AdditionalContributions:Wethankallthepatientswhoconsentedtothisstudy,andthefrontlinehealthcareprofessionalswhoareinvolvedinpatientcareduringthispandemic.1.ChenN,ZhouM,DongX,etal.Epidemiologicalandclinicalcharacteristicsof99casesof2019novelcoronaviruspneumoniainWuhan,China:adescriptivestudy.Lancet.2020;395(10223):507-513.doi:10.1016/S0140-6736(20)30211-72.WuYC,ChenCS,ChanYJ.TheoutbreakofCOVID-19:anoverview.JChinMedAssoc.2020;83(3):217-220.doi:10.1097/JCMA.00000000000002703.WangD,HuB,HuC,etal.Clinicalcharacteristicsof138hospitalizedpatientswith2019novelcoronavirus-infectedpneumoniainWuhan,China.JAMA.PublishedonlineFebruary7,2020.doi:10.1001/jama.2020.15854.KambojM,SepkowitzKA.Nosocomialinfectionsinpatientswithcancer.LancetOncol.2009;10(6):589-597.doi:10.1016/S1470-2045(09)70069-55.GuanWJ,NiZY,HuY,etal;ChinaMedicalTreatmentExpertGroupforCovid-19.Clinicalcharacteristicsofcoronavirusdisease2019inChina.NEnglJMed.PublishedonlineFebruary28,2020.doi:10.1056/NEJMoa2002032Table2.COVID-19PneumoniainPatientsWithNSCLCofDifferentAgeGroupsTreatedattheZhongnanHospitalofWuhanUniversityAge,yNo.(%)TotalNo.ofpatientswithNSCLC(n=228)PatientswithNSCLCwithCOVID-19(n=7)111(48.7)2of111(1.8)>60117(51.3)5of117(4.3)Abbreviations:COVID-19,2019novelcoronavirusdisease;NSCLC,non–smallcelllungcancer.Lettersjamaoncology.com(Reprinted)JAMAOncologyPublishedonlineMarch25,2020E3";30 mars 2020 
0;covid-et-pathologies-chroniques;Acute coronary syndromes during COVID-19;Serafina Valente and al;https://www.groupedeveillecovid.fr/blog/2020/05/26/acute-coronary-syndromes-during-covid-19/;3;"PatientsawaitingtheCOVID-19testresultmustbeconsideredaspossibleCOVID-19carriers,evenifasymptomatic;thus,theyshouldbeisolatedandmonitoredbydedicatedhealthcareprofessionals.Ifthetestispositive,thepatientsshouldbeadmittedtoCOVIDUnitsorequivalentwards.AsymptomaticpatientswithnegativeswabsshouldbeadmittedtocardiacICU.PatientswithnegativeswabandhighlysuggestivesymptomsforCOVID-19infectionshouldbeisolatedandundergoasecondswab;thedestinationdepartmentforthesubsequentadmissionistobedecidedonthebasisofthetestresults.Finally,inpatientshospitalizedinaCOVIDUnitshowingsignsandsymptomssuggestiveforSTEMI,theriskandbenefitsofapossiblecor-onaryrevascularizationshouldbeassessed,evaluatingthepatient™sclinicalconditionandcomorbiditiesandtheriskintransporttotheCathlab.Thrombolysiscouldbeconsideredasanalternativetopercutane-ouscoronaryintervention;11,12however,itshouldbeconsideredthatCOVID-19patients,especiallythosewithsevereconditions,areathighriskofhaemorrhagicanddisseminatedintravascularcoagulation.InthecaseofpatientswithsuspectedorconfirmedSARS-CoV-2,asanitizationoftheCathlabisnecessary,accordingtohospitalprotocols.Thecompleteindicationsforthemethodsofdressing/undressingofhealthcareprofessionalscanbefoundinspecificdocumentsoftheItalianSocietyofInterventionalCardiology(GISE)15andtheNationalHealthInstitute(ISS).17Low-andintermediate-riskNSTEMISincepatientswithlow-andintermediate-riskNSTEMIdonotneedimmediaterevascularization,18thestratificationtorevealCOVID-19patientsshouldbeperformedwiththesamemodalitiesbeforetheirtransfertotheCathlabortheiradmittancetotheCardiologyward,preferablyindedicatedareasoftheED.Regardingtheprotectivenor-mativeofhealthcareprofessionals,theindicationsarethesameasexplainedabove.WhilewaitingfortheSARS-CoV-2testresults,aproperriskassessmentshouldbecarriedouttoidentifypatientsneed-ingexpeditedangiographyandtofacilitateearlierdischarge.18Soonafterthetestresults,patientswithNSTEMIwithapositiveCOVID-19testshouldbeadmittedtoCOVIDUnitswithintheappro-priatecaresettings,dependingontheclinicalconditionandthethrom-boticandarrhythmicrisk,evaluatingtheriskŒbenefitratioderivingfromapossiblerevascularization.Conversely,patientswithNSTEMIwithanegativeCOVID-19testshouldfollowthestandardprotocolfortherapyandwillbeadmittedtotheCardiologydepartment.ConclusionsInthepresentglobalCOVID-19pandemic,acardiovascularemer-gencyisfacedwithbalancingtimelinessoftreatmentandthesafetyofotherpatientsandmedicalpersonnel.EachpatientreferredtotheEDordirectlytotheCathlabrequiresexclusionofCOVID-19infection,while,inthecaseswherethisisconfirmed,specificmeasuresshouldbeundertaken.Highprotectionlevelsofhealthcareworkersarerequired,duetothepotentialnecessityofperformingemergencyresuscitationmeasuresatanytimeduringtheprocedure.ThisdocumentprovidesasimpleandshortguidetoassistcliniciansinthemanagementofACSconsideringCOVID-19,basedonrecentworldwideevidenceandprotocolsofourcountry.ReferencesReferencesareavailableassupplementarymaterialatEuropeanHeartJournalonline.Matteo Cameli MD PhDDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena,Siena, Italy Corresponding Author: Departmentof Cardiovascular Diseases University of SienaViale Bracci 1, Siena, Italy+390577585377Email: matteo.cameli@yahoo.comFrancesca Anselmi MD Department of MedicalBiotechnologies, Division ofCardiology, University of Siena,Siena, ItalySerafina Valente MDDepartment of MedicalBiotechnologies, Division ofCardiology, University of Siena,Siena, ItalyCardioPulse3Downloaded from https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehaa457/5843749 by Universite de Strasbourg user on 26 May 2020";26 mai 2020 
0;covid-et-pathologies-chroniques;Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019;Cohorte de greffés cardiaques : 803 patients, dont 28 ont présenté une infection COVID-19 sur une période de 6 semaines (3,5%);https://www.groupedeveillecovid.fr/blog/2020/05/18/characteristics-and-outcomes-of-recipients-of-heart-transplant-with-coronavirus-disease-2019/;3;"11TangA,TongZD,WangHLetal.DetectionofnovelcoronavirusbyRT-PCRinstoolspecimenfromasymptomaticchild,China.EmergInfectDis2020;doi:10.3201/eid2606.200301.12HeY,WangZ,LiFetal.PublichealthmightbeendangeredbypossibleprolongeddischargeofSARS-CoV-2instool.JInfect2020;80:e18Ð9.13KupferschmidtK,CohenJ.WHOLaunchesGlobalMegatrialoftheFourMostPromisingCoronavirusTreatments.ScienceMagazine.https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments.ResearchletterJAC3of3Downloaded from https://academic.oup.com/jac/advance-article-abstract/doi/10.1093/jac/dkaa190/5837068 by guest on 17 May 2020";18 mai 2020 
0;covid-et-pathologies-chroniques;Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study;Cariou et al;https://www.groupedeveillecovid.fr/blog/2020/05/13/phenotypic-characteristics-and-prognosis-of-inpatients-with-covid-19-and-diabetes-the-coronado-study/;44;"DATA SHARING STATEMENT   What data will be made available (deidentified participant data, participant data with identifiers, data dictionary, or other specified data set): No sharing of participant data is allowed by our regulatory authorities. So far, French regulations have not validated deidentified data or avatar for data sharing. Our statement might be modified in case French law changes.  Whether additional, related documents will be available (eg, study protocol, statistical analysis plan, informed consent form) We will be happy to share study protocol, SAP and information document.  Ł When these data will be available (beginning and end date, or ﬁwith publicationﬂ, as applicable) Study protocol, SAP and information document will be made available with publication.  Data dictionary will be made available Summer 2020 (JULY 15th)  Ł Where the data will be made available (including complete URLs or email addresses if relevant); The CORONADO website is not active yet but we will give access to the scientific committee through our website, as soon as it is launched. Direct requests can be directed to PI (bertrand.cariou@univ-nantes.fr) or Chairman of the scientific committee (samy.hadjadj@univ-nantes.fr)  Ł By what access criteria data will be shared (including with whom, for what types of analyses, by what mechanism Œ eg, with or without investigator support, after approval of a proposal, with a signed data access agreement - or any additional restrictions). Our data-base is open for any collaborative work with priority to academic partnership. Any proposal for collaboration requires examination by the scientific committee and the sponsor (CHU Nantes). A structured application proposal for collaboration will be available on request. ";13 mai 2020 
0;covid-et-pathologies-chroniques;Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia e A systematic review, metaanalysis, and meta-regression;Ian Huang and al;https://www.groupedeveillecovid.fr/blog/2020/04/29/diabetes-mellitus-is-associated-with-increased-mortality-and-severity-of-disease-in-covid-19-pneumonia-e-a-systematic-review-metaanalysis-and-meta-regression/;9;"aclinicallyprovenproteaseinhibitor.Cell2020.https://doi.org/10.1016/j.cell.2020.02.052.[41]RossiGP,SangaV,BartonM.PotentialharmfuleffectsofdiscontinuingACE-inhibitorsandARBsinCOVID-19patients.Elife2020;9.https://doi.org/10.7554/eLife.57278.[42]FangL,KarakiulakisG,RothM.ArepatientswithhypertensionanddiabetesmellitusatincreasedriskforCOVID-19infection?LancetRespirMed2020;8:e21.https://doi.org/10.1016/S2213-2600(20)30116-8.[43]Roman™-P!erezM,Outeiri~no-IglesiasV,MoyaCM,SantistebanP,Gonz!alez-Mat™asLC,VigoE,etal.ActivationoftheGLP-1receptorbyliraglutidein-creasesACE2expression,reversingrightventriclehypertrophy,andimprovingtheproductionofSP-AandSP-Binthelungsoftype1diabetesrats.Endocrinology2015;156:3559e69.https://doi.org/10.1210/en.2014-1685.[44]GuptaR,MisraA.ContentiousissuesandevolvingconceptsintheclinicalpresentationandmanagementofpatientswithCOVID-19infectionwithreferencetouseoftherapeuticandotherdrugsusedinCo-morbiddiseases(Hypertension,diabetesetc).DiabetesMetabSyndrClinResRev2020;14:251e4.https://doi.org/10.1016/j.dsx.2020.03.012.[45]ImaiY,KubaK,RaoS,HuanY,GuoF,GuanB,etal.Angiotensin-convertingenzyme2protectsfromsevereacutelungfailure.Nature2005;436:112e6.https://doi.org/10.1038/nature03712.[46]AlGhatrifM,CingolaniO,LakattaEG.Thedilemmaofcoronavirusdisease2019,aging,andcardiovasculardisease:Insightsfromcardiovascularagingscience.JAMACardiol2020.https://doi.org/10.1001/jamacardio.2020.1329.[47]MaddaloniE,BuzzettiR.Covid-19anddiabetesmellitus:unveilingtheinteractionoftwopandemics.DiabetesMetabResRev2020:e33213321.https://doi.org/10.1002/dmrr.3321.[48]GeerlingsSE,HoepelmanAIM.Immunedysfunctioninpatientswithdiabetesmellitus(DM).FEMSImmunolMedMicrobiol1999;26:259e65.https://doi.org/10.1016/S0928-8244(99)00142-X.[49]MehtaP,McAuleyDF,BrownM,SanchezE,TattersallRS,MansonJJ.COVID-19:considercytokinestormsyndromesandimmunosuppression.Lancet2020;395:1033e4.https://doi.org/10.1016/S0140-6736(20)30628-0.I.Huangetal./Diabetes&MetabolicSyndrome:ClinicalResearch&Reviews14(2020)395e403403";29 avril 2020 
0;covid-et-pathologies-chroniques;Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms;Naveed Sattar and al;https://www.groupedeveillecovid.fr/blog/2020/04/28/obesity-a-risk-factor-for-severe-covid-19-infection-multiple-potential-mechanisms/;8;;28 avril 2020 
0;covid-et-pathologies-chroniques;Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab;Austin R. Morrison and al;https://www.groupedeveillecovid.fr/blog/2020/04/28/acute-hypertriglyceridemia-in-patients-with-covid-19-receiving-tocilizumab/;5;" This article is protected by copyright. All rights reserved. Accepted Article 7. Devaud JC, Berger MM, Pannatier A, et al. Hypertriglyceridemia: a potential side effect of propofol sedation in critical illness. Intensive Care Med. 2012 Dec;38(12):1990-8.  8. Devlin JW, Lau AK, Tanios MA. Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. Pharmacotherapy. 2005 Oct;25(10):1348-52.  9. Barrientos-Vega R, Mar Sánchez-Soria M, Morales-García C, Robas-Gómez A, Cuena-Boy R, Ayensa-Rincon A. Prolonged sedation of critically ill patients with midazolam or propofol: impact on weaning and costs. Crit Care Med. 1997 Jan;25(1):33-40.  10. Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 2012 Aug 20;13:138. Figure   ";28 avril 2020 
0;covid-et-pathologies-chroniques;Practical recommendations for the management of diabetes in patients with COVID-19;Marie‑Christine Copin and al;https://www.groupedeveillecovid.fr/blog/2020/04/25/practical-recommendations-for-the-management-of-diabetes-in-patients-with-covid-19/;3;di˜erent phenotypes? Intensive Care Med. https ://doi.org/10.1007/s0013 4-020-06033 -2 2. Beasley MB, Franks TJ, Galvin JR, Gochuico B, Travis WD (2002) Acute ˚brinous and organizing pneumonia: a histological pattern of lung injury and possible variant of di˜use alveolar damage. Arch Pathol Lab Med 126(9):1064Œ1070 3. Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J (2005) Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol 18(1):1Œ10 4. Wang Y, Li Y, Wang Q, Zhang L, Li J, Zhu C (2019) Acute ˚brinous and organizing pneumonia: a case report. Medicine (Baltimore) 98(8):e14537 5. López-Cuenca S, Morales-García S, Martín-Hita A, Frutos-Vivar F, Fernández-Segoviano P, Esteban A (2012) Severe acute respiratory failure secondary to acute ˚brinous and organizing pneumonia requiring mechanical ventilation: a case report and literature review. Respir Care 57(8):1337Œ1341;25 avril 2020 
0;covid-et-pathologies-chroniques;Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States;Bruce Bode and al;https://www.groupedeveillecovid.fr/blog/2020/04/23/6031/;17;"17  12 Ilyas R, Wallis R, Soilleux EJ, Townsend P, Zehnder D, Tan BK, et al. High glucose disrupts oligosaccharide recognition function via competitive inhibition: A potential mechanism for immune dysregulation in diabetes mellitus. Immunobiology. 2011;216:12631. 13 Price CL, Hassi HOSA, English NR, Blakemore AIF, Stagg AJ, Knight SC. Methylglyoxal modulates immune responses: relevance to diabetes. Journal of Cellular and Molecular Medicine. 2009;14:180615. 14 Geerlings SE, Hoepelman, AI. Immune dysfunction in patients with diabetes mellitus (DM). Pathogens and Disease. 1999;26:259-265 15 Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic Medicine. 2006;23:6238. 16 Liao Z. The Clinical Features of SARS Patients with Diabetes or Secondary Hyperglycemia [Internet]. The Clinical Features of SARS Patients with Diabetes or Secondary Hyperglycemia | American Diabetes Association. 1970 [cited 2020Apr12]. Available from: https://professional.diabetes.org/abstract/clinical-features-sars-patients-diabetes-or-secondary-hyperglycemia 17 Yang J-K, Lin S-S, Ji X-J, Guo L-M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetologica. 2009;47:1939. 18 American Diabetes Association. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2020 [Internet]. Diabetes Care. American Diabetes Association; 2020 [cited 2020Apr12]. Available from: https://care.diabetesjournals.org/content/43/Supplement_1/S193 19 Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304377. doi:10.1007/s00134-017-4683-6  20 Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med. 2012;40(12):32513276. doi:10.1097/CCM.0b013e3182653269    ";23 avril 2020 
0;covid-et-pathologies-chroniques;Finding Ways to Reduce Coronavirus Exposure During Dialysis;Rita Rubin;https://www.groupedeveillecovid.fr/blog/2020/04/20/finding-ways-to-reduce-coronavirus-exposure-during-dialysis/;3;Thecollaboration’sgoalistohelp“maintaincontinuityofcarefordialysispatientsbycreatingisolationcohortcapacitythatcanbeaccessedbythesedialysisproviders,ifneeded,”FreseniusChiefMedicalOfficerRobertKossmann,MD,saidinanemail.Incontrast,NorthwestKidneyCen-ters,whichhas4facilitieswithoutaprivateroom,decidedagainstdesignatingcentersforpatientswithCOVID-19andPUIs.“Wehavediscusseditthoroughlyandhaveback-upplansalongthoselinesifneeded,”Watnicksaid,explainingthatherorganiza-tionwouldrathernotshiftpatientstodif-ferent,unfamiliarcenters.“Thedialysisclinicisapatient’shome,sowearetryingtomain-tainthatparadigm.”NoPlaceLikeHomeAmid-MarchTwitterchathostedbytheASNandNephJC,aTwitter-basedjournalclub,touchedonOttawaHospital’splantocreateaCOVID-19–onlydialysisunit.Theunitwouldoccupy6roomscurrentlydedi-catedtotrainingpatientshowtodialyzeathome.LocatedwithintheOntario,Canada,hospital’soutpatientdialysiscenter,theunitwouldaccommodate36patientseachweek.TwoweeksaftertheTwitterchat,though,theplanhadfallenthrough,UniversityofOt-tawanephrologistSwapnilHiremath,MD,MPH,saidinaninterview.“Givenongoingcon-cerns[aboutCOVID-19],wedecidedthatthehomedialysistrainingprogramshouldnotbeshutdown,”heexplained.FewpeoplewithESRDdialyzeathome.Amongthosewhodo,thevastmajorityaretreatedwithperitonealdialy-sis,whichusestheabdominalcavitylininginsteadofahemodialysismachinetofilterblood.Attheendof2017,onlyabout7%ofpeoplewithESRDweretreatedwithperito-nealdialysis,while63%wereundergoinghemodialysis—only2%ofthemathome,accordingtotheUSRDS.ButtheCOVID-19pandemichasheight-enedinterestinhomedialysis,Kligersaid,addingthathisinstitutionisencouragingpeoplenewtodialysistoconsiderlearninghowtodoitathome.FewerHours?Dialysisorganizationshaveconsideredtem-porarilyreducingthenumberofhourspa-tientsdialyzeeachweekduringthepan-demic,whichwouldlimittheirpotentialexposuretoCOVID-19andincreasedialysiscenters’capacity.“Itwon’tbeoptimal,butwehopeitwouldprovideenoughdialysisforpeopletoatleastcontinuetobewithusuntilwecanprovidefulltreatmentsagain,”Watnicksaid,notingthatonaverage,treatmentsessionsarelongerathercentersthanatotherUSdi-alysisfacilities.Dialysiscentersmighteventuallyhavenochoicebuttoshortenordecreasetreat-mentsessions,Silberzweigsaid:“Depend-ingonhow[thepandemic]progresses,wemayneedtoresorttoextrememeasureslikethat.”Noteverypatientwouldbeacandidateforreducedtreatmenthours,henoted,becausesomeofthembuildupexcessivefluidbetweenregulartreat-ments,whichcancauserespiratoryandcardiacproblems.However,Silberzweigemphasized,forallpatientswithESRD,thepotentialharmofdialyzingfewerhoursperweekisnotasgreatasthatofCOVID-19.Fortunately,Watnicksaid,COVID-19fearshavenotstoppedpatientsfromgettingtreated.Theytellher,“Wefeelsafercomingtoyourdialysisfacilitythangoingoutinthecommunitytoourdoctorappointments.”Note:Sourcereferencesareavailablethroughembeddedhyperlinksinthearticletextonline.News&Analysisjama.com(Reprinted)JAMAPublishedonlineApril16,2020E3©2020AmericanMedicalAssociation.Allrightsreserved.;20 avril 2020 
0;covid-et-pathologies-chroniques;Réponses rapides dans le cadre du COVID-19 – Continuité de la prise en charge des patients atteints d’hépatites virales chroniques;null;https://www.groupedeveillecovid.fr/blog/2020/04/16/reponses-rapides-cadre-covid-19-continuite-de-prise-charge-patients-atteints-dhepatites-virales-chroniques/;13;" HAS Réponses rapides dans le cadre du COVID-19 - Continuité de l  avril 2020   13 Méthode    La méthode retenue pour cette réponse rapide est basée sur une synthèse narrative des données   disponibles les plus pertinentes, les recommandations nationales et internationales, ainsi que sur une consultation des parties prenantes (par voie électronique le 3 avril 2020).  Ce document a été élaboré collégialement entre la Haute Autorité de santé et des experts désignés par let a été relu par la SPILF, la SFPT et le CMG et ses différentes composantes.  Validation par le collège de la HAS en date du 8 avril 2020.  Liste des participants Haute Autorité de santé : Mme Karine Petitprez, chef de projet, SBPP Conseils Nationaux Professionnels et Sociétés savantes :  Rédacteurs Nathalie GANNE-CARRIE, hépatologue (AFEF) ; Hélène FONTAINE, hépatologue (AFEF) ; Vincent LEROY, hépatologue (AFEF) ; Marc BOURLIERE, hépatologue (AFEF) ;Florian LEMAITRE, pharma-cologue (SFPT)  Relecteurs Victor De Ledinghen, hépatologue (AFEF) ; Patrick Delasalle, hépatologue (CNP HGE) ; Christophe Bureau, hépatologue (AFEF) ; Guillaume Conort, médecin généraliste (CMG) ; Emile Escourrou, mé-decin généraliste (CMG) ; Matthieu Grégoire, pharmacologue (SFPT) ; Rodolphe Garraffo, pharmaco-logue (SFPT)  Associations  TRT-5-CHV : Marianne Lhenaff, Carole Damien, Mélanie Jaudon et Christophe Rouquette SOS hépatites : Frédéric Chaffrais, Pascal Mélin  Cette réponse rapide élaborée sur la base des connaissances disponibles à la date de publica-. Ces réponses rapides sont fondées sur ce qui apparaît souhaitable ou nécessaire au moment en équipements de protection individuelle.     © Haute Autorité de santé   avril 2020         Réponses rapides dans le cadre du COVID-19 - Continuité de la niques, méthode de réponse rapide, 8 avril 2020 Toutes nos publications sont téléchargeables sur www.has-sante.fr  ";16 avril 2020 
0;covid-et-pediatrie;The intriguing features of COVID-19 in children and its impact on the pandemic;Marco Aurélio Palazzi Safadi;https://www.groupedeveillecovid.fr/blog/2020/04/22/the-intriguing-features-of-covid-19-in-children-and-its-impact-on-the-pandemic/;4;"ARTICLE IN PRESS+Model4 Safadi MAhttp://dx.doi.org/10.1001/jama.2020.2648 [epub ahead ofprint].9. CDC COVID-19 Response Team. Severe outcomes among patientswith coronavirus disease 2019 (COVID-19) ---- United States,February 12---March 16, 2020. MWR Morb Mortal Wkly Rep.2020;69:343---6.10. Epicentro --- Istituto Superiore di Sanità. Characteristicsof COVID-19 patients dying in Italy; 2020. Available from:https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-analysis-of-deaths [cited 02.04.20].11. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al.SARS-CoV-2 infection in children. N Engl J Med. 2020,http://dx.doi.org/10.1056/NEJMc2005073 [epub ahead ofprint].12. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correla-tion of chest CT and RT-PCR testing in coronavirus disease 2019(COVID-19) in China: a report of 1014 cases. Radiology. 2020,http://dx.doi.org/10.1148/radiol.2020200642 [epub ahead ofprint].13. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z. Epidemio-logical characteristics of 2143 pediatric patients with2019 coronavirus disease in China. Pediatrics. 2020,http://dx.doi.org/10.1542/peds.2020-0702 [epub aheadof print].14. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinicaland epidemiological features of 36 children with coro-navirus disease 2019 (COVID-19) in Zhejiang, China: anobservational cohort study. Lancet Infect Dis. 2020 Mar 25,http://dx.doi.org/10.1016/S1473-3099(20)30198-5. pii:S1473-3099(20)30198-5 [epub ahead of print].15. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest.2020, http://dx.doi.org/10.1172/JCI137647, pii:137647 [epubahead of print].16. Brodin P. Why is COVID-19 so mild in children? Acta Paedi-atr. 2020, http://dx.doi.org/10.1111/apa.15271 [epub aheadof print].17. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding ofCOVID-19 based on current evidence. J Med Virol. 2020,http://dx.doi.org/10.1002/jmv.25722 [epub ahead of print].18. Rudolph M, McArthur MA, Barnes RS, Magder LS, Chen WH, SzteinMB. Differences between pediatric and adult T cell responsesto in vitro staphylococcal enterotoxin B stimulation. FrontImmunol. 2018;9:498.19. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor:molecular mechanisms and potential therapeutic target. Inten-sive Care Med. 2020;46:586---90.20. Zhu H, Wang L, Fang C, Peng S, Zhang L, Chang G, et al. Clin-ical analysis of 10 neonates born to mothers with 2019-nCoVpneumonia. Transl Pediatr. 2020;9:51---60.21. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al.Clinical characteristics and intrauterine vertical transmissionpotential of COVID-19 infection in nine pregnant women: aretrospective review of medical records. Lancet. 2020;395:809---15.22. Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, et al. Antibodiesin infants born to mothers with COVID-19 pneumonia. JAMA.2020, http://dx.doi.org/10.1001/jama.2020.4861 [epub aheadof print].23. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, et al. Possible verticaltransmission of SARS-CoV-2 from an infected mother to her new-born. JAMA. 2020, http://dx.doi.org/10.1001/jama.2020.4621[epub ahead of print].24. Brazilian Society of Pediatrics (SBP). O aleitamentomaterno nos tempos de COVID-19!; 2020. Available from:https://www.sbp.com.br/ﬁleadmin/user upload/22393c-Notade Alerta sobe Aleitam Materno nos Tempos COVID-19.pdf[cited 31.03.20].25. World Health Organization (WHO). Breast feeding advice duringCOVID-19 pandemic; 2020. Available from: http://www.emro.who.int/nutrition/nutrition-infocus/breastfeeding-advice-during-covid-19-outbreak.html [cited 31.03.20].26. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al.SARS-CoV-2 viral load in upper respiratory specimens of infectedpatients. N Engl J Med. 2020;382:1177---9.27. Wölfel R, Corman VM, Guggemos W, Seilmaier M, ZangeS, Müleer MA, et al. Clinical presentation and virologicalassessment of hospitalized cases of coronavirus disease 2019in a travel-associated transmission cluster. MedRxiv. 2020,http://dx.doi.org/10.1101/2020.03.05.20030502.28. Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M, et al.Viral dynamics in mild and severe cases of COVID-19. LancetInfect Dis. 2020, http://dx.doi.org/10.1016/S1473-3099(20).pii:S1473-3099(20)30232-2 [epub ahead of print].29. Kam K, Yung CF, Cui L, Pin RL, Mak TM, Maiwald M,et al. A well infant with coronavirus disease 2019(COVID-19) with high viral load. Clin Infect Dis. 2020,http://dx.doi.org/10.1093/cid/ciaa201, pii:ciaa201 [epubahead of print].30. Tang A, Tong ZD, Wang HL, Dai YX, Li KF, Liu JN, et al.Detection of novel coronavirus by RT-PCR in stool specimenfrom asymptomatic child, China. Emerg Infect Dis. 2020;26,http://dx.doi.org/10.3201/eid2606.200301 [epub ahead ofprint].31. Zhang T, Cui X, Zhao X, Wang J, Zheng J, Zheng G, et al.Detectable SARS-CoV-2 viral RNA in feces of three children dur-ing recovery period of COVID-19 Pneumonia, March 2020. J MedVirol. 2020, http://dx.doi.org/10.1002/jmv.25795 [epub aheadof print].32. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiol-ogy and transmission of COVID-19 in Shenzhen China: analysisof 391 cases and 1286 of their close contacts. MedRxiv. 2020,http://dx.doi.org/10.1101/2020.03.03.20028423.33. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, GarryRF. The proximal origin of SARS-CoV-2. Nat Med. 2020,http://dx.doi.org/10.1038/s41591-020-0820-9.34. Zimmermann P, Curtis N. Coronavirus infections in chil-dren including COVID-19: an overview of the epidemiol-ogy, clinical features, diagnosis, treatment and preven-tion options in children. Pediatr Infect Dis J. 2020,http://dx.doi.org/10.1097/INF.0000000000002660 [epub aheadof print].35. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirusdisease 2019 (COVID-19). Drug Discov Ther. 2020;14:58---60.36. Lurie N, Saville M, Hatchett R, Halton J. DevelopingCovid-19 vaccines at pandemic speed. N Engl J Med.2020, http://dx.doi.org/10.1056/NEJMp2005630 [epub aheadof print].";22 avril 2020 
0;covid-et-pediatrie;FECAL-ORAL TRANSMISSION OF SARS-COV-2 IN CHILDREN;Daniele Donà and al;https://www.groupedeveillecovid.fr/blog/2020/04/22/fecal-oral-transmission-of-sars-cov-2-in-children/;2;"Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.Donà et al The Pediatric Infectious Disease Journal Ł Volume XX, Number XX, XXX XXX2 | www.pidj.com © 2020 Wolters Kluwer Health, Inc. All rights reserved.Droplets are the main human-to-human mechanism of transmission of SARS-CoV-2, but fecal shedding with environ-mental contamination may play an important role in viral spread. As pointed out by Li et al,12 there is a great number of infec-tions not being documented, especially in paucisymptomatic or asymptomatic individuals, which may have helped the fast dif-fusion of the virus.12 The clinical pattern of disease presentation among children may have facilitated viral dissemination. Moreo-ver, there is evidence supporting viral viability in environmental settings that may predispose fecal-oral transmission, with recent evidence supporting that SARS-CoV-2 can remain viable in aero-sols up to 3 hours, and for 72 hours on solid surfaces, similarly to SARS-CoV.13Not only the importance of correct hand hygiene should be encouraged by every mean, but severe measures must also be observed handling the feces of infected patients, and sewage from hospitals requires proper disinfection.Current evidence brings concerns on excluding SARS-CoV-2 infection by single time point nasopharyngeal swabs, with sensitivity being dependent on the test™s characteristics and tech-nique of collection of the samples, with increasing data hinting at fecal transmission as an important alternative route.CONCLUSIONSSince gastrointestinal symptoms seem to be more frequently reported in children than adults, and in view of current evidence of fecal shedding, there are implications for every child being admit-ted or home-isolated, and for household contacts. Indeed, rectal swabs should be considered especially in children for diagnosis as well as to better de˚ne the duration of isolation, along with ˚ndings from nasopharyngeal swabs.Further evidence on gastrointestinal involvement and excretion of SARS-CoV-2 in stools is necessary to con˚rm fecal viral loads regardless of enteric symptoms, and to better explore viral RNA detection in the early incubation or late convalescence stages.A negativity in both nasopharyngeal and stool samples might be considered as a standard requirement for cessation of mandatory isolation, especially in those settings where there is a risk of infecting vulnerable populations (eg, retirement homes).ACKNOWLEDGMENTSAll authors have made substantial contributions to the conception, design, collection, and interpretation of data for this article, drafted the manuscript, revised it critically for content, and approved the ˜nal version.REFERENCES 1. Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19 an overview of the epidemiology, clinical features, diagnosis, treat-ment and prevention options in children. Pediatr Infect Dis J. 2020;XX:00Œ00. 2. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020. https://doi.org/10.1038/s41591-020-0817-4  3. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol. 2020;5:335Œ337. 4. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9:386Œ389. 5. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020 Mar 11. doi: 10.1001/jama.2020.3786. [Epub ahead of print] 6. Zhang J-F, Yan K, Ye H-H, et al. SARS-CoV-2 turned positive in a discharged patient with COVID-19 arouses concern regarding the present standard for discharge. Int J Infect Dis. 2020 Mar 18. pii: S1201-9712(20)30126-0. doi: 10.1016/j.ijid.2020.03.007. [Epub ahead of print] 7. Holshue ML, DeBolt C, Lindquist S, et al.; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382:929Œ936. 8. Zhang J, Wang S, Xue Y. Fecal specimen diagnosis 2019 Novel Coronavirus-Infected Pneumonia. J Med Virol. 2020 Mar 3. doi: 10.1002/jmv.25742. [Epub ahead of print] 9. He Y, Wang Z, Li F, et al. Public health might be endangered by possible pro-longed discharge of SARS-CoV-2 in stool. J infect. 2020 Mar 5. pii: S0163-4453(20)30111-0. doi: 10.1016/j.jinf.2020.02.031. [Epub ahead of print] 10. Park JY, Han MS, Park KU, et al. First pediatric case of Coronavirus Disease 2019 in Korea. J Korean Med Sci. 2020;35:e124.  11. Tang A, Tong Z-D, Wang H-L, et al. Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child, China. Emerg Infect Dis. 2020;26. 12. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science. 2020 Mar 16. pii: eabb3221. doi: 10.1126/science.abb3221. [Epub ahead of print]  13. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020 Mar 17. doi: 10.1056/NEJMc2004973. [Epub ahead of print]TABLE 1. Evidence of SARS-CoV-2 Detection in Stools and Rectal Swabs in Adults and ChildrenCountryPatientsSymptomsStool Sample  (RT-PCR)Live Virus  Detection (Electron  Microscopy)Rectal Swab  (RT-PCR)Xu et al2China10 children (2 months to 15 years)Non-speci˜c:FeverRespiratoryGastrointestinal (3 pts), asymptomatic (1 pt).ŠŠ8 positive (max.positivity 13 days after  discharge)Zhang et al4China16 adultsŠŠŠ10 positiveWang et al5China1070 specimens in 205 adultsRespiratory and/or gastrointestinal44/153 samples positive2 ˜ndings (no gastrointestinal symptoms)ŠZhang et al6China1 adultAsymptomatic after dischargePositive (10 days after discharge)ŠŠHolshue et al7US1 adultFeverPositive (until 7 days from onset)ŠŠRespiratoryGastrointestinalHe et al9China1 newbornGastrointestinalŠŠPositive after dischargePark et al10Korea1 child (10 years)FeverPositive (until 17 days from onset)ŠŠTang et al11China1 childAsymptomaticPositive (until 17 days from onset)ŠŠ";22 avril 2020 
0;covid-et-pediatrie;COVID-19, school closures, and child poverty: a social crisis in the making;et al;https://www.groupedeveillecovid.fr/blog/2020/04/17/covid-19-school-closures-and-child-poverty-a-social-crisis-in-the-making/;2;"2 www.thelancet.com/public-health   Published online April 7, 2020   https://doi.org/10.1016/S2468-2667(20)30084-0the pandemic subsides. At the local level, an adequate response must include targeted education and material support for children from low-income households to begin to close the learning gap that is likely to have occurred. From a policy perspective, legislators should consider providing regular income support for households with children during the impending economic crisis to prevent a deepening and broadening of child poverty. Without such action, the current health crisis could become a social crisis that will have long-lasting consequences for children in low-income families.We declare no competing interests.Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.*Wim Van Lancker, Zachary Parolinwim.vanlancker@kuleuven.beCentre for Sociological Research, University of Leuven, B-3000 Leuven, Belgium (WVL); and Center on Poverty and Social Policy, Columbia University, New York, NY, USA (ZP)1 Cohen J, Kupferschmidt K. Countries test tactics in ‚war™ against COVID-19. Science 2020; 367: 1287Œ88.2 Schwartz AE, Rothbart MW. Let them eat lunch: the impact of universal free meals on student performance. J Policy Anal Manage 2019; published online Oct 10. DOI:10.1002/pam.22175.3 Bitler MP, Seifoddini A. Health impacts of food assistance: evidence from the United States. Annu Rev Resour Economics 2019; 11: 261Œ87.4 United States Department of Agriculture. Food security in the United States. https://www.ers.usda.gov/data-products/food-security-in-the-united-states/ (accessed March 25, 2020).5 Alexander KL, Entwisle DR, Olson LS. Lasting consequences of the summer learning gap. Am Sociol Rev 2007; 72: 167Œ80.6 Cooper H, Nye B, Charlton K, Lindsay J, Greathouse S. The e˚ects of summer vacation on achievement test scores: a narrative and meta-analytic review. Rev Educ Res 1996; 66: 227Œ68.7 Morgan K, Melendez-Torres GJ, Bond A, et al. Socio-economic inequalities in adolescent summer holiday experiences, and mental wellbeing on return to school: analysis of the school health research network/health behaviour in school-aged children survey in Wales. Int J Environ Res Public Health 2019; 16: 1107.8 Guio AC, Gordon D, Marlier E, Najera H, Pomati M. Towards an EU measure of child deprivation. Child Indic Res 2018; 11: 835Œ60.9 National Center for Homeless Education. Federal Data Summary. School Year 2015Œ16 through 2017Œ18. 2020. https://nche.ed.gov/wp-content/uploads/2020/01/Federal-Data-Summary-SY-15.16-to-17.18-Published-1.30.2020.pdf (accessed April 3, 2020).10 Cantillon B, Chzhen Y, Handa S, Nolan B. Children of austerity. Impact of the great recession on child poverty in rich countries. New York: UNICEF, Oxford University Press, 2017. https://www.unicef-irc.org/publications/pdf/Children_of_austerity.pdf (accessed April 3, 2020).";17 avril 2020 
0;covid-et-pediatrie;Delayed access or provision of care in Italy resulting from fear of COVID-19;et al;https://www.groupedeveillecovid.fr/blog/2020/04/17/delayed-access-or-provision-of-care-in-italy-resulting-from-fear-of-covid-19/;2;"2 www.thelancet.com/child-adolescent   Published online April 9, 2020   https://doi.org/10.1016/S2352-4642(20)30108-5Institute for Maternal and Child Health Istituto di Ricovero e Cura a Carattere Scienti˚co Burlo Garofolo, Trieste, Italy (ML, EB); Department of Medicine, Surgery and Health Science, Department of Pediatrics, University of Trieste, Trieste, Italy (EB); Azienda Ospedaliera di Rilievo Nazionale Santobono Pausillipon, Napoli, Italy (AA); Department of Pediatrics, Santa Maria delle Croci Hospital, Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy (FM); Department of Pediatrics, Emergency Unit Regional Hospital ﬁGiovanni XXIIIﬂ, Bari, Italy (FC); and Azienda Ospedaliera per l™Emergenza Cannizzaro, Catania, Italy (GT)1 Istituto Superiore di Sanità. Epidemia COVID-19. April 2, 2020. https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_2-aprile-2020.pdf (accessed April 6, 2020).2 Dong Y, Mo X, Hu Y, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020; published online March 16. DOI:10.1542/peds.2020-0702.3 Chang HJ, Huang N, Lee CH, Hsu YJ, Hsieh CJ, Chou YJ. The impact of the SARS epidemic on the utilization of medical services: SARS and the fear of SARS. Am J Public Health 2004; 94: 562Œ64.4 Sokol DK. Virulent epidemics and scope of healthcare workers™ duty of care. Emerg Infect Dis 2006; 12: 1238Œ41.5 Voo TC, Capps B. In˛uenza pandemic and the duties of healthcare professionals. Singapore Med J 2010; 51: 275Œ81.presentation (eg, diabetes) that did not justify a diagnostic test according to the national criteria. Notably, no death occurred in the same hospitals during the same period in 2019, and the total yearly number of paediatric deaths in these hospitals ranges from zero to three.These cases are clearly a small sample compared with the overall number of paediatric visits recorded in the five hospitals during this week (12 [2%] of 502). However, since delay in access to care was not monitored systematically, this small case series might under-estimate the problem. We believe that further monitoring of access to routine clinical care is needed during the COVID-19 pandemic. There is a need to prevent delays in accessing hospital care and to increase provision of high-quality coordinated care by health-care providers. Both of these aspects should be considered as part of the overall public health impact of the COVID-19 pandemic, as evident in other epidemics,3,4 and must be adequately monitored.Both the general population and health-care workers need clear guidance and information. Speci˚cally, parents should be made fully aware that the risks of delayed access to hospital care for emergency conditions can be much higher than those posed by COVID-19. Specific duties and obligations of different types of health-care professionals should be clearly de˚ned, taking into consideration the risk level of the working environment, the health-care worker™s specialty, the probable harms and bene˚ts of treatment, and competing obligations deriving from workers™ multiple roles.4,5We obtained verbal consent from parents and caregivers of all patients reported here. We declare no competing interests. ML analysed the data and drafted the manuscript. All authors provided the data, and revised and approved the manuscript.*Marzia Lazzerini, Egidio Barbi, Andrea Apicella, Federico Marchetti, Fabio Cardinale, Gianluca Trobiamarzia.lazzerini@burlo.trieste.it";17 avril 2020 
0;covid-et-pediatrie;Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn;L Dong et al;https://www.groupedeveillecovid.fr/blog/2020/03/30/possible-vertical-transmission-of-sars-cov-2-from-an-infected-mother-to-her-newborn/;3;"Criticalrevisionofthemanuscriptforimportantintellectualcontent:Zhu,Wang,Liu,Yang.Statisticalanalysis:Dong,Tian,He,Liu.Obtainedfunding:Zhu,Wang,Liu,Yang.Supervision:Zhu,Yang.ConflictofInterestDisclosures:Nonereported.Funding/Support:ThisworkwassupportedbytheChongqingKeytechnologyandapplicationdemonstrationofmedicalimagingdepthintelligentdiagnosticplatform(cstc2018jszx-cyztzxX0017),theNationalKeyResearchandDevelopmentProject(2018YFC1002804,2016YFC1000600),andtheNationalNaturalScienceFoundationofChina(No.81771618andNo.81801524).RoleoftheFunder/Sponsor:Thefundershadnoroleinthedesignandconductofthestudy;collection,management,analysis,andinterpretationofthedata;preparation,review,orapprovalofthemanuscript;anddecisiontosubmitthemanuscriptforpublication.AdditionalContributions:Wethankthefamilymemberswhowereinvolvedinthisstudyandwethankthepatientforgrantingpermissiontopublishthisinformation.1.WangW,XuY,GaoR,etal.DetectionofSARS-CoV-2indifferenttypesofclinicalspecimens.JAMA.PublishedMarch11,2020.doi:10.1001/jama.2020.37862.WooPC,LauSK,WongBH,etal.Detectionofspecificantibodiestosevereacuterespiratorysyndrome(SARS)coronavirusnucleocapsidproteinforserodiagnosisofSARScoronaviruspneumonia.JClinMicrobiol.2004;42(5):2306-2309.doi:10.1128/JCM.42.5.2306-2309.20043.XuW,LiJ,HeX,etal.ThediagnosticvalueofjointdetectionofserumIgMandIgGantibodiesto2019-nCoVin2019-nCoVinfection.ChineseJLabMed.2020;43(00):E012-E012.doi:10.3760/cma.j.cn114452-20200223-001094.ChenH,GuoJ,WangC,etal.ClinicalcharacteristicsandintrauterineverticaltransmissionpotentialofCOVID-19infectioninninepregnantwomen:aretrospectivereviewofmedicalrecords.Lancet.2020;395(10226):809-815.doi:10.1016/S0140-6736(20)30360-3Lettersjama.com(Reprinted)JAMAPublishedonlineMarch26,2020E3©2020AmericanMedicalAssociation.Allrightsreserved.";30 mars 2020 
0;covid-et-pediatrie;Antibodies in Infants Born to Mothers With COVID-19 Pneumonia;H Zeng et al;https://www.groupedeveillecovid.fr/blog/2020/03/30/antibodies-in-infants-born-to-mothers-with-covid-19-pneumonia/;2;"byRT-PCRinanyoftheirnewborns.However,virus-specificantibodiesweredetectedinneonatalbloodserasamples.TheIgGconcentrationswereelevatedininfants.IgGispas-sivelytransferredacrosstheplacentafrommothertofetusbeginningattheendofthesecondtrimesterandreacheshighlevelsatthetimeofbirth.However,IgM,whichwasdetectedininfants,isnotusuallytransferredfrommothertofetusbecauseofitslargermacromolecularstructure.InastudyofmotherswithSARS,theplacentasofwomenwhowereconvalescingfromSARS-CoVinfectioninthethirdtri-mesterofpregnancyhadabnormalweightsandpathology.Whethertheplacentasofwomeninthisstudyweredamagedandabnormalisunknown.Alternatively,IgMcouldhavebeenproducedbytheinfantiftheviruscrossedtheplacenta.Thisstudyislimitedbythesmallsamplesize,lackofcordblood,amnioticfluid,andbreastmilkandbyincompletein-formationontheoutcomeoftheinfants.ThesefindingsareimportantforunderstandingtheserologicalcharacteristicsofinfantswhosemothersareinfectedwithSARS-CoV-andfur-therstudyisnecessary.HuiZeng,MDChenXu,BSJunliFan,MDYuetingTang,PhDQiaolingDeng,MDWeiZhang,MD,PhDXinghuaLong,MD,PhDAuthorAffiliations:DepartmentofLaboratoryMedicine,ZhongnanHospitalofWuhanUniversity,Wuhan,China(Zeng,Xu,Fan,Tang,Deng,Long);DepartmentofGynaecologyandObstetrics,ZhongnanHospitalofWuhanUniversity,Wuhan,China(Zhang).CorrespondingAuthors:XinghuaLong,MD,PhD(zhoulongxinghua@qq.com)andWeiZhang,MD,PhD(zw6676@163.com),ZhongnanHospitalofWuhanUniversity,169DonghuRd,Wuhan,China.PublishedOnline:March26,2020.doi:10.1001/jama.2020.4861AuthorContributions:DrsLongandZhanghadfullaccesstoallthedatainthestudyandtakeresponsibilityfortheintegrityofthedataandaccuracyofthedataanalysis.DrZengandMsXucontributedequallytothestudy.Conceptanddesign:Zeng,Xu,Long.Acquisition,analysis,orinterpretationofdata:Fan,Tang,Deng,Zhang.Draftingofthemanuscript:Zeng,Xu,Long.Criticalrevisionofthemanuscriptforimportantintellectualcontent:Fang,Tang,Deng,Zhang.Statisticalanalysis:Zeng,Xu,Fan,Tang,Deng.Obtainedfunding:Long.Supervision:Zhang.ConflictofInterestDisclosures:Nonereported.Funding/Support:Thisstudywassupportedbygrants81272372fromtheNationalNaturalScienceFoundationofChinaandznpy2016033fromZhongnanHospitalofWuhanUniversityScience,Technology,andInnovationSeedFund.RoleoftheFunder/Sponsor:Thesponsorshadnoroleinthedesignandconductofthestudy;collection,management,analysis,andinterpretationofthedata;preparation,review,orapprovalofthemanuscript;anddecisiontosubmitthemanuscriptforpublication.1.ChinaNHC.NewCoronavirusPneumoniaPreventionandControlProtocol.7thed.NationalHealthCommissionofthePeople’sRepublicofChina;2020.AccessedMarch4,2020.http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf2.ChenH,GuoJ,WangC,etal.ClinicalcharacteristicsandintrauterineverticaltransmissionpotentialofCOVID-19infectioninninepregnantwomen:aretrospectivereviewofmedicalrecords.Lancet.2020;395(10226):809-815.doi:10.1016/S0140-6736(20)30360-33.WorldHealthOrganization.Laboratorytestingfor2019novelcoronavirus(2019-nCoV)insuspectedhumancases:interimguidance2020.PostedJanuary17,2020.AccessedFebruary4,2020.https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-202001174.ContributiontoWuhanwithSARS-CoV-2IgG/IgMAssays.Newsrelease.YHLO,March4,2020.AccessedMarch4,2020.http://www.szyhlo.com/en/news_detail.php?menuid=75&id=125&from=singlemessage&isappinstalled=0.5.KohlerPF,FarrRS.ElevationofcordovermaternalIgGimmunoglobulin:evidenceforanactiveplacentalIgGtransport.Nature.1966;210(5040):1070-1071.doi:10.1038/2101070a06.NgWF,WongSF,LamA,etal.Theplacentasofpatientswithsevereacuterespiratorysyndrome:apathophysiologicalevaluation.Pathology.2006;38(3):210-218.doi:10.1080/00313020600696280LettersE2JAMAPublishedonlineMarch26,2020(Reprinted)jama.com©2020AmericanMedicalAssociation.Allrightsreserved.";30 mars 2020 
0;dietetique;Stratégie de prise en charge nutritionnelle à l’hôpital : COVID-19;Ronan Thibault et al;https://www.groupedeveillecovid.fr/blog/2020/03/31/strategie-de-prise-charge-nutritionnelle-a-lhopital-covid-19/;14;"8.  ConclusionFace à l™épidémie Covid-19, la mobilisation urgente des acteurs de la diététique et de la nutrition clinique en appui des équipes soignantes doit permettre d™identi˜er dès l™admission les patients dénutris et d™instaurer chez tous les patients Covid-19 une stratégie active de prise en charge ou de prévention chez les moins sévèrement atteints.Ces recommandations, basées sur des principes généraux et l™expérience de situations cliniques analogues sont proposées comme repères pour les non-spécialistes.Les retours d™expérience et questions soulevées dans la mise en œuvre de ces recommandations d™experts seront accueillis avec grand intérêt sur contact@sfncm.org, objet Covid-19, pour enrichir nos connaissances dans ce domaine pathologique nouveau et adapter nos modes de prise en charge.Références[1]  https://solidarites-sante.gouv.fr/IMG/pdf/ Covid-19_doctrine_ville_v16032020˜nalise.pdf[2]  Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for Covid-19 infection? Lancet Respir Med 2020, DOI:https://doi.org/10.1016/S2213-2600(20)30116-8[3] https://www.has-sante.fr/jcms/p_3118872/fr/diagnostic-de-la-denutrition-de-l-enfant-et-de-l-adulte[4]  Bouteloup C, Thibault R. Decision tree for nutritional care. Nutr Clin Metab 2014; 28: 52Œ56.[5]  https://clinicaltrials.gov/ct2/show/NCT04315948?term=discovery&cond=Coronavirus&draw=2&rank=1[6]  Singer P, Blaser AR, Berger MM, Alhazzani W, Calder PC, Casaer MP, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr 2019;38:48-79.[7]  https://www.promosante-idf.fr/alimentation-activite-physique-les-bons-re˚exes-en-periode-de-con˜nement14";31 mars 2020 
0;document-institutionnels;Préparation à la phase épidémique de Covid-19;null;https://www.groupedeveillecovid.fr/blog/2020/03/20/preparation-a-phase-epidemique-de-covid-19/;54;          ;20 mars 2020 
0;depistage;First experience of COVID-19 screening of health-care workers in England;E Hunter et al;https://www.groupedeveillecovid.fr/blog/2020/05/03/first-experience-of-covid-19-screening-of-health-care-workers-in-england/;2;"e78 www.thelancet.com   Vol 395   May 2, 2020Ewan Hunter, David A Price, Elizabeth Murphy, Ina Schim van der Loe˜, Kenneth F Baker, Dennis Lendrem, Clare Lendrem, Matthias L Schmid, Lucia Pareja-Cebrian, Andrew Welch, Brendan A I Payne, *Christopher J A Duncanchristopher.duncan@newcastle.ac.ukDepartment of Infection and Tropical Medicine (EH, DAP, MLS, BAIP, CJAD), Occupational Health Department (EM), Microbiology and Virology Services (LP-C, BAIP), and Department of Ear Nose and Throat Surgery (AW), Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; and Immunity and In˙ammation Theme (ISvdL, KFB, CJAD), National Institute of Health Research (NIHR) Biomedical Research Centre (DL), NIHR In Vitro Diagnostics Cooperative (CL), and Mitochondrial and Neuromuscular Diseases Theme (BAIP), Newcastle University, Newcastle upon Tyne NE2 4HH, UK1 Chowell G, Abdirizak F, Lee S, et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med 2015; 13: 210.2 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; published online Feb 24. DOI:10.1001/jama.2020.2648.3 Chan JF, Yip CC, To KK, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and speci˛c COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens. J Clin Microbiol 2020; published online Mar 4. DOI:10.1128/JCM.00310-20.to direct patient care. Beyond this obvious benefit, we speculate that testing might have additional positive effects on health behaviour, by providing health-care workers with the confidence that they can self-isolate with mild symptoms, knowing that a rapid negative result will enable them to return to work in a timely manner. This might lessen the desire of sta˜ with mild symptoms to soldier on, in fear of abandoning colleagues for 7Œ14 days, thereby inadvertently contrib uting to nosocomial trans mission.Several limitations to these data should be acknowledged. We were unable to identify staff roles for more than a third of those tested. Furthermore, no data on symptoms or outcomes are available. Ongoing prospective data collection will aim to capture both of these elements in due course. The small number of non-clinical sta˜ tested meant that it was not possible to meaningfully compare transmission dynamics between these groups, where more complex patterns might exist. Finally, we acknowledge possible insensitivity of the SARS-CoV-2 RdRp assay,3 which might provide unwarranted reassurance in some cases. Nevertheless, we view this as a risk reduction rather than elimination strategy, and continue to stress that sta˜ with a negative test should not return to work until their symptoms have substantially improved. National guidance is anticipated on this issue.CJAD reports grants from the Wellcome Trust during the conduct of the study reported in this Correspondence. All other authors declare no competing interests. We are grateful to S Graziadio (NIHR Newcastle) for helpful advice regarding statistical analysis. We acknowledge the assistance of many sta˜ involved in establishing and supporting the screening pod. CJAD is funded by the Wellcome Trust (211153/Z/18/Z). KFB is funded by a National Institute for Health Research (NIHR) Clinical Lectureship (CL-2017-01-004). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The funders had no role in study design, data collection, or decision to publish this Correspondence. The corresponding author had full access to all data and had ˛nal responsibility for the decision to submit for publication. CJAD and BAIP contributed equally to this work.";3 mai 2020 
0;echantillons-biologiques;Detection of SARS-CoV-2 in Different Types of Clinical Specimens;Wenling Wang, Yanli Xu, Ruqin Gao et al;https://www.groupedeveillecovid.fr/blog/2020/03/24/detection-of-sars-cov-2-in-different-types-of-clinical-specimens/;2;"Themeancyclethresholdvaluesofallspecimentypesweremorethan×copies/mL)exceptfornasalswabswithameancyclethresholdvalueof.×copies/mL),indicatinghigherviralloads(Table).Twentypatientshadtospecimenscollectedsimultane-ously(Figure).ViralRNAwasdetectedinsinglespecimensfrompatients(respiratoryspecimens,feces,orblood),whilepa-tientsexcretedvirusinrespiratorytractspecimensandinfeces(n=)orblood(n=).LiveSARS-CoV-wasobservedinthestoolsamplefrompatientswhodidnothavediarrhea.Discussion|Inthisstudy,SARS-CoV-wasdetectedinspeci-mensfrommultiplesitesofpatientswithCOVID-,withlowerrespiratorytractsamplesmostoftentestingpositiveforthevirus.Importantly,theliveviruswasdetectedinfeces,im-plyingthatSARS-CoV-maybetransmittedbythefecalroute.AsmallpercentageofbloodsampleshadpositivePCRtestre-sults,suggestingthatinfectionsometimesmaybesystemic.Transmissionofthevirusbyrespiratoryandextrarespiratoryroutesmayhelpexplaintherapidspreadofdisease.Inaddi-tion,testingofspecimensfrommultiplesitesmayimprovethesensitivityandreducefalse-negativetestresults.TwosmallerstudiesreportedthepresenceofSARS-CoV-inanalororalswabsandbloodfrompatientsinHubeiProvince,andvi-ralloadinthroatswabsandsputumfromconfirmedcases.Thelimitationsofthisstudyincludethatsomepatientsdidnothavedetailedclinicalinformationavailable,sothedatacouldnotbecorrelatedwithsymptomsordiseasecourseandthatthenumberofsometypesofsampleswassmall.Furtherinvestigationofpatientswithdetailedtemporalandsymp-tomdataandconsecutivelycollectedspecimensfromdiffer-entsitesiswarranted.WenlingWang,PhDYanliXu,MDRuqinGao,MDRoujianLu,MPHKaiHan,BSGuizhenWu,MDWenjieTan,MD,PhDAuthorAffiliations:NationalInstituteforViralDiseaseControlandPrevention,ChinaCDC,Beijing,China(Wang,Lu,Wu,Tan);BeijingDitanHospital,CapitalMedicalUniversity,Beijing,China(Xu,Han);QingdaoMunicipalCenterforDiseaseControlandPrevention,Qingdao,China(Gao).AcceptedforPublication:March5,2020.CorrespondingAuthor:WenjieTan,MD,PhD,NationalInstituteforViralDiseaseControlandPrevention,ChinaCDC,155ChangbaiRd,ChangpingDistrict,Beijing102206,China(tanwj@ivdc.chinacdc.cn).PublishedOnline:March11,2020.doi:10.1001/jama.2020.3786AuthorContributions:DrsWangandTanhadfullaccesstoallofthedatainthestudyandtakeresponsibilityfortheintegrityofthedataandtheaccuracyofthedataanalysis.DrsWangandXucontributedequally.Conceptanddesign:Wang,Xu,Wu,Tan.Acquisition,analysis,orinterpretationofdata:Xu,Gao,Lu,Han,Tan.Draftingofthemanuscript:Wang,Xu,Gao,Han,Tan.Criticalrevisionofthemanuscriptforimportantintellectualcontent:Xu,Lu,Wu,Tan.Statisticalanalysis:Wang.Obtainedfunding:Wang,Tan.Administrative,technical,ormaterialsupport:Xu,Gao,Lu,Han,Wu.Supervision:Xu,Wu,Tan.ConflictofInterestDisclosures:Nonereported.Funding/Support:Thisworkwassupportedbygrants2016YFD0500301and2020YFC0840900fromtheNationalKeyResearchandDevelopmentProgramofChinaand2018ZX10101002fromtheNationalMajorProjectforControlandPreventionofInfectiousDiseaseinChina.RoleoftheFunder/Sponsor:Thesponsorshadnoroleinthedesignandconductofthestudy;collection,management,analysis,andinterpretationofthedata;preparation,review,orapprovalofthemanuscript;anddecisiontosubmitthemanuscriptforpublication.AdditionalContributions:WethankGaryWong,PhD(CASKeyLaboratoryofMolecularVirology&Immunology,InstitutePasteurofShanghai,ChineseAcademyofSciences,Shanghai,China)forEnglishrevisionofthemanuscript,andclinicalstaffmembersinhospitalsinHubeiProvince,ShandongProvince,andBeijingforcollectionofspecimens.Noneoftheseindividualsreceivedcompensationfortheircontributions.1.TanW,ZhaoX,MaX,etal.Notesfromthefield:anovelcoronavirusgenomeidentifiedinaclusterofpneumoniacases—Wuhan,China2019-2020.ChinaCDCWeekly.2020;2(4):61-62.2.WangD,HuB,HuC,etal.Clinicalcharacteristicsof138hospitalizedpatientswith2019novelcoronavirus–infectedpneumoniainWuhan,China.JAMA.PublishedFebruary7,2020.doi:10.1001/jama.2020.15853.ZhangW,DuRH,LiB,etal.Molecularandserologicalinvestigationof2019-nCoVinfectedpatients:implicationofmultiplesheddingroutes.EmergMicrobesInfect.2020;9(1):386-389.doi:10.1080/22221751.2020.17290714.PanY,ZhangD,YangP,PoonLLM,WangQ.ViralloadofSARS-CoV-2inclinicalsamples.LancetInfectDis.PublishedonlineFebruary24,2020.doi:10.1016/S1473-3099(20)30113-4LettersE2JAMAPublishedonlineMarch11,2020(Reprinted)jama.com©2020AmericanMedicalAssociation.Allrightsreserved.";24 mars 2020 
0;gastroenterologie;Covid-19 infection in Crohn’s disease under treatment with adalimumab. Gut 2020;Tursi A, et al;https://www.groupedeveillecovid.fr/blog/2020/04/25/covid-19-infection-in-crohns-disease-under-treatment-with-adalimumab-gut-2020/;1;"  1LETTERCovid-19 infection in Crohn™s disease under treatment with˜adalimumabJin et al described recently 74 cases of people having COVID-19 and experiencing gastrointestinal symptoms.1 In Italy, we are managing a dramatically increasing number of people infected with severe acute respi-ratory syndrome corona virus 2, the virus causing COVID-19.2 3 Despite the Italian Government has implemented extraordinary measures to restrict viral spread, including significant decrease of air and train traffic within the country, cases are increasing (>75 000 people until 26 March 2020) also in other regions than Lombardy, which is the main Italian region affected from covid-19 (>35 000 people until 26 March 2020).4 This means that a lot of people under immunosuppressive- immunomodulating therapies could be infected by this virus, and that the immunosuppressive status could influence both the status of the basic disease and both the course of pulmonary disease.A 30- year- old male was admitted on emergency department of the Bari University Hospital, Puglia Region, Southern Italy, on 12 March 2020 (with a low number of cases until that date) due to sudden occurrence of fever (38°C) associated with chest pain during breaths. He underwent to oral and nasal specimens, which resulted positive for covid-19, and he was admitted to infectious disease division. He was affected from ileal Crohn™s disease (CD), and was under treatment with mesalazine 3 g/day and adalimumab 40 mg subcutaneously every other week for 5 years due to steroid dependency. He was under sustained remission for 2 years, and no other comorbidities was reported. At entry, he needed just oxygen support; thoracic CT scan showed mild interstitial inflamma-tion and laboratory examination (including erythrocyte sedimentation rate and C reac-tive protein) was normal except for a mild thrombocytopenia (1643/µL, n.v. 179Œ3733/µL). No abdominal pain was reported, and bowel movements were normal. Any specific therapy was started except for suspension of adalimumab, and he had a rapid clinical improvement: fever and chest pain disap-peared within 24 hours, and at the fifth day of hospital stay he was asymptomatic (an Rx of the chest did not find sign of inflammation at that time). Significantly, no occurrence of abdominal pain or changes in bowel habits were recorded, and also faecal calprotectin assessment was normal (38 mg/kg, n.v. <50 mg/kg).This case is of interest for two main reason. Although this infection is characterised by typical respiratory symptoms, Jin et al1 and Wang et al5 reported less common features like diarrhoea, nausea, vomiting and abdom-inal discomfort. Moreover, covid-19- RNA was found recently in the stool of 53.42% of people tested positive for covid-19.6 If covid-19 colonises gastrointestinal tract (unfortunately, we did not check covid-19- RNA in stools of our patient), it could cause a worsening of a pre- existing intestinal disease as CD. Our case seems to exclude this. Since covid-19 binds ACE 2,7 a possible explanation of our case could be because the patient was in clinical remission with no active inflammation, so less risk of having ACE 2 expression upregulation in the gut.8Another interesting feature is that pulmo-nary disease recovered quickly despite our patient was under immunosuppressive treat-ment with an antitumour necrosis factor ˜ (TNF˜). Of course, this could be explained by the young age of our patient, because in Italy younger patients seem to have a more favourable course.4 Another hypothesis is that not all immunosuppressive treatment can cause clinical worsening, probably due to different mechanisms in suppressing immune system activity. We know that TNF˜ is over-expressed also in severe respiratory distress syndrome.9 In this way, current treatment with adalimumab not only could not be a risk factor for both severity of pulmonary disease and recurrence of the intestinal disease in patients with CD infected by covid-19, but also could reinforce the hypothesis to use adalimumab in treating at least some of the infected people.2 Of course, the questions raised by this case have to be addressed by the large epidemiological studies currently ongoing.Antonio Tursi    ,1 Gioacchino Angarano,2 Laura Monno,2 Annalisa Saracino,2 Fabio Signorile,2 Aurelia Ricciardi,2 Alfredo Papa31Gastroenterology Service, Azienda Sanitaria Locale Barletta Andria Trani, Andria, Puglia, Italy2Division of Infectious Diseases, Bari University Hospital, University of Bari, Bari, Puglia, Italy3Division of Internal Medicine and Gastroenterology, Complesso Integrato ﬁColumbusﬂ, Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Roma, Lazio, ItalyCorrespondence to Professor Antonio Tursi, Gastroenterology Service, Azienda Sanitaria Locale Barletta Andria Trani, 76123 Andria BT, Italy;   antotursi@ tiscali. itContributors Acquisition, analysis and interpretation of data: AT, GA, LM, AS, FS, AR and AP; drafting the work or revising it critically for important intellectual content: AT and AP; ˜nal approval of the version published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: AT, GA, LM, AS, FS, AR and AP.Funding The authors have not declared a speci˜c grant for this research from any funding agency in the public, commercial or not- for- pro˜t sectors.Competing interests None declared.Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.Patient consent for publication Obtained.Provenance and peer review Not commissioned; internally peer reviewed.© Author(s) (or their employer(s)) 2020. No commercial re- use. See rights and permissions. Published by BMJ.To cite Tursi˚A, Angarano˚G, Monno˚L, et˜al. Gut Epub ahead of print: [please include Day Month Year]. doi:10.1136/gutjnl-2020-321240Received 27 March 2020Revised 2 April 2020Accepted 6 April 2020Gut 2020;0:1. doi:10.1136/gutjnl-2020-321240ORCID iDAntonio˚Tursi http:// orcid. org/ 0000- 0001- 5767- 5541REFERENCES 1 Jin X, Lian J- S, Hu J- H, et˜al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus- infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020. doi:10.1136/gutjnl-2020-320926. [Epub ahead of print: 24 Mar 2020]. 2 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA 2019;2020:25Œ8. 3 WHO. Statement on the second meeting of the International health regulations (2005) emergency Committee regarding the outbreak of novel coronavirus (2019- nCoV), 2020. Available: https://www. who. int/ news- room/ detail/ 30- 01- 2020- statement- on- the- second- meeting- of- the- international- health- regulations-( 2005)- emergency- committee- regarding- the- outbreak- of- novel- coronavirus-( 2019- ncov) [Accessed 16 Mar 2020]. 4 Protezione Civile proseguono. Coronavirus: sono 62.013 I positivi, 2020. Available: http:// www1. protezionecivile. gov. it/ media- comunicazione/ comunicati- stampa/-/ content- view/ view/ 1237989 5 Wang D, Hu B, Hu C, et˜al. Clinical characteristics of 138 hospitalized patients with 2019 novel CoronavirusŒInfected pneumonia in Wuhan, China. JAMA 2020;323:1061. 6 Xiao F, Tang M, Zheng X, et˜al. Evidence for gastrointestinal infection of SARS- CoV-2. Gastroenterology 2020. doi:10.1053/j.gastro.2020.02.055. [Epub ahead of print: 03 Mar 2020]. 7 Ciulla MM. Coronavirus uses as binding site in humans angiotensin- converting enzyme 2 functional receptor that is involved in arterial blood pressure control and ˜brotic response to damage and is a drug target in cardiovascular disease. is this just a phylogenetic coincidence? J Med Virol 2020. doi:10.1002/jmv.25774. [Epub ahead of print: 26 Mar 2020]. 8 Garg M, Royce SG, Tikellis C, et˜al. Imbalance of the renin- angiotensin system may contribute to in˛ammation and ˜brosis in IBD: a novel  therapeutic target? Gut 2020;69:841Œ51. 9 Malaviya R, Laskin JD, Laskin DL. Anti- TNF˜ therapy in in˛ammatory lung diseases. Pharmacol Ther 2017;180:90Œ8.PostScriptProtected by copyright. on April 21, 2020 at Societe Nationale Francaise de Gastroenterologie-SNFGE.http://gut.bmj.com/Gut: first published as 10.1136/gutjnl-2020-321240 on 20 April 2020. Downloaded from ";25 avril 2020 
0;gastroenterologie;Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy;Lorenzo Norsa and al;https://www.groupedeveillecovid.fr/blog/2020/04/25/uneventful-course-in-ibd-patients-during-sars-cov-2-outbreak-in-northern-italy/;8;"˘ˇˆ˙˝˛· ˚˙˜ˆ·  !""˚#""$%ˆ&˘˝'˛· (˝)!˝(˘ˇ· '˙*˙+(˘ˇ· %˘!$+,&, -&.&/,0(˘ˇ· )&(˘ˇ· 1˙'!,˚˝!,**!(˘ˇ· 1˙˝(˘ˇ ";25 avril 2020 
0;gastroenterologie;IMPACT OF ANTI-TNFα ANTIBODIES ON THE RISK OF COVID-19 AND ITS SEVERITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES;Tursi A, et al;https://www.groupedeveillecovid.fr/blog/2020/04/25/impact-of-anti-tnf%ce%b1-antibodies-on-the-risk-of-covid-19-and-its-severity-in-patients-with-inflammatory-bowel-diseases/;5;Figure 1  Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/doi/10.1093/ecco-jcc/jjaa076/5821495 by guest on 21 April 2020;25 avril 2020 
0;greffe;Covid-19 and Kidney Transplantation;Enver Akalin and al;https://www.groupedeveillecovid.fr/blog/2020/04/27/covid-19-and-kidney-transplantation/;3;"n engl j med   nejm.org 3VariableValueC-reactive proteinMedian (range) Š mg/dl7.9 (0.5Œ48.7)Patients with level >5 mg/dl Š no./total no. (%)13/28 (46)ProcalcitoninMedian (range) Š ng/ml0.2 (0.1Œ5.1)Patients with level >0.2 ng/ml Š no./total no. (%)12/28 (43)Lactate dehydrogenaseMedian (range) Š U/liter336 (158Œ309)Patients with level >1.5 times upper limit of normal range Š no./total no. (%)10/28 (36)Creatine kinaseMedian (range) Š U/liter145 (48Œ815)Patients with level >200 U/liter Š no./total no. (%)9/28 (32)Outcomes˜at˜a˜median˜of˜21˜days˜(range,˜14Œ28)˜Š˜no./total˜no.˜(%)Death10/36 (28)Intubation11/28 (39)Death after intubation7/11 (64)Renal replacement therapy6/28 (21)Remained hospitalized12/28 (43)Discharged from hospital10/28 (36)Table˜1.˜(Continued)the reported 1% to 5% mortality among patients with Covid-19 in the general population who have undergone testing in the United States and the reported 8 to 15% mortality among patients with Covid-19 who are older than 70 years of age.Enver Akalin, M.D. Yorg Azzi, M.D. Rachel Bartash, M.D. Harish Seethamraju, M.D. Michael Parides, Ph.D. Vagish Hemmige, M.D. Michael Ross, M.D. Stefanie Forest, M.D., Ph.D. Yitz D. Goldstein, M.D. Maria Ajaimy, M.D. Luz Liriano-Ward, M.D. Cindy Pynadath, M.D. Pablo Loarte-Campos, M.D. Purna B. Nandigam, M.D. Jay Graham, M.D. Marie Le, M.D. Juan Rocca, M.D. Milan Kinkhabwala, M.D.Montefiore Medical Center Bronx, NY eakalin@montefiore.orgDrs. Akalin and Azzi contributed equally to this letter.Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.This letter was published on April 24, 2020 at NEJM.org.1. Alberici F, Delbarba E, Manenti C, et al. A single center ob-servational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int 2020 April 9 (Epub ahead of print).2. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Phar-macologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020 April 13 (Epub ahead of print).3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.4. Diao B, Wang C, Tan Y, et al. Reduction and functional ex-haustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv. February 20, 2020 (https://www .medrxiv .org/ content/ 10 .1101/ 2020 .02 .18 .20024364v1).DOI:˜10.1056/NEJMc2011117Correspondence Copyright © 2020 Massachusetts Medical Society.Correspondence";27 avril 2020 
0;gerontologie;Covid-19 and Immunity in Aging Populations — A New Research Agenda;Wayne C. Koff, and Michelle A. Williams;https://www.groupedeveillecovid.fr/blog/2020/04/20/covid-19-and-immunity-in-aging-populations-a-new-research-agenda/;3;"PERSPECTIVE3Covid-19 and Immunity in Aging Populationsn engl j med   nejm.org  tions, and has emerged globally in our highly interconnected world. Short-term efforts to quick-ly develop lifesaving vaccines and therapeutics are of the utmost importance.In the long term, however, we will have to shift from investing primarily in disease-specific re-search to simultaneously target-ing sufficient resources toward decoding the human immune sys-tem, particularly for the world™s most vulnerable populations. Such an effort could accelerate the de-velopment of new vaccines, diag-nostics, and treatments Š not just for Covid-19, but also for fu-ture emerging pathogens as well as the noncommunicable diseas-es of aging that are our major global killers. We need bold ac-tion as soon as possible to help all of humanity live longer and healthier lives.Disclosure forms provided by the au-thors are available at NEJM.org.From the Human Vaccines Project, New York (W.C.K.); and the Harvard T.H. Chan School of Public Health, Boston (M.A.W.). This article was published on April 17, 2020, at NEJM.org.1. Alpert A, Pickman Y, Leipold M, et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nat Med 2019; 25: 487-95.2. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Re-ninŒangiotensinŒaldosterone system inhibi-tors in patients with Covid-19. N Engl J Med. DOI:  10.1056/NEJMsr2005760.3. Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vac-cine 2018; 36: 5350-7.4. World population prospects 2019. New York:  United Nations (https://population .un .org/ wpp/ ).5. Tsang J, Dobaño C, VanDamme P, et al. Improving vaccine-induced immunity: can baseline predict outcome? Trends Immunol 2020 April 8 (Epub ahead of print).DOI:˜10.1056/NEJMp2006761Copyright © 2020 Massachusetts Medical Society.Covid-19 and Immunity in Aging Populations";20 avril 2020 
0;imagerie;Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to DDimer Levels;Ian LEONARD-LORANT and al;https://www.groupedeveillecovid.fr/blog/2020/04/27/acute-pulmonary-embolism-in-covid-19-patients-on-ct-angiography-and-relationship-to-ddimer-levels/;12;"Accepted Article This article is protected by copyright. All rights reserveds                                                                                                                                                                                      36 Ko JH, Müller MA, Seok H, et al. Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity. Diagn Microbiol Infect Dis. 2017;89:106-111.  37 Agence national de sécurité des médicaments et des produits de santé (ANSM) Principes et bonnes pratiques pour les établissements de transfusion sanguine et les dépôts de sang hospitaliers. Décision du 18/7/2018 38 Nurtop E, Villarroel PMS, Pastorino B, et al. Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J. 2018;15:192 Erratum in: Virol J. 2019;16:12.  39 Wong HK, Lee CK, Hung IF, et al. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion. 2010;50:1967-71. 40 Hashem AM, Hassan AM, Tolah AM, et al. Amotosalen and ultraviolet A light efficiently inactivate MERS-coronavirus in human platelet concentrates. Transfus Med. 2019;29:434-441 41 Keil SD, Bowen R, Marschner S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. Transfusion. 2016;56:2948-2952.  42 Geisen C, Kann G, Strecker T, et al. Pathogen-reduced Ebola virus convalescent plasma: first steps towards  standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies. Vox Sang. 2016;110:329335.  43 Dean CL, Hooper JW, Dye JM, et al. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. Transfusion. 2020 Mar 4. 44 Lan L, Xu D, Ye G, et al. Positive RT-PCR Test Results in Patients Recovered From COVID-19. JAMA.2020; 10.1001/jama.2020. 45Baden LR, Rubin EJ, Morrissey S, et al. We Can Do Better - Improving Outcomes in the Midst of an Emergency. N Engl J Med. 2017;377:14821484. 46 Zhao J, Yang Y, Huang HP, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. medRxiv 2020.03.11.20031096 (not peer-reviewed yet) 47 https://europeanbloodalliance.eu/  ";27 avril 2020 
0;imagerie;Diagnostic Performance of CT and Reverse Transcriptase-Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis;Hyungjin Kim and al;https://www.groupedeveillecovid.fr/blog/2020/04/22/diagnostic-performance-of-ct-and-reverse-transcriptase-polymerase-chain-reaction-for-coronavirus-disease-2019-a-meta-analysis/;31;"Proportion of asymptomatic patients   73a <0.01   91a 0.19  0% 26 98 (94, 99) 92   8 83 (70, 92) 79    <20% 12 95 (84, 99) 95  5 93 (87, 96) 0   20% 9 63 (57, 69) 0   2 90 (53, 99) 0    Unknown 16 92 (88, 94) 86   4 89 (61, 97) 97   ORF genes as RT-PCR targets       91a 0.98  Yes     7 88 (69, 96) 93   No     7 88 (73, 95) 53   Unknown     5 91 (76, 97) 84   Numbers in parentheses are 95% confidence intervals. CT = computed tomography; ORF = open reading frame; RT-PCR = reverse transcriptase-polymerase chain reaction. aResidual heterogeneity in the meta-regression analysis bp-value is for the association between the variable and the magnitude of the effect size (i.e., sensitivity). ";22 avril 2020 
0;imagerie;Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China;Yuan M et al;https://www.groupedeveillecovid.fr/blog/2020/03/26/association-of-radiologic-findings-with-mortality-of-patients-infected-with-2019-novel-coronavirus-in-wuhan-china/;10;"5.ChenN,ZhouM,DongX,QuJ,GongF,HanY,etal.Epidemiologicalandclinicalcharacteristicsof99casesof2019novelcoronaviruspneumoniainWuhan,China:adescriptivestudy.Lancet.2020.https://doi.org/10.1016/S0140-6736(20)30211-7PMID:32007143.6.HuangC,WangY,LiX,RenL,ZhaoJ,HuY,etal.Clinicalfeaturesofpatientsinfectedwith2019novelcoronavirusinWuhan,China.Lancet.2020.https://doi.org/10.1016/S0140-6736(20)30183-5PMID:31986264.7.WangD,HuB,HuC,ZhuF,LiuX,ZhangJ,etal.ClinicalCharacteristicsof138HospitalizedPatientsWith2019NovelCoronavirus-InfectedPneumoniainWuhan,China.Jama.2020.https://doi.org/10.1001/jama.2020.1585PMID:32031570.8.Globalsurveillanceforhumaninfectionwithnovelcoronavirus(2019-ncov)interimguidancev3.2020;1:31.https://www.Who.Int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)(accessedfeb8,2020).9.FengF,JiangY,YuanM,ShenJ,YinH,GengD,etal.AssociationofradiologicfindingswithmortalityinpatientswithavianinfluenzaH7N9pneumonia.PloSone.2014;9(4):e93885.https://doi.org/10.1371/journal.pone.0093885PMID:24705783.10.YinY,WunderinkRG.MERS,SARSandothercoronavirusesascausesofpneumonia.Respirology(Carlton,Vic).2018;23(2):130±7.https://doi.org/10.1111/resp.13196PMID:29052924.11.WangW,TangJ,WeiF.Updatedunderstandingoftheoutbreakof2019novelcoronavirus(2019-nCoV)inWuhan,China.Journalofmedicalvirology.2020.https://doi.org/10.1002/jmv.25689PMID:31994742.12.LiQ,GuanX,WuP,WangX,ZhouL,TongY,etal.EarlyTransmissionDynamicsinWuhan,China,ofNovelCoronavirus-InfectedPneumonia.TheNewEnglandjournalofmedicine.2020.https://doi.org/10.1056/NEJMoa2001316PMID:31995857.13.ShiH,HanX,ZhengC.EvolutionofCTManifestationsinaPatientRecoveredfrom2019NovelCoro-navirus(2019-nCoV)PneumoniainWuhan,China.Radiology.2020:200269.https://doi.org/10.1148/radiol.2020200269PMID:32032497.14.FangY,ZhangH,XuY,XieJ,PangP,JiW.CTManifestationsofTwoCasesof2019NovelCoronavi-rus(2019-nCoV)Pneumonia.Radiology.2020:200280.https://doi.org/10.1148/radiol.2020200280PMID:32031481.15.SongF,ShiN,ShanF,ZhangZ,ShenJ,LuH,etal.EmergingCoronavirus2019-nCoVPneumonia.Radiology.2020:200274.PMID:32027573.16.GrinblatL,ShulmanH,GlickmanA,MatukasL,PaulN.Severeacuterespiratorysyndrome:radio-graphicreviewof40probablecasesinToronto,Canada.Radiology.2003;228(3):802±9.https://doi.org/10.1148/radiol.2283030671PMID:12853655.17.MarchioriE,ZanettiG,FontesCA,SantosML,ValiantePM,ManoCM,etal.InfluenzaA(H1N1)virus-associatedpneumonia:high-resolutioncomputedtomography-pathologiccorrelation.Europeanjournalofradiology.2011;80(3):e500±4.https://doi.org/10.1016/j.ejrad.2010.10.003PMID:21035974.18.WangQ,ZhangZ,ShiY,JiangY.EmergingH7N9influenzaA(novelreassortantavian-origin)pneumo-nia:radiologicfindings.Radiology.2013;268(3):882±9.https://doi.org/10.1148/radiol.13130988PMID:23821754.19.OoiGC,KhongPL,MullerNL,YiuWC,ZhouLJ,HoJC,etal.Severeacuterespiratorysyndrome:tem-porallungchangesatthin-sectionCTin30patients.Radiology.2004;230(3):836±44.https://doi.org/10.1148/radiol.2303030853PMID:14990845.20.WongKT,AntonioGE,HuiDS,LeeN,YuenEH,WuA,etal.Severeacuterespiratorysyndrome:radio-graphicappearancesandpatternofprogressionin138patients.Radiology.2003;228(2):401±6.https://doi.org/10.1148/radiol.2282030593PMID:12759474.21.Al-TawfiqJA,ZumlaA,MemishZA.Coronaviruses:severeacuterespiratorysyndromecoronavirusandMiddleEastrespiratorysyndromecoronavirusintravelers.Currentopinionininfectiousdiseases.2014;27(5):411±7.https://doi.org/10.1097/QCO.0000000000000089PMID:25033169.22.AjlanAM,AhyadRA,JamjoomLG,AlharthyA,MadaniTA.MiddleEastrespiratorysyndromecoronavi-rus(MERS-CoV)infection:chestCTfindings.AJRAmericanjournalofroentgenology.2014;203(4):782±7.https://doi.org/10.2214/AJR.14.13021PMID:24918624.Radiologicfindingsofpatientsinfectedwith2019novelcoronavirusPLOSONE|https://doi.org/10.1371/journal.pone.0230548March19,202010/10";26 mars 2020 
0;imagerie;Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study;Wei Zhao, Zheng Zhong,Xingzhi Xie, Qizhi Yu, Jun Liu;https://www.groupedeveillecovid.fr/blog/2020/03/21/relation-between-chest-ct-findings-and-clinical-conditions-of-coronavirus-disease-covid-19-pneumonia-a-multicenter-study/;6;6 AJR:214, May 2020Zhao et al.-------------N Engl J Med-N Engl J MedN Engl J MedJ Virol-Lancet-N Engl J Med-N Engl J MedLancetLancet-Radiology-Radiology Radiology-RadiologyRadiologyAJR-RadiologyEur  RadiolRadi-ology;21 mars 2020 
0;imagerie;Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients;Sana Salehi, Aidin Abedi, Sudheer Balakrishnan, Ali Gholamrezanezhad;https://www.groupedeveillecovid.fr/blog/2020/03/19/coronavirus-disease-2019-covid-19-a-systematic-review-of-imaging-findings-in-919-patients/;7;AJR:215, November 2020 7Systematic Review of COVID-19 Imaging FindingsRadiol Cardiotho-rac ImagingRadiology-JAMALancet Radiology ---AJRAJRRadiology-Radiology Euro Surveill-Precis Clin Medclinical characteristics of novel coronavirus infec-JAMA-istics of novel coronavirus cases in tertiary hospi-Chin Med J (Engl)---Lancetcharacteristics and therapeutic procedure for four -Biosci Trends--J Am Coll Radiol RadiologyRadiol Cardiothorac Imaging --Sci China Life SciFOR YOUR INFORMATIONA data supplement for this article can be viewed in the online version of the article at: www.ajronline.org.;19 mars 2020 
0;immunoglobuline;Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19);Li Guo, Lili Ren, Siyuan Yang, Meng Xiao, De Chang, Fan Yang, Charles S Dela Cruz, Yingying Wang, Chao Wu, Yan Xiao, Lulu Zhang, Lianlian Han, Shengyuan Dang, Yan Xu, Qiwen Yang, Shengyong Xu, Huadong Zhu, Yingchun Xu, Qi Jin, Lokesh Sharma, Linghang Wang, Jianwei Wang;https://www.groupedeveillecovid.fr/blog/2020/03/24/profiling-early-humoral-response-to-diagnose-novel-coronavirus-disease-covid-19/;28; 28  Figure 4  Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciaa310/5810754 by guest on 23 March 2020;24 mars 2020 
0;neurologie;Réponses rapides dans le cadre du COVID-19 – Suivi des patients atteints de maladie de Parkinson;null;https://www.groupedeveillecovid.fr/blog/2020/05/06/reponses-rapides-cadre-covid-19-suivi-patients-atteints-de-maladie-de-parkinson/;5;;6 mai 2020 
0;neurologie;Réponses rapides dans le cadre du COVID-19 – Prise en charge ambulatoire des patients ayant une épilepsie;null;https://www.groupedeveillecovid.fr/blog/2020/05/06/reponses-rapides-cadre-covid-19-prise-charge-ambulatoire-patients-ayant-epilepsie/;5;" HAS Réponses rapides dans le cadre du COVID-19 - Prise en charge ambulatoire des patients ayant une épilepsie  avril 2020   5 Liste des participants  HAS : Dr Muriel Dhénain, chef de projet ; Mme Sylvie Lascols, aide-documentaliste.  Conseils nationaux professionnels et Sociétés savantes : Pr Stéphane Auvin, neuropédiatre, Pa-ris ; Pr Philippe Derambure, neurologue, Lille ; Pr Sophie Dupont, neurologue, Paris ; Pr Jean-Louis Mas, neurologue, Paris ; Pr Sylvie Nguyen The Tich, pédiatre, Lille ; Dr François Sellal, neurologue, Colmar.  Associations de malades et ds : Mme Sophie Chouaki, représentante des usagers, Paris ; Mme Françoise Thomas-Vialettes, représentante des usagers, Egrève.   Ces réponses rapides élaborées sur la base des connaissances disponibles à la date de publi-.  Ces réponses rapides sont fondées sur ce qui apparaît souhaitable ou nécessaire au moment en équipements de protection individuelle.     © Haute Autorité de santé   avril 2020         Réponses rapides dans le cadre du COVID-19 - Prise en charge ambulatoire des patients ayant une épilepsie, méthode de ré-ponse rapide, 9 avril 2020 Toutes nos publications sont téléchargeables sur www.has-sante.fr  ";6 mai 2020 
0;neurologie;Neurologic Features in Severe SARS-CoV-2 Infection;Julie Helms and al;https://www.groupedeveillecovid.fr/blog/2020/04/20/neurologic-features-in-severe-sars-cov-2-infection/;2;"n engl j med   nejm.org 2Magnetic resonance imaging (MRI) of the brain was performed in 13 patients (Figs. S1 through S3 in the Supplementary Appendix, avail-able with the full text of this letter at NEJM.org). Although these patients did not have focal signs that suggested stroke, they underwent MRI be-cause of unexplained encephalopathic features. Enhancement in leptomeningeal spaces was noted in 8 patients, and bilateral frontotemporal hypo-perfusion was noted in all 11 patients who under-went perfusion imaging. Two asymptomatic pa-tients each had a small acute ischemic stroke with focal hyperintensity on diffusion-weighted imaging and an overlapping decreased apparent diffusion coefficient, and 1 patient had a sub-acute ischemic stroke with superimposed in-creased diffusion-weighted imaging and appar-ent diffusion coefficient signals.In the 8 patients who underwent electroen-cephalography, only nonspecific changes were detected; 1 of the 8 patients had diffuse bifron-tal slowing consistent with encephalopathy. Examination of cerebrospinal fluid (CSF) sam-ples obtained from 7 patients showed no cells; in 2 patients, oligoclonal bands were present with an identical electrophoretic pattern in serum, and protein and IgG levels were elevated in 1 patient. RT-PCR assays of the CSF samples were negative for SARS-CoV-2 in all 7 patients.In this consecutive series of patients, ARDS due to SARS-CoV-2 infection was associated with encephalopathy, prominent agitation and confu-sion, and corticospinal tract signs. Two of 13 patients who underwent brain MRI had single acute ischemic strokes. Data are lacking to deter-mine which of these features were due to critical illnessŒrelated encephalopathy, cytokines, or the effect or withdrawal of medication, and which features were specific to SARS-CoV-2 infection.Julie Helms, M.D., Ph.D. Stéphane Kremer, M.D., Ph.D. Hamid Merdji, M.D. Raphaël Clere-Jehl, M.D. Malika Schenck, M.D. Christine Kummerlen, M.D. Olivier Collange, M.D., Ph.D. Clotilde Boulay, M.D. Samira Fafi-Kremer, Pharm.D., Ph.D. Mickaël Ohana, M.D., Ph.D. Mathieu Anheim, M.D., Ph.D.Strasbourg University Hospital Strasbourg, FranceFerhat Meziani, M.D., Ph.D.University of Strasbourg Strasbourg, FranceDisclosure forms provided by the authors are available with the full text of this letter at NEJM.org.This letter was published on April 15, 2020, at NEJM.org.DOI:˜10.1056/NEJMc2008597Correspondence Copyright © 2020 Massachusetts Medical Society.";20 avril 2020 
0;oncologie;Immunothérapie anticancéreuse et COVID -19;Nathalie Ganne-Carrié;https://www.groupedeveillecovid.fr/blog/2020/03/26/immunotherapie-anticancereuse-covid-19/;15; 15 © 2020 AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES WWW.AASLD.ORG | Released March 23, 2020 28. Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020. H.R. 6074. 116th Congress (2019-2020). https://congress.gov/bill/116th-congress/house-bill/6074. Published March 6, 2020. Accessed March 2020. ;26 mars 2020 
0;oncologie;Immunothérapie anticancéreuse et COVID -19;Nathalie Ganne-Carrié;https://www.groupedeveillecovid.fr/blog/2020/03/26/immunotherapie-anticancereuse-covid-19/;2;"2 www.thelancet.com/gastrohep   Published online March 17, 2020   https://doi.org/10.1016/S2468-1253(20)30080-7Yong Xiao, Hong Pan, Qian She, Fen Wang, *Mingkai Chenkaimingchen@163.comDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China (YX, QS, MC); Department of Plastic Surgery, TongRen Hospital of Wuhan University, Wuhan Third Hospital, Wuhan, China (HP); and Department of Gastroenterology, Third XiangYa Hospital Central South University, Changsha, China (FW)1 Zhang C, Shi L, Wang F. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020; published online March 4. DOI:10.1016/S2468-1253(20)30057-1.2 Strnad P, Tacke F, Koch A, Trautwein C. LiverŠguardian, modi˝er and target of sepsis. Nat Rev Gastroenterol Hepatol 2017; 14: 55Œ66.appendix p 4). This simple approach could be an effective means of preventing COVID-19 in patients with decompensated cirrhosis. However, our sample size is small and larger studies are needed.We declare no competing interests. We thank Xia Tian (Department of Gastroenterology, TongRen Hospital of Wuhan University, Wuhan Third Hospital, Wuhan, China), Hui Long (Department of Gastroenterology, Tianyou Hospital A˙liated to Wuhan University of Science and Technology, Wuhan, China); Xiaowei Wu and Ji Wang (Department of Gastroenterology, Hanyang Hospital A˙liated to Wuhan University of Science and Technology, Wuhan, China); Huimin Liu (Department of Gastroenterology, The Second A˙liated Hospital of Jianghan University, Wuhan Fifth Hospital, Wuhan, China); and Ying Xu (Department of Gastroenterology, Wuhan Hankou Hospital, Wuhan, China) for providing data regarding their inpatients with cirrhosis. YX and HP contributed equally.suggestive of SARS-CoV-2 infection. By contrast, ˝ve (2%) of 250 patients without cirrhosis and six (16%) of 38 health-care workers were diagnosed with COVID-19 by casual testing in our ward. Several outpatients complained about mild gastrointestinal and respiratory symptoms, which were resolved by rest, proton pump inhibitors, and probiotics (appendix p 2).As an additional comparator, we calculated the incidence of COVID-19 among 101 inpatients with decompensated cirrhosis at ˝ve other hospitals in Wuhan over the same period, where our approach had not been implemented. 17 (17%) of these 101 patients were diagnosed with COVID-19 (p=0·018 vs our group; ";26 mars 2020 
0;oncologie;Immunothérapie anticancéreuse et COVID -19;Nathalie Ganne-Carrié;https://www.groupedeveillecovid.fr/blog/2020/03/26/immunotherapie-anticancereuse-covid-19/;18;" !""#$%!&!$'()*+,-!./!0!1,*2-!-3!4'(,5-!6-2!4(34-,2!6*5-2+*72!-+!$89:%&/;!&!.<=><=.>.>!/q!.qX!:\(3*4e*&$(,D3!:M!%*!G*D,-!GM!ODSA-!:!-+!(CX!P2-7AC3-22!D7!+'-!F-,AN!$(,4*3D-NE,cD3*4!Q3+*5-3!d*3-+*4!7D,!$'-ND+'-,()c!^D3*+D,*35!*3!1(+*-3+2!f*+'!P3,-2-4+(EC-!^-+(2+(2*2!D7!$DCD,-4+(C!$(34-,X!`!$C*3!834DC!.>>qx!.p0<pq/&p!.;X!?(A,-3+!?M!F-7,*DA*!%M!U*53D3!Q?!-+!(CX!$Q/;X;!6-4,-(2-!•/jm!*2!(!),-6*4+D,!D7!7(BDA,(EC-!DA+4DN-!*3!)(+*-3+2!+,-(+-6!7D,!(6B(34-6!)(34,-(+*4!4(,4*3DN(0!(3(Cc2*2!D7!+\D!*36-)-36-3+!4D'D,+2X!T1U!.>/;x./0jq.&q!";26 mars 2020 
0;pharmacologie;Hydroxychloroquine et Azithromycine Rappel sur le risque cardiaque;null;https://www.groupedeveillecovid.fr/blog/2020/03/29/hydroxychloroquine-azithromycine-rappel-risque-cardiaque/;2;"*(ˇ(˙˝˘ˇ(9˙%&)˘)'˛ˇ&˙˝˛˚˜ !#$)ˇˆ8ˇ˙':˙(ˇAˇ)˙ˇ)˙<"" ˇ(ˇ()("" '*˘ˇˆ˙˝˛˚˜ <<77""'ˆ)'˙7""""ˇ7ˇ7ˇ""˙7)7*˘!ˇˆ˙˝˛˜ <<77˙""˙'ˆ7)#$*!˘˘!""(B#$%()˛+*˜<77CCC'˙)'˙7"")"")7ˆˇ)ˇ%<<77ˆˇ'""'ˆ)'˙7ˆDˇD7'ˇE7";29 mars 2020 
0;pharmacologie;Traditional Chinese medicine for COVID-19 treatment;Ren JL, Zhang AH, Wang XJ;https://www.groupedeveillecovid.fr/blog/2020/03/26/traditional-chinese-medicine-for-covid-19-treatment/;2;"-0..˝˛.(˝(1˙˝˝˙%(˝(2˝˝2(˙1,%(˝˛,1,+)%(˝˛˙1(˝(%(˝+1˙˙˛10%˚˘.#˝$H.@.K.F.M.K.F.@.:.K.@.Kˇ%I.@ˇ%I.:.@.7ˆ˙˝˛%H.M.1(ˆ-(0-ˆ˙ˆ˙0,ˆ,N,11.#ˆ$Pˆ1%ˆ˙ˆ˙R#1$˝,%ˆ˙ˆ˙.ˆ1%ˆ˙ˆ˙R#+$J.Kˇ%L.M.M.L.-ˆ˙ˆ˙0%.#)$M.M.M.:..#2$6.@ˇ%M.;.L.@.˘.L.L.M.L.K.;ˇ%L.M.L.G.˝˙.˝2+1(CD.˙)˝1˚+(,˙.ˆ˙ˆ˙˚˙˝12.#,$L.K.S+""˚/0˘-K.˚M.ˆ+Rˆ(R1˙R+.";26 mars 2020 
0;pharmacologie;Recommandations pour le Suivi Thérapeutique Pharmacologique du lopinavir/r et de l’hydroxychloroquine chez les patients traités pour une infection à SARS-CoV-2 (COVID-19);Marie-Claude Gagnieu, Rodolphe Garraffo, Matthieu Grégoire, Florian Lemaitre, Patrice Muret, Gilles Peytavin, Caroline Solas, Nicolas Venisse. Romain Guilhaumou (invité, président groupe STP-PT de la SFPT);https://www.groupedeveillecovid.fr/blog/2020/03/25/recommandations-suivi-therapeutique-pharmacologique-lopinavirr-de-lhydroxychloroquine-chez-patients-traites-infection-a-sars-cov-2-covid-19/;2;"Attention !! aux patients traités concomitamment par Lopinavir/r et Hydroxychloroquine : risque pharmacocinétique (augmentation  de ) et pharmacodynamique (allongement du QT).  2. STP Hydroxychloroquine Proposition de dosage chez les patients ambulatoires et de réanimation  CE50 de 0.72 µM soit 0.24 µg/ml (Yao et al, CID, 2020). Au décours de leur modèle PB/PK et des simulations réalisées, ils proposent une dose de charge de 400 mg BID à J1, suivi de 200 mg BID de J2 à J5. A ces posologies, les simulations montrent des concentrations plasmatiques apparemment faibles  mais qui pourraient néanmoins permettre une exposition pulmonaire importante avec des quotients inhibiteurs tissulaires libres très élevés de l. Un STP est à proposer avec dosage à effectuer en résiduel, et ce dautant plus si les comprimés dhydroxychloroquine doivent être écrasés pour les mettre dans la SNG. La fréquence des dosages peut être identique à celle du lopinavir en cas de co-administration et si  des capacités du service,  de un 1er dosage précoce entre J2 et J4. Un suivi peut être proposé 2x/semaine chez les patients hospitalisés. la valeur de CE50 mais, aucune niveau plasmatique valeurs attendues selon le schéma  et l'utilisation d'une dose de charge. Avec une posologie de 200 mg (>15 jours de traitement) varient de 0.2-faibles en période précoce. Une valeur seuil de 0.1 µg/ml doit être a minima obtenue. Proposition de conclusion si Cmin précoce faible (à l:  « Concentration à Jx inférieure aux valeurs habituellement observées à la posologie administrée, en lien avec un état d'équilibre pharmacocinétique non atteint (>15j après initiation du traitement). A confronter au contexte clinique. Un nouveau contrôle de la concentration est indiqué. »    Références 1. Yao X et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).Clin Infect Dis 2020 Mar 9[Online ahead of print]  2. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11: 222.  ";25 mars 2020 
0;precarite;Prevalence of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston;T Baggett;https://www.groupedeveillecovid.fr/blog/2020/05/04/prevalence-of-sars-cov-2-infection-in-residents-of-a-large-homeless-shelter-in-boston-2/;2;"COVID-atoutsidefacilitiesonApril,orApril(n=hadbeenremovedfromtheshelterpopulationandwereexcludedfromthisstudy.Participantswereaskedtoreporttheirage,sex,race,eth-nicity,andhistoryofcoughandshortnessofbreathandweregiventheoptiontoreportothersymptoms.Raceandethnic-itywerebasedonfixedresponsecategories.Otherreportedsymptomsweregroupedintocategoriesbytheinvestigators.Bodytemperaturemeasurementswereobtainedusingoralthermometers,withfeverdefinedasabodytemperatureofatleast°F.°C).Nasopharyngealspecimenswerecol-lectedbyBHCHPclinicalstaffusingapolyesterswabandsenttotheMassachusettsDepartmentofPublicHealthStatePub-licHealthLaboratoryforSARS-CoV-polymerasechainreac-tion(PCR)testing.Weuseddescriptivestatisticstocharacterizethestudysample,thepercentageofpositivePCRtestresults,andthesymptomprofileofindividualswithPCR-confirmedinfec-tions.ThisstudywasexemptedbythePartnersHealthCareHu-manResearchCommitteewithawaiverofinformedconsent.Results|Allindividualsresidingintheshelter(N=)un-derwentsymptomassessmentandSARS-CoV-PCRtesting.Therewerenoknownrefusals.Themeanageofthepartici-pantswasyears;%ofparticipantsweremen,%wereblackorAfricanAmerican,and.%wereHispanicorLatino(Table).Amongallparticipants,hadfever;.%reportedcough;.%reportedshortnessofbreath;andreportedothersymptoms,including%withnasalorsinussymptomsandwithdiarrhea.Overall,individuals(.%)reportednosymptoms.Atotalofparticipants.hadPCRtestresultspositiveforSARS-CoV-.Menconstituted%ofindividu-alswithPCR-positiveresultsand%ofindividualswithPCR-negativeresults.AmongindividualswithPCRtestresultspositiveforSARS-CoV-,cough(%),shortnessofbreath%),andfever(.%)werealluncommon,and.%wereasymptomatic.Discussion|UniversalSARS-CoV-PCRtestingofanadulthome-lessshelterpopulationinBostonshortlyaftertheidentifica-tionofaCOVID-caseclusteryieldeda%positivityrate.Themajorityofindividualswithnewlyidentifiedinfectionshadnosymptomsandnofeveratthetimeofdiagnosis,sug-gestingthatsymptomscreeninginhomelesssheltersmaynotadequatelycapturetheextentofdiseasetransmissioninthishigh-risksetting.Limitationsofthisstudyincludethecross-sectionalnatureofthestudyatasingleshelterinBostonwhereseveralsymptomaticindividualshadbeenremovedthroughpriorsymptomscreeningorself-referralstooutsidecare.TheseresultssupportPCRtestingofasymptomaticshelterresi-dentsifasymptomaticindividualwithCOVID-isidentifiedinthesameshelter.TravisP.Baggett,MD,MPHHarrisonKeyes,MPAS,PA-CNoraSporn,MA,MPHJessieM.Gaeta,MDAuthorAffiliations:InstituteforResearch,Quality,andPolicyinHomelessHealthCare,BostonHealthCarefortheHomelessProgram,Boston,Massachusetts(Baggett,Keyes,Gaeta);DivisionofGeneralInternalMedicine,MassachusettsGeneralHospital,Boston(Sporn).CorrespondingAuthor:TravisP.Baggett,MD,MPH,DivisionofGeneralInternalMedicine,MassachusettsGeneralHospital,100CambridgeSt,16thFloor,Boston,MA02114(tbaggett@mgh.harvard.edu).PublishedOnline:April27,2020.doi:10.1001/jama.2020.6887ConflictofInterestDisclosures:DrBaggettreportedreceivingroyaltiesfromUpToDateforauthorshipofatopicreviewonhomelesshealthcare.MrKeyesreportedreceivingnonfinancialsupportfromtheMassachusettsDepartmentofPublicHealthandtheshelterwherethetestingwasconductedduringtheconductofthestudy.Nootherdisclosureswerereported.PreviousPosting:ThismanuscriptwaspostedasapreprintonmedRxiv.orgonApril15,2020.doi:10.1101/2020.04.12.20059618AdditionalContributions:WethankAlfredDeMaria,MD,andcolleaguesattheMassachusettsDepartmentofPublicHealthBureauofInfectiousDiseaseforfacilitatingthetestingdescribedinthisarticle.WethankJoanaBarbosaTeixeira,MA;AndreaJoyce,MA;ElijahRodriguez,BA;ErinFord,BA(MassachusettsGeneralHospital);andAlexeiAlvarado,BA(BostonHealthCarefortheHomelessProgram),fortheirassistancewithdataentry.Noneoftheseindividualswerecompensatedfortheircontributions.1.HenryM,WattR,MahatheyA,OuelletteJ,SitlerA.The2019AnnualHomelessAssessmentReport(AHAR)toCongress.Part1:Point-in-TimeEstimatesofHomelessness.USDepartmentofHousingandUrbanDevelopment;2020.2.Interimguidanceforhomelessserviceproviderstoplanandrespondtocoronavirusdisease2019(COVID-19).CentersforDiseaseControlandPrevention.AccessedApril2,2020.https://www.cdc.gov/coronavirus/2019-ncov/community/homeless-shelters/plan-prepare-respond.htmlLettersE2JAMAPublishedonlineApril27,2020(Reprinted)jama.com©2020AmericanMedicalAssociation.Allrightsreserved.";4 mai 2020 
0;psychiatrie;Mitigating the psychological effects of social isolation during the covid-19 pandemic;Mohammad S Raza and al;https://www.groupedeveillecovid.fr/blog/2020/05/26/mitigating-the-psychological-effects-of-social-isolation-during-the-covid-19-pandemic/;5;"HowpatientswereinvolvedinthecreationofthisarticleApatientreadthemanuscriptandprovidedfeedbackontherelevanceandusefulnessofthescreeningquestions,especiallyforloneliness.Shebelievedsocialprescribingsuchasremotevideoortelephonewelfarecallsandcounsellingmakeapositivedifferenceinovercominganxietyandloneliness.HowthisarticlewasmadeThisarticleusesbestavailableevidence,recentresearchpapers,andthelatestadvicefromtheWHO.SearchstrategyWeusedweb-basedsystematicreviews,otherrelevantpublishedresearchandlatestguidelines.Additionalresourcesweredrawnfromourpersonaldatasets.Competinginterests:WehavereadandunderstoodBMJpolicyondeclarationofinterestsandhavenorelevantintereststodeclare.Patientconsent:Patientconsentnotrequired(patientanonymised,dead,orhypothetical).Provenanceandpeerreview:Commissioned,basedonanideafromtheauthor;externallypeerreviewed.WethanktheBMJeditorsandindependentpeerreviewersfortheirhelpfulcommentsandfeedback.1WorldHealthOrganization.MentalhealthandpsychosocialconsiderationsduringtheCOVID-19outbreak.2020.https://www.who.int/docs/default-source/coronaviruse/mental-health-consider-ations.pdf.2PublicHealthEngland.Guidanceforthepubliconthementalhealthandwellbeingaspectsofcoronavirus(COVID-19).2020.https://www.gov.uk/government/publications/covid-19-guidance-for-the-public-on-mental-health-and-wellbeing/guidance-for-the-public-on-the-mental-health-and-wellbeing-aspects-of-coronavirus-covid-19.3HawryluckL,GoldWL,RobinsonS,PogorskiS,GaleaS,StyraR.SARScontrolandpsychologicaleffectsofquarantine,Toronto,Canada.EmergInfectDis2004;10:1206-12.doi:10.3201/eid1007.030703pmid:153245394JeongH,YimHW,SongY-J,etal.MentalhealthstatusofpeopleisolatedduetoMiddleEastrespiratorysyndrome.EpidemiolHealth2016;38:.doi:10.4178/epih.e2016048doi:10.4178/epih.e2016048pmid:281964095BrooksSK,WebsterRK,SmithLE,etal.Thepsychologicalimpactofquarantineandhowtoreduceit:rapidreviewoftheevidence.Lancet2020;395:912-20.doi:10.1016/S0140-6736(20)30460-8pmid:321127146TaylorMR,AghoKE,StevensGJ,RaphaelB.Factorsinfluencingpsychologicaldistressduringadiseaseepidemic:datafromAustraliasfirstoutbreakofequineinfluenza.BMCPublicHealth2008;8:347.doi:10.1186/1471-2458-8-347pmid:188317707SprangG,SilmanM.Posttraumaticstressdisorderinparentsandyouthafterhealth-relateddisasters.DisasterMedPublicHealthPrep2013;7:105-10.doi:10.1017/dmp.2013.22pmid:246181428ReynoldsDL,GarayJR,DeamondSL,MoranMK,GoldW,StyraR.Understanding,complianceandpsychologicalimpactoftheSARSquarantineexperience.EpidemiolInfect2008;136:997-1007.doi:10.1017/S0950268807009156pmid:176621679PeplauLA,PerlmanD.Perspectivesonloneliness.In:PeplauLA,PerlmanD,eds.Loneliness:Asourcebookofcurrenttheory,researchandtherapy.Wiley,1982:1-8.10Holt-LunstadJ,SmithTB,BakerM,HarrisT,StephensonD.Lonelinessandsocialisolationasriskfactorsformortality:ameta-analyticreview.PerspectPsycholSci2015;10:227-37..doi:10.1177/1745691614568352pmid:2591039211CourtinE,KnappM.Socialisolation,lonelinessandhealthinoldage:ascopingreview.HealthSocCareCommunity2017;25:799-812..pmid:2671258512DrussBG.AddressingtheCOVID-19pandemicinpopulationswithseriousmentalillness.JAMAPsychiatry2020;.doi:10.1001/jamapsychiatry.2020.0894pmid:3224288813TeutonJ.SocialisolationandlonelinessinScotland:areviewofprevalenceandtrends.NHSHealthScotland,2018.http://www.healthscotland.scot/media/1712/social-isolation-and-loneliness-in-scotland-a-review-of-prevalence-and-trends.pdf.14HeathI.Themysteryofgeneralpractice.NuffieldProvincialHospitalTrust,1995.15RiddM,ShawA,LewisG,SalisburyC.Thepatient-doctorrelationship:asynthesisofthequalitativeliteratureonpatientsperspectives.BrJGenPract2009;59:e116-33.pmid:1934154716PereiraGrayDJ,Sidaway-LeeK,WhiteE,ThorneA,EvansPH.Continuityofcarewithdoctors-amatteroflifeanddeath?Asystematicreviewofcontinuityofcareandmortality.BMJOpen2018;8:..doi:10.1136/bmjopen-2017-021161pmid:2995914617AdviceServicesAlliance.Theroleofadviceservicesinhealthoutcomes:evidencereviewandmappingstudy.2015.https://www.thelegaleducationfoundation.org/wp-content/up-loads/2015/06/Role-of-Advice-Services-in-Health-Outcomes.pdf.18KroenkeK,SpitzerRL,WilliamsJB,LöweB.Anultra-briefscreeningscaleforanxietyanddepression:thePHQ-4.Psychosomatics2009;50:613-21.pmid:1999623319FerenchickEK,RamanujP,PincusHA.Depressioninprimarycare:part1-screeninganddiagnosis.BMJ2019;365:l794.doi:10.1136/bmj.l794pmid:3096218420HughesME,WaiteLJ,HawkleyLC,CacioppoJT.Ashortscaleformeasuringlonelinessinlargesurveys:resultsfromtwopopulation-basedstudies.ResAging2004;26:655-72.doi:10.1177/0164027504268574pmid:1850450621ParkIH,RachmatullahA,ParkIS,LiuY.AssessmentofthequalityandgeneralizabilityoftherevisedUCLAlonelinessscaleinChineseandKoreancommunity-dwellingelderlypopulationsusingitemresponsetheory(IRT)-RaschmodelingandhybridIRT-logisticregression.EducGerontol2019;45:581-99.doi:10.1080/03601277.2019.167090822DurakM,Senol-DurakE.PsychometricqualitiesoftheUCLALonelinessScale-Version3asappliedinaTurkishculture.EducGerontol2010;36:988-1007doi:10.1080/0360127100375662823SteptoeA,ShankarA,DemakakosP,WardleJ.Socialisolation,loneliness,andall-causemortalityinoldermenandwomen.ProcNatlAcadSciUSA2013;110:5797-801.doi:10.1073/pnas.1219686110pmid:2353019124vanderKriekeL,WunderinkL,EmerenciaAC,deJongeP,SytemaS.E-mentalhealthself-managementforpsychoticdisorders:stateoftheartandfutureperspectives.PsychiatrServ2014;65:33-49.doi:10.1176/appi.ps.201300050pmid:2412984225AndrewsG,BasuA,CuijpersP,etal.Computertherapyfortheanxietyanddepressiondisordersiseffective,acceptableandpracticalhealthcare:anupdatedmeta-analysis.JAnxietyDisord2018;55:70-8..doi:10.1016/j.janxdis.2018.01.001pmid:2942240926LalS,AdairCE.E-mentalhealth:arapidreviewoftheliterature.PsychiatrServ2014;65:24-32.doi:10.1176/appi.ps.201300009pmid:2408118827ChoiNG,HegelMT,MartiN,MarinucciML,SirrianniL,BruceML.Telehealthproblem-solvingtherapyfordepressedlow-incomehomeboundolderadults.AmJGeriatrPsychiatry2014;22:263-71.doi:10.1016/j.jagp.2013.01.037pmid:2356737628ChavooshiB,MohammadkhaniP,DolatshahiB.Arandomizeddouble-blindcontrolledtrialcomparingDavanloointensiveshort-termdynamicpsychotherapyasinternet-deliveredvstreatmentasusualformedicallyunexplainedpain:a6-monthpilotstudy.Psychosomatics2016;57:292-300.doi:10.1016/j.psym.2016.01.001pmid:2701745029McKinstryB,WatsonP,PinnockH,HeaneyD,SheikhA.Telephoneconsultinginprimarycare:atriangulatedqualitativestudyofpatientsandproviders.BrJGenPract2009;59:e209-18.doi:10.3399/bjgp09X420941pmid:1952001930ShawS,WhertonJ,VijayaraghavanS,etal.Healthservicesanddeliveryresearch.AdvantagesandlimitationsofvirtualonlineconsultationsinaNHSacutetrust:theVOCALmixed-methodsstudy.NIHRJournalsLibrary,2018.31DonaghyE,AthertonH,HammersleyV,etal.Acceptability,benefits,andchallengesofvideoconsulting:aqualitativestudyinprimarycare.BrJGenPract2019;69:e586-94.doi:10.3399/bjgp19X704141pmid:3116036832GreenhalghT,KohGCH,CarJ.Covid-19:aremoteassessmentinprimarycare.BMJ2020;368:m1182..doi:10.1136/bmj.m1182pmid:3221350733TsaiH-H,ChengC-Y,ShiehW-Y,ChangY-C.Effectsofasmartphone-basedvideoconferencingprogramforoldernursinghomeresidentsondepression,loneliness,andqualityoflife:aquasi-experimentalstudy.BMCGeriatr2020;20:27.doi:10.1186/s12877-020-1426-2pmid:3199221734KurtzSM,SilvermanJD.TheCalgary-CambridgeReferencedObservationGuides:anaidtodefiningthecurriculumandorganizingtheteachingincommunicationtrainingprogrammes.MedEduc1996;30:83-9..doi:10.1111/j.1365-2923.1996.tb00724.xpmid:873624235DrinkwaterC,WildmanJ,MoffattS.Socialprescribing.BMJ2019;364:l1285.doi:10.1136/bmj.l1285pmid:3092303936WorldHealthOrganization.Whatistheevidenceontheroleoftheartsinimprovinghealthandwell-being?Ascopingreview.2019.http://www.euro.who.int/en/publications/abstracts/what-is-the-evidence-on-the-role-of-the-arts-in-improving-health-and-well-being-a-scoping-review-2019.37MahaseE.Newhealthsecretarypledges£4.5mtowardsGPsocialprescribingUK.Pulse2018.http://www.pulsetoday.co.uk/clinical/clinical-specialties/prescribing/new-health-secretary-pledges-45m-towards-gp-social-prescribing/20037122.article.38JensenA,StickleyT,TorrissenW,StigmarK.ArtsonprescriptioninScandinavia:areviewofcurrentpracticeandfuturepossibilities.PerspectPublicHealth2017;137:268-74.doi:10.1177/1757913916676853pmid:2785283739AlderwickHAJ,GottliebLM,FichtenbergCM,AdlerNE.SocialprescribingintheUSandEngland:emerginginterventionstoaddresspatientssocialneeds.AmJPrevMed2018;54:715-8.doi:10.1016/j.amepre.2018.01.039pmid:2955132640NHSEngland.Socialprescribingandcommunity-basedsupport.2020.https://www.eng-land.nhs.uk/personalisedcare/social-prescribing/.41OfficeforNationalStatistics.Internetusers,UK:2019.https://www.ons.gov.uk/businessindus-tryandtrade/itandinternetindustry/bulletins/internetusers/2019.42BeaneyT,SalmanD,VishnubalaD.Theeffectsofisolationonthephysicalandmentalhealthofolderadults.BMJOpinion2020.https://blogs.bmj.com/bmj/2020/04/09/the-effects-of-isolation-on-the-physical-and-mental-health-of-older-adults/.5the bmj | BMJ 2020;369:m1904 | doi: 10.1136/bmj.m1904PRACTICE on 26 May 2020 at Universite Louis Pasteur Strasbourg. Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.m1904 on 21 May 2020. Downloaded from ";26 mai 2020 
0;psychiatrie;Enjeux de l’utilisation des psychotropes dans le cadre de la pandémie au SARS-Cov-2;H. Javelot et al;https://www.groupedeveillecovid.fr/blog/2020/05/06/enjeux-de-lutilisation-psychotropes-cadre-de-pandemie-sars-cov-2/;3;"Pour citer cet article : Javelot H, et al. Enjeux de l’utilisation des psychotropes dans le cadre de la pandémie au SARS-Cov-2. Encéphale(2020), https://doi.org/10.1016/j.encep.2020.04.009ARTICLE IN PRESSG ModelENCEP-1260; No. of Pages 3H. Javelot et al. / L’Encéphale xxx (2020) xxx–xxx 3[9] Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief ofbreathlessness in advanced malignant and non-malignant diseases in adults.Cochrane Database Syst Rev 2016;10:CD007354.[10] Mason M, Welsh EJ, Smith I. Drug therapy for obstructive sleep apnoea in adults.Cochrane Database Syst Rev 2013;(5):CD003002.[11] Lovell N, Bajwah S, Maddocks M, et al. Use of mirtazapine in patients withchronic breathlessness: A case series. Palliat Med 2018;32(9):1518–21.[12] Lovell N, Wilcock A, Bajwah S, et al. Mirtazapine for chronic breathlessness?A review of mechanistic insights and therapeutic potential. Expert Rev RespirMed 2019;13(2):173–80.[13] Dzahini O, Singh N, Taylor D, et al. Antipsychotic drug use and pneumonia: Sys-tematic review and meta-analysis. J Psychopharmacol 2018;32(11):1167–81.[14] de Leon J, Sanz EJ, Norén GN, et al. Pneumonia may be more frequent andhave more fatal outcomes with clozapine than with other second-generationantipsychotics. World Psychiatry 2020;19(1):120–1.[15] Siskind D, Honer WG, Clark S, et al. Consensus statement on the use of clozapineduring the COVID-19 pandemic. J Psychiatry Neurosci 2020;45(3):2.[16] Javelot H, Llorca P-M, Drapier D, et al. Soins Troubles psychiques pendantSARS-CoV-2. Informations relatives aux psychotropes et à leurs adaptationséventuelles pour les patients souffrant de troubles psychiques en France pen-dant l’épidémie à SARS-CoV-2. Encéphale 2020 [sous presse].[17] Colbert SA, McCarron S, Ryan G, et al. Images in Clinical ECT: Immediate impactof COVID-19 on ECT Practice. J ECT 2020.[18] ANSM. Monographie de l’aripiprazole, consultée via http://base-donnees-publique.medicaments.gouv.fr/index.php le19/04/2020.[19] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of2019 novel coronavirus: implications for virus origins and receptor binding.Lancet 2020;395(10224):565–74.[20] Yang SY, Liao YT, Liu HC, et al. Antipsychotic drugs, mood stabilizers, and riskof pneumonia in bipolar disorder: a nationwide case-control study. J Clin Psy-chiatry 2013;74(1):e79–86.[21] Chen L, Gui C, Luo X, et al. Cinanserin is an inhibitor of the 3C-like proteinaseof severe acute respiratory syndrome coronavirus and strongly reduces virusreplication in vitro. J Virol 2005;79(11):7095–103.";6 mai 2020 
0;psychiatrie;COVID-19 and (hydroxy)chloroquine-Azithromycin combination: Should we take the risk for our patients?;H. Javelot et al;https://www.groupedeveillecovid.fr/blog/2020/05/06/covid-19-and-hydroxychloroquine-azithromycin-combination-should-we-take-the-risk-for-our-patients/;4;"  This article is protected by copyright. All rights reserved. References:  1Yao H, Chen J, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):e21. 2Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020:105938.  3Hancox JC, Hasnain M, Vieweg WV, Crouse EL, Baranchuk A. Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports. Ther Adv Infect Dis. 2013;1(5):155-65. 4Woosley RL, Black K, Heise CW, Romero K. CredibleMeds.org: What does it offer? Trends Cardiovasc Med. 2018;28(2):94-99.  5Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39(1):16-25.   ";6 mai 2020 
0;psychiatrie;Informations relatives aux psychotropes et à leurs adaptations éventuelles pour les patients souffrant de troubles psychiques en France pendant l’épidémie à SARS-CoV-2;H. Javelot et al;https://www.groupedeveillecovid.fr/blog/2020/05/06/informations-relatives-aux-psychotropes-a-leurs-adaptations-eventuelles-patients-souffrant-de-troubles-psychiques-france-pendant-lepidemie-a-sars-cov-2/;21;"Pour citer cet article : Javelot H, et al. Informations relatives aux psychotropes et à leurs adaptations éventuellespour les patients souffrant de troubles psychiques en France pendant l’épidémie à SARS-CoV-2. Encéphale (2020),https://doi.org/10.1016/j.encep.2020.04.006ARTICLE IN PRESSG ModelENCEP-1257; No. of Pages 21H. Javelot et al. / L’Encéphale xxx (2020) xxx–xxx 21[59] ANSM 2020 (point d’information COVID-19). https://www.ansm.sante.fr/S-informer/Points-d-information-Points-d-information/COVID-19-l-ANSM-prend-des-mesures-pour-favoriser-le-bon-usage-du-paracetamol.[60] ANSM. 18/04/2019. https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Anti-inﬂammatoires-non-steroidiens-AINS-et-complications-infectieuses-graves-Point-d-Information.[61] Willsher K. Anti-inﬂammatories may aggravate Covid-19, Franceadvises [Internet]; 2020 [Available from: https://www.theguardian.com/world/2020/mar/14/anti-inﬂammatory-drugs-may-aggravate-coronavirusinfection. Accessed March 16, 2020].[62] Day M. Covid-19: ibuprofen should not be used for managing symptoms, saydoctors and scientists. BMJ 2020;368:m1086.[63] Little P. Non-steroidal anti-inﬂammatory drugs and covid-19. BMJ2020;368:m1185.[64] Russell B, Moss C, Rigg A, et al. COVID-19 and treatment with NSAIDs and cor-ticosteroids: should we be limiting their use in the clinical setting? ecancer2020;14:1023.[65] Ciriaco M, Ventrice P, Russo G, et al. Corticosteroid-related central nervoussystem side effects. J Pharmacol Pharmacother 2013;4(Suppl. 1):S94–8.[66] Dubovsky AN, Arvikar S, Stern TA, et al. The neuropsychiatric compli-cations of glucocorticoid use: steroid psychosis revisited. Psychosomatics2012;53(2):103–15.[67] Ricoux A, Guitteny-Collas M, Sauvaget A, et al. Oral glucocorticoid-induced psy-chiatric side effects: focus on clinical speciﬁcities, incidence, risk factors andtreatment. Rev Med Interne 2013;34(5):293–302.[68] Franke AG, Bagusat C, Rust S, et al. Substances used and prevalence rates ofpharmacological cognitive enhancement among healthy subjects. Eur ArchPsychiatry Clin Neurosci 2014;264(Suppl. 1):S83–90.[69] Woosley RL, Black K, Heise CW, et al. CredibleMeds.org: what does it offer?Trends Cardiovasc Med 2018;28(2):94–9.[70] Vandael E, Vandenberk B, Vandenberghe J, et al. Risk factors for QTc prolonga-tion: systematic review of the evidence. Int J Clin Pharm 2017;39(1):16–25.[71] Rochoy M, Auffret M, Béné J, et al. Antiemetics and cardiac effects potentiallylinked to prolongation of the QT interval: Case/non-case analysis in the nationalpharmacovigilance database. Rev Epidemiol Sante Publique 2017;65(1):1–8.[72] HAS. 2019 [mise en ligne 27 mai 2019]. https://www.has-sante.fr/jcms/c 2966830/fr/medicaments-antiemetiques-dans-le-traitement-symptomatique-des-nausees-et-vomissements.[73] Couchman L, Morgan PE, Spencer EP, et al. Plasma clozapine, norclozapine,and the clozapine:norclozapine ratio in relation to prescribed dose and otherfactors: data from a therapeutic drug monitoring service, 1993–2007. Ther DrugMonit 2010;32(4):438–47.[74] ANSM 11/12/2012. https://ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Decongestionnants-de-la-sphere-ORL-renfermant-un-vasoconstricteur-Mise-en-garde-de-l-ANSM-Point-d-information-actualise.[75] ANSM 30/03/2020. https://ansm.sante.fr/S-informer/Actualite/Plaquenil-et-Kaletra-les-traitements-testes-pour-soigner-les-patients-COVID-19-ne-doivent-etre-utilises-qu-a-l-hopital-Point-d-information.[76] Hancox JC, Hasnain M, Vieweg WV, et al. Azithromycin, cardiovascular risks,QTc interval prolongation, torsade de pointes, and regulatory issues: a nar-rative review based on the study of case reports. Ther Adv Infect Dis2013;1(5):155–65.[77] Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr2020;14(3):247–50.[78] Carvalho PMM, Moreira MM, de Oliveira MNA, et al. The psychiatric impact ofthe novel coronavirus outbreak. Psychiatry Res 2020;286:112902.[79] Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infec-tion with COVID-19 and other coronaviruses. Brain Behav Immun 2020,http://dx.doi.org/10.1016/j.bbi.2020.03.031 [pii: S0889-1591(20)30357-3].[80] Moriguchi T, Harii N, Goto J, et al. A ﬁrst case of meningitis/encephalitisassociated with SARS-Coronavirus-2. Int J Infect Dis 2020, http://dx.doi.org/10.1016/j.ijid.2020.03.062 [pii: S1201-9712(20)30195-8].";6 mai 2020 
0;psychiatrie;Mise en œuvre des actions de prévention en santé mentale;null;https://www.groupedeveillecovid.fr/blog/2020/04/03/mise-oeuvre-actions-de-prevention-sante-mentale/;8;COVID-19 : Actions de prévention en santé mentale  version n°1  21/03/2020 - Page 8 sur 8  Agence régionale de santé Île-de-France  Le Millénaire 2, 35 rue de la Gare, 75935 PARIS Cedex 19  https://www.iledefrance.ars.sante.fr   - The psychological impact of quarantine and how to reduce it: rapid review of the evidence. oks PhD, R K Webster PhD, L E Smith PhD, L Woodland MSc, Prof S Wessely FMedSci, Prof N Greenberg FRCPsych, G J Rubin PhD) Published online February 26, 2020 https://doi.org/10.1016/S0140-6736(20)30460-8  www.thelancet.com Vol 395 March 14, 2020  - Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. Published Online February 4, 2020 https://doi.org/10.1016/S2215-0366(20)30046-8 www.thelancet.com/psychiatry Vol 7 March 2020  - Prendre soin des patients pendant l'épidémie de coronavirus : Un guide pour les psychiatres, psychologues et soignants de santé mentale. Fiche traduite & adaptée de Center for Study of Traumatic Stress, www.CSTSonline.org par S Guillaume, Ph Courtet, E Olié, Dpt UPUP CHU Montpellier grâce à la veille du Dr A Chevance (U Paris)  - Coronavirus Disease 2019 (COVID-19) Manage Anxiety & Stress. Information for parents. CDC Centers for disease control and prevention cité dans Covid-19 : point par point, des confinement. Publié en ligne 16 mars 2020, 23:43 CET, par Catherine Tourette-Turgis sur la page The Conversation France https://theconversation.com/covid-19-point-par-point-des-recommandations-dexperts-pour-reduire-les-effets-psychologiques-negatifs-lies-au-confinement-133811    ;3 avril 2020 
0;psychiatrie;CONSIGNES ET RECOMMANDATIONS APPLICABLES À L’ORGANISATION DES PRISES EN CHARGE DANS LES SERVICES DE PSYCHIATRIE ET LES ÉTABLISSEMENTS SANITAIRES AUTORISÉS EN PSYCHIATRIE;null;https://www.groupedeveillecovid.fr/blog/2020/04/03/consignes-recommandations-applicables-a-lorganisation-prises-charge-services-de-psychiatrie-etablissements-sanitaires-autorises-psychiatrie/;7;" 23/03/2020  7   Corriger la désinformation et limiter l'exposition aux médias et leur impact ;  Soutenir la fonction soignante et éduquer sur les réactions psychologiques et comportementales courantes en cas d'épidémies, sur les interventions pour gérer la détresse et les comportements à risque pour la santé, et sur l'importance d'une communication adaptée en ce qui concerne les risques ;  s'occuper de ceux qui en ont besoin.  4.2. Défis pour le personne   Forte augmentation des demandes de soins / personnel insuffisant   Crainte de contracter la maladie et de la transmettre à sa famille, ses amis, et ses collègues.  Gestion de la pénurie de matériel  Soutenir psychologiquement quand on est soi-même en difficulté (peur, tristesse, frustration, culpabilité, troubles du sommeil, épuisement).  4.3.  Préconisations à destination des encadrants et des encadrés pour le maintien du bien-être du personnel de santé   Rester en forme pour pouvoir continuer à aider les autres. Manger, boire et dormir régulièrement.   Encourager les pauses. Certaines personnes peuvent se sentir coupables si elles ne travaillent pas à plein temps ou prennent le temps de se détendre alors que d'autres souffrent. Promouvoir des temps de repos appropriés qui permettent de prendre soin des patients par la suite.  concentration de personnes dans une même salle et encourager les contacts, de préférence téléphoniques, entre collègues. Promouvoir le soutien réciproque et la lutte   Encourager les soignants à maintenir des liens avec leurs de leur soutien  Lutter collectivement contre la désinformation et la panique et limiter l'exposition aux médias. Les images et messages inquiétants augmentent le stress et peuvent nuire à   -surveillance   Mettre en valeur la fonction soignante  ";3 avril 2020 
0;radiologie;Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children;Zaigham M et Andersson O;https://www.groupedeveillecovid.fr/blog/2020/04/13/clinical-and-ct-imaging-features-of-the-covid-19-pneumonia-focus-on-pregnant-women-and-children/;7;"H. Liu, F. Liu and J. Li et al. / Journal of Infection xxx (xxxx) xxx 7 ARTICLE IN PRESS JID: YJINF [m5G; March 21, 2020;1:51 ] COVID-19 pneumonia were non-speciﬁc, while the exposure his- tory and clinical symptoms could be more helpful for the screen- ing. Contributors HL, FL, DW, and WL conceived the study conception and design. HL and FL contributed to the literature search. HL, FL, JL, and TZ performed the acquisition of data. HL and JL conducted the analysis and interpretation of data. HL and FL contributed to the ﬁgures. HL, FL and JL drafted the manuscript. DW and WL contributed to critical revision of the manuscript. Declaration of Competing Interest We declare no competing interests. References 1. Zhu N , Zhang D , Wang W , Li X , Yang B , Song J , et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020; 382 (8):727–33 . 2. Huang C , Wang Y , Li X , Ren L , Zhao J , Hu Y , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet 2020; 395 (10223):497–506 . 3. Chen N , Zhou M , Dong X , Qu J , Gong F , Han Y , et al. Epidemiological and clini- cal characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223):507–13 . 4. The International Committee on Taxonomy of Viruses (ICTV) Coronaviridae Study Group. Naming the 2019 Coronavirus. https://talk.ictvonline.org/ . 5. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneu- monia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. 2020;395(10223):514-523. 6. Phan LT , Nguyen TV , Luong QC , Nguyen TV , Nguyen HT , Le HQ , et al. Importa- tion and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med 2020; 382 (9):872–4 . 7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 Feb 7 Epub ahead of print. doi: 10.1001/jama.2020. 1585 . 8. National Health Commission of China. “Report of the latest situation of novel coronavirus pneumonia in China as of February 18, 2020”. http://www.nhc.gov. cn/xcs/yqtb/202002/8f2cfd17f4c040d89c69a4b29e99748c.shtml . 9. Yang Y , Lu Q , Liu M , Wang Y , Zhang A , Jalali N , et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv. 2020; 2020 02.10.20021675 . 10. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020 Jan 29 Epub ahead of print. doi: 10.1056/NEJMoa2001316 . 11. Guan WJ , Ni ZY , Hu Y , Liang WH , Ou CQ , He JX , et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv. 2020; 2020 02.06.20020974 . 12. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical 2019- nCoV Pneumonia: Relationship to Negative RT-PCR Testing. Radiology 2020 Feb 12 200343. Epub ahead of print. doi: 10.1148/radiol.2020200343 . 13. Huang P , Liu T , Huang L , Liu H , Lei M , Xu W , et al. Use of Chest CT in Com- bination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion. Radiology 2020; 295 (1):22–3 . 14. National Health Commission of China. “Diagnosis and Treatment for COVID-19 Pneumonia (Fifth Trial Version)”. http://www.nhc.gov.cn/ . 15. Mor G , Cardenas I , Abrahams V , Guller S . Inﬂammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci 2011; 1221 :80–7 . 16. Chen H , Guo J , Wang C , Luo F , Yu X , Zhang W , et al. Clinical characteris- tics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet 2020; 395 (10226):809–15 . 17. Zhu H , Wang L , Fang C , Peng S , Zhang L , Chang G , et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Translational Pediatrics 2020; 9 (1):51–60 . 18. World Health Organization. Technical-guidance for 2019-nCoV RT-PCR. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical- guidance/laboratory-guidance 19. Chung M , Bernheim A , Mei X , Zhang N , Huang M , Zeng X , et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology 2020; 295 (1):202–7 . 20. Song F , Shi N , Shan F , Zhang Z , Shen J , Lu H , et al. Emerging Coronavirus 2019-nCoV Pneumonia. Radiology 2020; 295 (1):210–17 . 21. Chang YC , Yu CJ , Chang SC , Galvin JR , Liu HM , Hsiao CH , et al. Pulmonary seque- lae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT. Radiology 2005; 236 (3):1067–75 . 22. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology 2020 Feb 26 200642. Epub ahead of print. doi: 10.1148/ radiol.2020200642 . 23. Toma P , Bartoloni A , Salerno S , Granata C , Cannata V , Magistrelli A , et al. Pro- tecting sensitive patient groups from imaging using ionizing radiation: effects during pregnancy, in fetal life and childhood. Radiol Med 2019; 124 (8):736–44 . 24. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological ﬁndings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases 2020 Feb 24 pii: S1473-3099(20)30086-4. Epub ahead of print. doi: 10.1016/S1473- 3099(20)30086- 4 . 25. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological ﬁndings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020 Feb 18 pii: S2213-260 0(20)30 076-X. Epub ahead of print. doi: 10.1016/ S2213-260 0(20)30 076-X . 26. Gourgoulianis KI , Karantanas AH , Diminikou G , Molyvdas PA . Benign postpar- tum pleural effusion. Eur Respir J 1995; 8 (10):1748–50 . 27. Koo HJ , Lim S , Choe J , Choi SH , Sung H , Do KH . Radiographic and CT Features of Viral Pneumonia. Radiographics 2018; 38 (3):719–39 . 28. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneu- monia. Radiology 2020 Feb 13 200370. Epub ahead of print. doi: 10.1148/radiol. 2020200370 . Please cite this article as: H. Liu, F. Liu and J. Li et al., Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children, Journal of Infection, https://doi.org/10.1016/j.jinf.2020.03.007 ";13 avril 2020 
0;radiologie;Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases;Tao Ai MD, Zhenlu Yang MD, Hongyan Hou , Chenao Zhan, Chong Chen, Wenzhi, Qian Tao, Ziyong Sun, Liming Xia ;https://www.groupedeveillecovid.fr/blog/2020/03/25/correlation-of-chest-ct-and-rt-pcr-testing-in-coronavirus-disease-2019-covid-19-in-china-a-report-of-1014-cases/;23;"23                 Figure 7: Analysis of serial RT-PCR assays in correlation with serial chest CT scans. (A) The subgroup of positive to negative RT-PCR results (n = 57). (B) The subgroup of negative to positive RT-PCR results (n = 15). The horizontal axis is the time point of initial chest CT and follow-up chest CT scans relative to the time point of the consecutive two RT-PCR tests (before positive RT-PCR, negative numbers; after RT-PCR, positive numbers). ";25 mars 2020 
0;radiologie;Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study;Wei Zhao, Zheng Zhong,Xingzhi Xie, Qizhi Yu, Jun Liu;https://www.groupedeveillecovid.fr/blog/2020/03/21/relation-between-chest-ct-findings-and-clinical-conditions-of-coronavirus-disease-covid-19-pneumonia-a-multicenter-study/;6;6 AJR:214, May 2020Zhao et al.-------------N Engl J Med-N Engl J MedN Engl J MedJ Virol-Lancet-N Engl J Med-N Engl J MedLancetLancet-Radiology-Radiology Radiology-RadiologyRadiologyAJR-RadiologyEur  RadiolRadi-ology;21 mars 2020 
0;radiologie;Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients;Sana Salehi, Aidin Abedi, Sudheer Balakrishnan, Ali Gholamrezanezhad;https://www.groupedeveillecovid.fr/blog/2020/03/19/coronavirus-disease-2019-covid-19-a-systematic-review-of-imaging-findings-in-919-patients/;7;AJR:215, November 2020 7Systematic Review of COVID-19 Imaging FindingsRadiol Cardiotho-rac ImagingRadiology-JAMALancet Radiology ---AJRAJRRadiology-Radiology Euro Surveill-Precis Clin Medclinical characteristics of novel coronavirus infec-JAMA-istics of novel coronavirus cases in tertiary hospi-Chin Med J (Engl)---Lancetcharacteristics and therapeutic procedure for four -Biosci Trends--J Am Coll Radiol RadiologyRadiol Cardiothorac Imaging --Sci China Life SciFOR YOUR INFORMATIONA data supplement for this article can be viewed in the online version of the article at: www.ajronline.org.;19 mars 2020 
0;reanimation;Covid-19 in Critically Ill Patients in the Seattle Region — Case Series;Pavan K. Bhatraju and al;https://www.groupedeveillecovid.fr/blog/2020/04/01/covid-19-in-critically-ill-patients-in-the-seattle-region-case-series/;3;Journal of Endocrinological Investigation  7. Zoppini G, Fedeli U, Schievano E, Dauriz M, Targher G, Bonora E, Corti MC (2018) Mortality from infectious diseases in diabetes. Nutr Metab Cardiovasc Dis 28:444Œ450Publisher™s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional a˝liations.;1 avril 2020 
0;serologie;Performance of SARS-CoV-2 antibody assays in different stages of the infection: Comparison of commercial ELISA and rapid tests;The Journal of Infectious Diseases;https://www.groupedeveillecovid.fr/blog/2020/06/08/performance-of-sars-cov-2-antibody-assays-in-different-stages-of-the-infection-comparison-of-commercial-elisa-and-rapid-tests/;16; 16  Figure 2  Downloaded from https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiaa305/5849070 by guest on 03 June 2020;8 juin 2020 
0;serologie;Seroprevalence of SARS-CoV-2 specific antibodiesamong adults in Los Angeles county, California, on april 10-11, 2020;Sood N. et al;https://www.groupedeveillecovid.fr/blog/2020/05/26/seroprevalence-of-sars-cov-2-specific-antibodiesamong-adults-in-los-angeles-county-california-on-april-10-11-2020/;2;"specificity%;%CI,..%)ofthetestkitswereobtainedfromdifferentsamples.%Confidenceinter-valsforunweighteddatawereestimatedusingexactbino-mialmodelsandforweightedandadjustedestimatesusingbootstrapmethods.WeusedStataversionfortheanalysis.Results|Ofindividualsinvitedtoparticipateinantibodytest-ing,(.providedconsentand.weretested.Thosenottestedcouldnotscheduletestingordidnotappear.Twotestresultswereinconclusiveduetofaultytestkitsandwereremovedfromtheanalysissample.Ofadultsincluded,werewomen,%wereagedtoyearsold,%werewhite,and%hadyearlyhouseholdincomesgreaterthan.Thirteenpercentreportedfeverwithcough,feverwithshort-nessofbreath,and%lossofsmellortaste(Table).Thirty-fiveindividuals(.%[exactbinomialCI,%-testedpositive.Thefractionthattestedpositivevar-iedbyrace/ethnicity,sex,andincome(Table).Theweightedproportionofparticipantswhotestedpositivewas%(boot-strapCI,.%).Afteradjustingfortestsensitivityandspecificity,theunweightedandweightedprevalenceofSARS-CoV-antibodieswas%(bootstrapCI,.%)and%(bootstrapCI,.%),respectively.Discussion|InthiscommunityseroprevalencestudyinLosAngelesCounty,theprevalenceofantibodiestoSARS-CoV-was%.TheestimateimpliesthatapproximatelyadultshadSARS-CoV-antibodies,whichissubstan-tiallygreaterthanthecumulativenumberofconfirmedinfectionsinthecountyonApril.Therefore,fatalityratesbasedonconfirmedcasesmaybehigherthanratesbasedonnumberofinfections.Inaddition,contacttracingmethodstolimitthespreadofinfectionwillfaceconsiderablechallenges.Thisstudyhaslimitations.Selectionbiasislikely.Thees-timatedprevalencemaybebiasedduetononresponseorthatsymptomaticpersonsmayhavebeenmorelikelytopartici-pate.Prevalenceestimatescouldchangewithnewinforma-tionontheaccuracyoftestkitsused.Also,thestudywaslim-itedtocounty.Serologictestinginotherlocationsiswarrantedtotracktheprogressoftheepidemic.NeerajSood,PhDPaulSimon,MDPeggyEbner,BADanielEichner,PhDJeffreyReynolds,MAEranBendavid,MDJayBhattacharya,MD,PhDAuthorAffiliations:SchaefferCenterforHealthPolicyandEconomics,SolPriceSchoolofPublicPolicy,UniversityofSouthernCalifornia,LosAngeles(Sood);LosAngelesCountyDepartmentofPublicHealth,LosAngeles,California(Simon);KeckSchoolofMedicine,UniversityofSouthernCalifornia,LosAngeles(Ebner);SportsMedicineResearchandTestingLaboratory,SaltLakeCity,Utah(Eichner);LRWGroup,LosAngeles,California(Reynolds);StanfordUniversitySchoolofMedicine,PaloAlto,California(Bendavid,Bhattacharya).CorrespondingAuthor:NeerajSood,PhD,UniversityofSouthernCalifornia,UniversityParkCampus,Verna&PeterDauteriveHall,635DowneyWay,LosAngeles,CA90089(nsood@healthpolicy.usc.edu).AcceptedforPublication:May1,2020.PublishedOnline:May18,2020.doi:10.1001/jama.2020.8279AuthorContributions:DrSoodhadfullaccesstoallofthedatainthestudyandtakesresponsibilityfortheintegrityofthedataandtheaccuracyofthedataanalysis.Conceptanddesign:Allauthors.Acquisition,analysis,orinterpretationofdata:Sood,Simon,Ebner,Reynolds,Bendavid,Bhattacharya.Draftingofthemanuscript:Sood,Bendavid,Bhattacharya.Criticalrevisionofthemanuscriptforimportantintellectualcontent:Allauthors.Statisticalanalysis:Sood,Simon,Reynolds,Bendavid,Bhattacharya.Obtainedfunding:Sood,Eichner,Reynolds,Bendavid.Administrative,technical,ormaterialsupport:Sood,Simon,Ebner,Eichner,Reynolds,Bhattacharya.Supervision:Sood,Simon,Ebner,Reynolds,Bhattacharya.ConflictofInterestDisclosures:DrSoodreportedreceivingfundingfromJedelFoundation,USCSchwarzeneggerInstitute,USCLuskCenter,USCPresident'sOffice,CatherineAhmed,BrentBayless,CaroleKing,DanielEichner,ReginaNordhal,ToreNordhal,andGauriJauharduringtheconductofthestudy;andreportedservingasascientificadvisortoPayssuranceandVirtaHealth;servingasanexpertwitnessfortheAmericanMedicalAssociationandGoldman,Ismail,Tomaselli,Brennan,andBaum;servingasaninternationalexpertfortheChinaDevelopmentResearchFoundationandthePharmaceuticalResearchandManufacturersofAmerica;andreceivinggrantsfromtheAgencyforHealthcareResearchandQuality,theNationalInstitutesofHealth,theNationalInstituteforHealthCareManagementFoundation,HealthCareServicesCorporation,andthePatient-CenteredOutcomesResearchInstituteoutsidethesubmittedwork.DrsBhattacharyaandBendavidreportedreceivingsupportfromJedelFoundationandtheStanfordCOVID-19SeroprevalenceStudiesFundduringtheconductofthestudy.Nootherdisclosureswerereported.Funding/Support:WereceivedpartialfinancialsupportforthisprojectthroughtheStanfordCOVID-19SeroprevalenceStudiesfund.WeacknowledgefundingfromUSCSchwarzeneggerInstitute,USCLuskCenter,USCPresident’sOffice,JedelFoundation,LRWGroup,SoapBoxSample,FoundationforCleanCompetition,PartnershipforCleanCompetition,andseveralindividualdonors.RoleoftheFunder/Sponsor:Fundingorganizationsanddonorshadnoroleinthedesignandconductofthestudy;collection,management,analysis,andinterpretationofthedata;preparation,review,orapprovalofthemanuscript;anddecisiontosubmitthemanuscriptforpublication.AdditionalContributions:WethankJimTedrow,BS,MT,TheComplianceResourceGroup;ThomasKupiec,PhD,ARLBioPharmaInc;ManishJ.Butte,MD,PhD,UniversityofCalifornia,LosAngeles;JasonBrooks,LRWGroup;andThomasMaCurdy,FrankWolak,andJohnP.A.Ioannidis,MD,DSc,StanfordUniversity,forcontributingtostudydesign.WethankRicardoBasurto-Davila,PhD,andIreneVidyanti,PhD,LosAngelesCountyChiefInformationOffice,forcontributingtostudydesignanddatacollection.WethankKevindeLeon,BA,andConyersDavis,MA,SchwarzeneggerInstituteforStateandGlobalPolicyattheUniversityofSouthernCalifornia;andCaroleKing,MEd,SolPriceSchoolofPublicPolicy,UniversityofSouthernCalifornia,LosAngeles,forlogisticalsupportduringdatacollectionandsecuringfunding.WethankJohnWaltonSenterfittandAlysiaKwon,ScM,LosAngelesCountyDepartmentofPublicHealth,forIRBsupport.WethankElinorGaida,MBA,MPH,andJacquelineRosales,BS,LRWGroup,forcontributingtorecruitinganddatacollection.WethankJanelleCyprich,BS,AcaciaHori,BA,AlexandraObremskey,BS,KatharineB.Stiers,BA,SilenaTe,BA,OmarToubat,BA,andothermedicalstudentvolunteersfromUSCKeckSchoolofMedicineforcontributionstodatacollection.Noneoftheindividualsacknowledgedreceivedcompensationfromthestudyteam.1.SpychalskiP,a-SpychalskaA,KobielaJ.EstimatingcasefatalityratesofCOVID-19.LancetInfectDis.2020;S1473-3099(20)30246-2.AccessedApril9,2020.PublishedonlineMarch31,2020.doi:10.1016/S1473-3099(20)30246-22.BendavidE,MulaneyB,SoodN,etal.COVID-19antibodyseroprevalenceinSantaClaraCounty,California.medRxiv.PreprintpostedonlineApril30,2020.doi:10.1101/2020.04.14.200624633.LosAngelesCountyannounces18newdeathsrelatedto2019novelcoronavirus(COVID-19)—475newcasesofconfirmedCOVID-19inLosAngelesCounty.Newsrelease.LosAngelesCountyDepartmentofPublicHealth.April10,2020.AccessedApril26,2020.http://publichealth.lacounty.gov/phcommon/public/media/mediapubdetail.cfm?unit=media&ou=ph&prog=media&prid=2309LettersE2JAMAPublishedonlineMay18,2020(Reprinted)jama.com©2020AmericanMedicalAssociation.Allrightsreserved.";26 mai 2020 
0;serologie;The Promise and Peril of Antibody Testing for COVID-19;Jennifer Abbasi;https://www.groupedeveillecovid.fr/blog/2020/04/20/the-promise-and-peril-of-antibody-testing-for-covid-19/;3;disease’sprevalencethere.Otherareasmaysoonfollowsuit:UnitedBiomedicalco-founderandTellurideresidentMeiMeiHusaidinanemailthatscreeningsinaddi-tionalcommunitiesarebeingplanned.GovernmentofficialsandhealthsystemsneedaccurateinfectioncountstounderstandCOVID-19’sspread,con-ductcontacttracing,craftpublichealthrecommendations,andprepareforhealthcaresurges.Whenthedusthassettled,epi-demiologistswillusewidespreadserosur-veillancedatatomoreaccuratelyestimatejusthowmanypeoplewhocontractedthevirusbecameseriouslyillordied.Tothatend,aNationalInstitutesofHealth–fundedantibodysurveyisenrolling10000volunteersfromaroundthecountryand,accordingtonewsreports,nationallyrepresentative,CDC-fundedserosurveysareslatedtobeginlaterthisyear.Mean-while,theWHOisprovidingcountrieswithanearlyprotocolandtechnicalsupportforseroepidemiologicalstudiesandislaunch-ingamulticountryantibodytestingstudycalledSOLIDARITYII.Crucially,manybelievethatantibodytestingcanalsobeusedtoreturnpeoplewithimmunitytotheworkforceorkeepthemthere,startingwithhealthcareprofession-alsandemergencyfirstresponders.Krammersuggestedthatstaffingnursinghomeswithimmuneworkerscouldbringdowntheirhighcase-fatalityrates,forexample.“[S]erosurveillanceisgoingtoplayama-jorrolein…aframeworkforgettingbacktonormal,”AnthonyFauci,MD,directoroftheNationalInstituteofAllergyandInfectiousDiseasesandaWhiteHouseCoronavirusTaskForceadvisor,saidinanApril8JAMAlivestream.TwoprominentCOVID-19roadmaps—onefromformerFDADirectorScottGottlieb,MD,andtheotherfromtheUniversityofPennsylvania’sEzekielEmanuel,MD—includewidespreadanti-bodytestingasacriticalsteptowardreopen-ingsociety.“Ithinkitmakestotalsensethatifimmu-nityisincreasingandwehave,let’ssay,50%ofpeopleimmuneagainstthis,thenwehaveamuchlesschancethattheviruswillspread,”saidMelanieOtt,MD,PhD,aseniorinvestigatorattheGladstoneInstituteofVirologyandImmunologyinSanFrancisco.“Atacertainpoint,wewillbeabletomini-mizethatriskwithpotentiallyminimaladdi-tionalmeasuresthathavetobetaken.”Alongthoselines,mediaoutletshavere-portedthatresearchersinGermanyandItalywillconductandstudylarge-scaleantibodytesting,withGermanyplanningtoissue“im-munitycertificates”totransitionitscitizensoutoflockdown.PublicHealthEngland,whichprovidesevidence-basedsupporttotheNationalHealthService,recentlydiscussedplansfornationwideantibodyscreeningthatwouldbeginoncearapid,at-homefinger-pricktestunderconsiderationwasassessedforaccuracy.Atpresstime,theWhiteHousehadn’tannouncedsimilarplans.Allowingpeopletoreentersocietybasedontheirantibodystatusassumesthatpastinfectionguardsagainstreinfection,somethingthatresearcherssaidwaslikelybutnotyetwelldefined.“Howbroadandhowlongandhoweffectivethisimmunere-sponseisisstillnotclear,”Ottsaid.Scientistsaroundtheworldwillbeworkingtounderstandwhatsortofprotec-tioninfectionbestows,bothinthelabora-toryandbyfollowinguprecoveredpatientstoseeifreinfectionsoccur.Sofar,thenovelcoronavirusdoesn’tappeartomutatequickly.This,coupledwithexperiencewithotherviralinfections,suggeststhatpeoplewithSARS-CoV-2antibodiesmaybepro-tectedatleastforsometime,Wetzlersaid.There’sanotherpotentialsnag,how-ever.IndividualscanbePCRpositiveevenafterantibodiesdevelop.“Thequestionis,isthatlivevirusthatwe’redetecting?Isitreplicating?Andisittransmissible?AndIthinkthat’sstillanunknownatthispoint,”Theelsaid.CouplingapositiveantibodytestwithanegativePCRresultcouldreducethechancethatpeoplewhoarestillcontagiousreentersociety.Ultimately,apositiveantibodytestcouldbeasortofget-out-of-isolationcard.“Inthelongrun,Ithinkitwouldbenicetoprovidethisforthewholepopulationbe-causeeverybodywhoisimmunecouldba-sicallygobacktonormallifebecausetheycan’tinfectanybodyelse,”Krammersaid.Fornow,hecautionedthatnovelcoro-navirusinfectionsareprobablynotyetwide-spreadamongthegeneralpopulationintheUS,whichisjustinthe“beginningofalargeepidemic.”Butasmorepeoplebecomein-fectedandimmune,theycouldhelpjump-starttheeconomybygoingbacktowork.Theycouldalsoprovidepracticalsupportforthosewhoarevulnerabletoseriousinfec-tion,potentiallyuntilavaccinearrives.InearlyApril,Cordon-CardosaidMountSinaiwouldlikelyexpanditsassay’susebe-yondexperimentaltherapeuticstotestinghealthcareworkers.AndattheMayoClinic,clinicalantibodytestingbeganinmid-April.Iftheseapplicationsarefollowedbyaroll-outofwidespreadantibodytestingforthegeneralpublic,theycouldleadtoagradualreopeningofsocietytoaworldchangedbyCOVID-19.Note:Sourcereferencesareavailablethroughembeddedhyperlinksinthearticletextonline.News&Analysisjama.com(Reprinted)JAMAPublishedonlineApril17,2020E3©2020AmericanMedicalAssociation.Allrightsreserved.;20 avril 2020 
0;serologie;Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19);Li Guo, Lili Ren, Siyuan Yang, Meng Xiao, De Chang, Fan Yang, Charles S Dela Cruz, Yingying Wang, Chao Wu, Yan Xiao, Lulu Zhang, Lianlian Han, Shengyuan Dang, Yan Xu, Qiwen Yang, Shengyong Xu, Huadong Zhu, Yingchun Xu, Qi Jin, Lokesh Sharma, Linghang Wang, Jianwei Wang;https://www.groupedeveillecovid.fr/blog/2020/03/24/profiling-early-humoral-response-to-diagnose-novel-coronavirus-disease-covid-19/;28; 28  Figure 4  Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciaa310/5810754 by guest on 23 March 2020;24 mars 2020 
0;therapeutique;Remdesivir for the Treatment of Covid-19 — Preliminary Report;Beigel and al;https://www.groupedeveillecovid.fr/blog/2020/06/18/remdesivir-for-the-treatment-of-covid-19-preliminary-report/;12;"n engl j med   nejm.org 12The new england journal of medicine4. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of rem-desivir and combination lopinavir, ritona-vir, and interferon beta against MERS-CoV. Nat Commun 2020; 11: 222.5. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the anti-viral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018; 9(2): e00221-18.6. Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir in-hibits human endemic and zoonotic del-tacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivi-ral Res 2019; 169: 104541.7. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 in-hibits both epidemic and zoonotic coro-naviruses. Sci Transl Med 2017; 9: eaal3653.8. Wang M, Cao R, Zhang L, et al. Rem-desivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-71.9. de Wit E, Rasmussen AL, Falzarano D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A 2013; 110: 16598-603.10. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus ma-caque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020; 117: 6771-6.11. Royal College of Physicians. National Early Warning Score (NEWS) 2. 2017 (https://www .rcplondon .ac .uk/ projects/ outputs/ national - early - warning - score  - news - 2).12. King JC, Beigel JH, Ison MG, et al. Clinical development of therapeutic agents for hospitalized patients with in-fluenza: challenges and innovations. Open Forum Infect Dis 2019; 6: ofz137.13. Wang Y, Zhang D, Du G, et al. Remde-sivir in adults with severe COVID-19: a randomised, double-blind, placebo-con-trolled, multicentre trial. Lancet 2020; 395: 1569-78.14. The CONSORT Group. 3b. Changes to trial design (http://www .consort - statement .org/ consort - 2010).Copyright © 2020 Massachusetts Medical Society.";18 juin 2020 
0;therapeutique;Remdesivir for the Treatment of Covid-19 — Preliminary Report;Beigel and al;https://www.groupedeveillecovid.fr/blog/2020/06/18/remdesivir-for-the-treatment-of-covid-19-preliminary-report/;12;"n engl j med   nejm.org 12The new england journal of medicine4. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of rem-desivir and combination lopinavir, ritona-vir, and interferon beta against MERS-CoV. Nat Commun 2020; 11: 222.5. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the anti-viral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018; 9(2): e00221-18.6. Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir in-hibits human endemic and zoonotic del-tacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivi-ral Res 2019; 169: 104541.7. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 in-hibits both epidemic and zoonotic coro-naviruses. Sci Transl Med 2017; 9: eaal3653.8. Wang M, Cao R, Zhang L, et al. Rem-desivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-71.9. de Wit E, Rasmussen AL, Falzarano D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A 2013; 110: 16598-603.10. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus ma-caque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020; 117: 6771-6.11. Royal College of Physicians. National Early Warning Score (NEWS) 2. 2017 (https://www .rcplondon .ac .uk/ projects/ outputs/ national - early - warning - score  - news - 2).12. King JC, Beigel JH, Ison MG, et al. Clinical development of therapeutic agents for hospitalized patients with in-fluenza: challenges and innovations. Open Forum Infect Dis 2019; 6: ofz137.13. Wang Y, Zhang D, Du G, et al. Remde-sivir in adults with severe COVID-19: a randomised, double-blind, placebo-con-trolled, multicentre trial. Lancet 2020; 395: 1569-78.14. The CONSORT Group. 3b. Changes to trial design (http://www .consort - statement .org/ consort - 2010).Copyright © 2020 Massachusetts Medical Society.";18 juin 2020 
0;therapeutique;Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19;null;https://www.groupedeveillecovid.fr/blog/2020/06/08/effect-of-convalescent-plasma-therapy-on-time-to-clinical-improvement-in-patients-with-severe-and-life-threatening-covid-19/;11;"(R.Yang);PekingUniversityClinicalResearchInstitute,PekingUniversityHealthScienceCenter,Beijing,China(Yu);DepartmentofBiomedicalEngineering,SchoolofMedicine,TsinghuaUniversity,Beijing,China(Guo,Su);DepartmentofEmergency,UnionHospital,TongjiMedicalCollege,HuazhongUniversityofScienceandTechnology,Wuhan,China(X.Wu);MianyangCentralHospital,Mianyang,China(Z.Xu);DepartmentofOrganTransplantation,FirstAffiliatedHospital,theSecondMilitaryMedicalUniversity,Shanghai,China(Zeng);DepartmentofNeurology,UnionHospital,TongjiMedicalCollege,HuazhongUniversityofScienceandTechnology,Wuhan,China(Xiong);WuhanPulmonaryHospital,Wuhan,China(Chen);DepartmentofRespiratoryMedicine,WuhanAsiaGeneralHospital,Wuhan,China(Man);CenterforGlobalHealthandInfectiousDiseases,ComprehensiveAIDSResearchCenter,andBeijingAdvancedInnovationCenterforStructuralBiology,SchoolofMedicine,TsinghuaUniversity,Beijing,China(L.Zhang);DepartmentofPathology,UniversityofMiami,Miami,Florida(Y.Wu).AuthorContributions:DrZ.Liuhadfullaccesstoallofthedatainthisstudyandtakesresponsibilityfortheintegrityofthedataandtheaccuracyofthedataanalysis.DrsL.Li,W.Zhang,andY.Huareco–firstauthors.DrsL.Li,W.Zhang,Y.Hu,X.Tong,S.Zheng,J.Yang,Y.Kong,L.Ren,Q.Wei,H.Mei,C.Hu,C.Tao,R.Yang,J.Wang,andY.Yucontributedequallytothestudy.Conceptanddesign:L.Li,W.Zhang,X.Tong,J.Yang,N.Xiong,L.Zhang,J.W.Wang,Y.Wu,Z.Liu.Acquisition,analysis,orinterpretationofdata:W.Zhang,S.Zheng,Y.Kong,L.Ren,Q.Wei,H.Mei,C.Hu,C.Tao,R.Yang,JueWang,Y.Yu,Y.Guo,X.Wu,Z.Xu,N.Xiong,L.Chen,JuanWang,N.Man,Y.Liu,H.Xu,E.Deng,X.Zhang,C.Li,C.Wang,S.Su,Y.Hu,Y.Wu,Z.Liu.Draftingofthemanuscript:L.Li,W.Zhang,Y.Kong,L.Ren,H.Xu,E.Deng,C.Wang,Y.Wu,Z.Liu.Criticalrevisionofthemanuscriptforimportantintellectualcontent:W.Zhang,X.Tong,S.Zheng,J.Yang,Q.Wei,H.Mei,C.Hu,C.Tao,R.Yang,JueWang,Y.Yu,Y.Guo,X.Wu,Z.Xu,L.Zeng,N.Xiong,L.Chen,JuanWang,N.Man,Y.Liu,X.Zhang,C.Li,S.Su,L.Zhang,JuanWang,Y.Hu,Y.Wu,Z.Liu.Statisticalanalysis:J.Yang,Y.Kong,Y.Yu.Obtainedfunding:L.Li,Z.Liu.Administrative,technical,ormaterialsupport:L.Li,W.Zhang,X.Tong,L.Ren,H.Mei,JueWang,Y.Guo,N.Xiong,Y.Liu,H.Xu,E.Deng,C.Wang,S.Su,J.W.Wang,Z.Liu.Supervision:W.Zhang,J.Yang,H.Mei,Y.Hu.ConflictofInterestDisclosures:DrLiureportsholdingapendingpatentonCOVID-19testing.DrWureportsconsultingforVeraxMedicalandGrifols,receivingroyaltiesfromUptoDateandAABB,andbeingavolunteervisitingprofessorandreceivingtravelsupportforgivingmedicaleducationfromtheChineseInstituteofBloodTransfusion.Nootherdisclosureswerereported.Funding/Support:ThisworkwassupportedbytheChineseAcademyofMedicalSciencesInnovationFundforMedicalSciences(CIFMS)grants2020-I2M-CoV19-006,2016-I2M-3-024(DrZ.Liu),and2017-I2M-1-009(DrL.Li)andtheNonprofitCentralResearchInstituteFundofChineseAcademyofMedicalSciencesgrant2018PT32016(DrZ.Liu).RoleoftheFunder/Sponsor:Thefundershadnoroleinthedesignandconductofthestudy;collection,management,analysis,andinterpretationofthedata;preparation,review,orapprovalofthemanuscript;anddecisiontosubmitthemanuscriptforpublication.DataSharingStatement:SeeSupplement4.AdditionalContributions:Wewouldliketothankthefollowingindividualsfortheirguidance,expertise,andassistancewiththestudydesign:PeterW.Marks,MD,PhD,CenterforBiologicsEvaluationandResearch,FDA;AnneEder,MD,PhD,CenterforBiologicsEvaluationandResearch,FDA;NicoleVerdun,MD,CenterforBiologicsEvaluationandResearch,FDA;TimUyeki,MD,MPH,MPP,NationalCenterforImmunizationandRespiratoryDiseases,CDC;ScottKoepsell,MD,PhD,UniversityofNebraskaMedicalCenter;AnnieWinkler,MD,InstrumentationLaboratory;XuanQin,PhD,SeattleChildren’sHospitalandUniversityofWashington.Nonereceivedcompensationrelatedtothisstudy.REFERENCES1.WangD,HuB,HuC,etal.Clinicalcharacteristicsof138hospitalizedpatientswith2019novelcoronavirus-infectedpneumoniainWuhan,China.JAMA.2020;323(11):1061-1069.doi:10.1001/jama.2020.15852.WuZ,McGooganJM.Characteristicsofandimportantlessonsfromthecoronavirusdisease2019(COVID-19)outbreakinChina:summaryofareportof72314casesfromtheChineseCenterforDiseaseControlandPrevention.JAMA.2020;323(13):1239-1242.doi:10.1001/jama.2020.26483.GarraudO,HeshmatiF,PozzettoB,etal.Plasmatherapyagainstinfectiouspathogens,asofyesterday,todayandtomorrow.TransfusClinBiol.2016;23(1):39-44.doi:10.1016/j.tracli.2015.12.0034.ChengY,WongR,SooYO,etal.UseofconvalescentplasmatherapyinSARSpatientsinHongKong.EurJClinMicrobiolInfectDis.2005;24(1):44-46.doi:10.1007/s10096-004-1271-95.YehKM,ChiuehTS,SiuLK,etal.ExperienceofusingconvalescentplasmaforsevereacuterespiratorysyndromeamonghealthcareworkersinaTaiwanhospital.JAntimicrobChemother.2005;56(5):919-922.doi:10.1093/jac/dki3466.ArabiYM,HajeerAH,LukeT,etal.FeasibilityofusingconvalescentplasmaimmunotherapyforMERS-CoVinfection,SaudiArabia.EmergInfectDis.2016;22(9):1554-1561.doi:10.3201/eid2209.1511647.KraftCS,HewlettAL,KoepsellS,etal;NebraskaBiocontainmentUnitandtheEmorySeriousCommunicableDiseasesUnit.TheuseofTKM-100802andconvalescentplasmain2patientswithEbolavirusdiseaseintheUnitedStates.ClinInfectDis.2015;61(4):496-502.doi:10.1093/cid/civ3348.ShenC,WangZ,ZhaoF,etal.Treatmentof5criticallyillpatientswithCOVID-19withconvalescentplasma.JAMA.2020;323(16):1582-1589.doi:10.1001/jama.2020.47839.DuanK,LiuB,LiC,etal.EffectivenessofconvalescentplasmatherapyinsevereCOVID-19patients.ProcNatlAcadSciUSA.2020;117(17):9490-9496.doi:10.1073/pnas.200416811710.RecommendationsforInvestigationalCOVID-19ConvalescentPlasma.USFDA.PublishedMay1,2020.AccessedMay26,2020.https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma11.PositionPaperonUseofConvalescentPlasma,SerumorImmuneGlobulinConcentratesasanElementinResponsetoanEmergingVirus.In:NetworkWBR,ed.2017.AccessedApril18,2020.https://www.who.int/bloodproducts/brn/en/12.NationalHealthCommissionofthePeople’sRepublicofChina.Covid-19treatmentplan(trialversion6).AccessedApril20,2020.http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b81713.WangY,ZhangD,DuG,etal.RemdesivirinadultswithsevereCOVID-19:arandomised,double-blind,placebo-controlled,multicentretrial.Lancet.2020;395(10236):1569-1578.doi:10.1016/S0140-6736(20)31022-914.KleinbaumDG.Evaluatingtheproportionalhazardsassumption.In:SurvivalAnalysis.StatisticsintheHealthSciences.Springer;1996:183-184.15.Dailyupdateoncovid-19.NationalHealthCommissionofthePeople’sRepublicofChina.AccessedMay24,2020.http://www.nhc.gov.cn/xcs/yqtb/202003/f01fc26a8a7b48debe194bd1277fdba3.shtml16.AnnualSHOT(SeriousHazardsofTransfusion)Report2018.PublishedJuly2019.AccessedMay25,2020.https://www.shotuk.org/17.BeigelJH,AgaE,Elie-TurenneMC,etal;IRC005StudyTeam.Anti-influenzaimmuneplasmaforthetreatmentofpatientswithsevereinfluenzaA:arandomised,double-blind,phase3trial.LancetRespirMed.2019;7(11):941-950.doi:10.1016/S2213-2600(19)30199-718.SooYO,ChengY,WongR,etal.Retrospectivecomparisonofconvalescentplasmawithcontinuinghigh-dosemethylprednisolonetreatmentinSARSpatients.ClinMicrobiolInfect.2004;10(7):676-678.doi:10.1111/j.1469-0691.2004.00956.xConvalescentPlasmaTherapyandClinicalImprovementinSevereandLife-threateningCOVID-19OriginalInvestigationResearchjama.com(Reprinted)JAMAPublishedonlineJune3,2020E11©2020AmericanMedicalAssociation.Allrightsreserved.";8 juin 2020 
0;therapeutique;Early Short Course Corticosteroids in Hospitalized Patients with COVID-19;Fadel R. et al;https://www.groupedeveillecovid.fr/blog/2020/05/26/early-short-course-corticosteroids-in-hospitalized-patients-with-covid-19/;19;Accepted Manuscript 19    Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciaa601/5840526 by guest on 24 May 2020;26 mai 2020 
0;therapeutique;Continuité du suivi des personnes vivant avec le VIH et de l’offre de soins en santé sexuelle;null;https://www.groupedeveillecovid.fr/blog/2020/05/22/continuite-suivi-personnes-vivant-vih-de-loffre-de-soins-sante-sexuelle/;12;" HAS Réponses rapides dans le cadre du COVID-19 - Continuité du suivi des sexuelle  avril 2020   12 Méthode  La méthode retenue pour cette réponse rapide est basée sur une synthèse des données probantes disponibles les plus pertinentes, les recommandations nationales et internationales, ainsi que sur une consultation des parties prenantes (par voie électronique le 4 avril 2020).  Ce document a été élaboré collégialement entre la HAS et les référents des CNP, des sociétés sa-vantes et des associations de malades cités ci-dessous. Validation par le collège de la HAS en date du 8 avril 2020.  Liste des participants  HAS : Mme Karine Petitprez, chef de projet.  Conseils Nationaux Professionnels et Sociétés savantes :  Rédacteurs Pascal Pugliese, infectiologue (SFLS) ; Pierre Tattevin, infectiologue (SPILF) ; Philippe Morlat, infec-tiologue (SNFMI) ; Pierre Delobel, infectiologue (SPILF) ; Florian Lemaitre, pharmacologue (SFPT). Relecteurs Patrick Yeni, infectiologue (CNS) ; Michel Celse (CNS) ; François Dabis, infectiologue (ANRS) ; Lionel Piroth, infectiologue (SPILF) ; Sophie Matheron, infectiologue (SPILF) ; Guillaume Conort, médecin généraliste (CMG) ; Emile Escourrou, médecin généraliste (CMG) ; Jean-Philippe Joseph, médecin généraliste (CNGE) ; Matthieu Gregoire, pharmacologue (SFPT) ; Rodolphe Garraffo, pharmacologue (SFPT) ; Cécile Goujard, infectiologue (SNFMI).  Associations  : TRT-5 : Marianne , Hélène Pollard, Mickaël Ploquin, Diane Leriche  Ces recommandations élaborées sur la base des connaissances disponibles à la date de publi-. Ces réponses rapides sont fondées sur ce qui apparaît souhaitable ou nécessaire au moment en équipements de protection individuelle.    © Haute Autorité de santé   avril 2020         Réponses rapides dans le cadre du COVID-19 - santé sexuelle, méthode de réponse rapide, 8 avril 2020 Toutes nos publications sont téléchargeables sur www.has-sante.fr  ";22 mai 2020 
0;therapeutique;Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?;concentrations 3 fois plus élevées que dans le traitement de l’infection VIH;https://www.groupedeveillecovid.fr/blog/2020/05/18/lopinavirritonavir-in-covid-19-patients-maybe-yes-but-at-what-dose/;3;"11TangA,TongZD,WangHLetal.DetectionofnovelcoronavirusbyRT-PCRinstoolspecimenfromasymptomaticchild,China.EmergInfectDis2020;doi:10.3201/eid2606.200301.12HeY,WangZ,LiFetal.PublichealthmightbeendangeredbypossibleprolongeddischargeofSARS-CoV-2instool.JInfect2020;80:e18Ð9.13KupferschmidtK,CohenJ.WHOLaunchesGlobalMegatrialoftheFourMostPromisingCoronavirusTreatments.ScienceMagazine.https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments.ResearchletterJAC3of3Downloaded from https://academic.oup.com/jac/advance-article-abstract/doi/10.1093/jac/dkaa190/5837068 by guest on 17 May 2020";18 mai 2020 
0;therapeutique;Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State;Rosenberg and al;https://www.groupedeveillecovid.fr/blog/2020/05/13/association-of-treatment-with-hydroxychloroquine-or-azithromycin-with-in-hospital-mortality-in-patients-with-covid-19-in-new-york-state/;10;"8.GautretP,LagierJC,ParolaP,etal.HydroxychloroquineandazithromycinasatreatmentofCOVID-19:resultsofanopen-labelnon-randomizedclinicaltrial.IntJAntimicrobAgents.2020:105949.doi:10.1016/j.ijantimicag.2020.1059499.ChenZ,HuJ,ZhangZ,etalEfficacyofhydroxychloroquineinpatientswithCOVID-19:resultsofarandomizedclinicaltrial.medRxiv.PreprintpostedApril10,2020.doi:10.1101/2020.03.22.2004075810.McGhieTK,HarveyP,SuJ,AndersonN,TomlinsonG,ToumaZ.Electrocardiogramabnormalitiesrelatedtoanti-malarialsinsystemiclupuserythematosus.ClinExpRheumatol.2018;36(4):545-551.11.HungYM,WangYH,LinL,WangPYP,ChiouJY,WeiJC.Hydroxychloroquinemaybeassociatedwithreducedriskofcoronaryarterydiseasesinpatientswithrheumatoidarthritis:Anationwidepopulation-basedcohortstudy.IntJClinPract.2018;72(5):e13095.doi:10.1111/ijcp.1309512.ChorinE,DaiM,ShulmanE,etal.TheQTintervalinpatientswithCOVID-19treatedwithhydroxychloroquineandazithromycin.NatMed.PublishedonlineApril24,2020.doi:10.1038/s41591-020-0888-213.BorbaMGS,ValFFA,SampaioVS,etalEffectofhighvslowdosesofchloroquinediphosphateasadjunctivetherapyforpatientshospitalizedwithsevereacuterespiratorysyndromecoronavirus2(SARS-CoV-2)infection:arandomizedclinicaltrial.JAMANetwOpen.2020;3(4):e208857.doi:10.1001/jamanetworkopen.2020.885714.FDA.Factsheetforhealthcareproviders:emergencyuseauthorization(EUA)ofhydroxychloroquinesulfatesuppliedfromthestrategicnationalstockpilefortreatmentofCOVID-19incertainhospitalizedpatients.PostedApril27,2020.AccessedMay7,2020.https://www.fda.gov/media/136537/download15.GargS,KimL,WhitakerM,etal.Hospitalizationratesandcharacteristicsofpatientshospitalizedwithlaboratory-confirmedcoronavirusdisease2019-COVID-NET,14States,March1-30,2020.MMWRMorbMortalWklyRep.2020;69(15):458-464.doi:10.15585/mmwr.mm6915e316.CDCCOVID-19ResponseTeam.Preliminaryestimatesoftheprevalenceofselectedunderlyinghealthconditionsamongpatientswithcoronavirusdisease2019-UnitedStates,February12-March28,2020.MMWRMorbMortalWklyRep.2020;69(13):382-386.doi:10.15585/mmwr.mm6913e217.MagagnoliJ,NarendranS,PereiraF,etalOutcomesofhydroxychloroquineusageinUnitedStatesveteranshospitalizedwithCovid-19.medRxiv.PreprintpostedApril23,2020.doi:10.1101/2020.04.16.2006592018.GoyalP,ChoiJJ,PinheiroLC,etal.ClinicalcharacteristicsofCovid-19inNewYorkCity.NEnglJMed.PublishedonlineApril17,2020.doi:10.1056/NEJMc201041919.PetrilliCM,JonesSA,YangJ,etalFactorsassociatedwithhospitalizationandcriticalillnessamong4,103patientswithCOVID-19diseaseinNewYorkCity.medRxiv.PreprintpostedApril11,2020.doi:10.1101/2020.04.08.2005779420.DavisCE,HydeJE,BangdiwalaSI,NelsonJJ.Anexampleofdependenciesamongvariablesinaconditionallogisticregression.In:ModernStatisticalMethodsinChronicDiseaseEpidemiology.JohnWiley&Sons;1986:140-147.21.LinDY,WeiLJ.TheRobustinferencefortheCoxproportionalhazardsmodel.JAmStatAssoc.1989;84(408):1074-1078.doi:10.1080/01621459.1989.1047887422.VanderWeeleTJ,DingP.Sensitivityanalysisinobservationalresearch:introducingtheE-value.AnnInternMed.2017;167(4):268-274.doi:10.7326/M16-260723.MahevasM,TranV-T,RoumierM,etal.NoevidenceofclinicalefficacyofhydroxychloroquineinpatientshospitalizedforCOVID-19infectionwithoxygenrequirement:resultsofastudyusingroutinelycollecteddatatoemulateatargettrial.medRxiv.PreprintpostedApril14,2020.doi:10.1101/2020.04.10.2006069924.GelerisJ,SunY,PlattJ,etal.ObservationalstudyofhydroxychloroquineinhospitalizedpatientswithCovid-19.NEnglJMed.PublishedonlineMay7,2020.doi:10.1056/NEJMoa201241025.GorgelsAPM,GijsbersC,deVreede-SwagemakersJ,LousbergA,WellensHJJ.Out-of-hospitalcardiacarrest:therelevanceofheartfailure.EurHeartJ.2003;24(13):1204-1209.doi:10.1016/S0195-668X(03)00191-X26.LowLS,KernKB.Importanceofcoronaryarterydiseaseinsuddencardiacdeath.JAmHeartAssoc.2014;3(5):e001339.doi:10.1161/JAHA.114.00133927.RichardsonS,HirschJS,NarasimhanM,etal;andtheNorthwellCOVID-19ResearchConsortium.Presentingcharacteristics,comorbidities,andoutcomesamong5700patientshospitalizedwithCOVID-19intheNewYorkCityarea.JAMA.PublishedonlineApril22,2020.doi:10.1001/jama.2020.677528.ZhouF,YuT,DuR,etal.ClinicalcourseandriskfactorsformortalityofadultinpatientswithCOVID-19inWuhan,China:aretrospectivecohortstudy.Lancet.2020;395(10229):1054-1062.doi:10.1016/S0140-6736(20)30566-329.YancyCW.COVID-19andAfricanAmericans.JAMA.PublishedonlineApril15,2020.doi:10.1001/jama.2020.654830.NIH.COVID-19treatmentguidelines.AccessedApril24,2020.https://covid19treatmentguidelines.nih.gov/introduction/31.InfectiousDiseasesSocietyofAmericaGuidelinesontheTreatmentandManagementofPatientswithCOVID-19.PostedApril11,2020.AccessedApril24,2020.https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/32.FDADrugSafetyCommunication.FDAcautionsagainstuseofhydroxychloroquineorchloroquineforCOVID-19outsideofthehospitalsettingoraclinicaltrialduetoriskofheartrhythmproblems.PostedApril24,2020.AccessedMay8,2020.https://www.fda.gov/media/137250/downloadResearchOriginalInvestigationTreatmentWithHydroxychloroquineorAzithromycinandIn-HospitalMortalityinPatientsWithCOVID-19E10JAMAPublishedonlineMay11,2020(Reprinted)jama.com©2020AmericanMedicalAssociation.Allrightsreserved.";13 mai 2020 
0;therapeutique;Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19;Joshua Geleris and al;https://www.groupedeveillecovid.fr/blog/2020/05/11/observational-study-of-hydroxychloroquine-in-hospitalized-patients-with-covid-19/;8;"n engl j med   nejm.org 8The new england journal of medicineour observational cohort, we have tried to mini-mize possible confounding in a variety of ways.In the main analysis, a multivariable regres-sion model with inverse probability weighting according to the propensity score, there was no significant association between hydroxychloro-quine use and the risk of intubation or death. We also performed a series of analyses using several propensity-score approaches. Findings were sim-ilar in multiple sensitivity analyses. The consis-tency of the results across these analyses is reas-suring. In our analysis, we adjusted for likely confounders, including age, race and ethnic group, body-mass index, diabetes, underlying kidney dis-ease, chronic lung disease, hypertension, baseline vital signs, PaO2:FIO2, and inflammatory markers of the severity of illness. Despite this extensive adjustment, it is still possible that some amount of unmeasured confounding remains. Addition-al limitations of our study include missing data for some variables and potential for inaccuracies in the electronic health records, such as lack of documentation of smoking and coexisting illness for some patients. Nonetheless, we used contem-porary methods to deal with missing data to minimize bias. Finally, the single-center design may limit the generalizability of these results.Clinical guidance at our medical center has been updated to remove the suggestion that pa-tients with Covid-19 be treated with hydroxy-chloroquine. In our analysis involving a large sample of consecutive patients who had been hospitalized with Covid-19, hydroxychloroquine use was not associated with a significantly higher or lower risk of intubation or death (hazard ra-tio, 1.04; 95% CI, 0.82 to 1.32). The study results should not be taken to rule out either benefit or harm of hydroxychloroquine treatment, given the observational design and the 95% confidence in-terval, but the results do not support the use of hydroxychloroquine at present, outside random-ized clinical trials testing its efficacy.Supported in part by grants (RO1-LM006910, RO1-HL077612, RO1-HL093081, and RO1-HL121270) from the National Institutes of Health.Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.We acknowledge the dedication, commitment, and sacrifice of the staff, providers, and personnel in our institution through the Covid-19 crisis and the suffering and loss of our patients as well as in their families and our community.References1. Biot C, Daher W, Chavain N, et al. De-sign and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem 2006; 49: 2845-9.2. Fox RI. Mechanism of action of hy-droxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993; 23: Suppl 1: 82-91.3. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavi-rus: what to expect for COVID-19? Int J Antimicrob Agents 2020 March 12 (Epub ahead of print).4. Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular model-ling studies reveal a new mechanism of action of chloroquine and hydroxychloro-quine against SARS-CoV-2 infection. Int J Antimicrob Agents 2020 April 3 (Epub ahead of print).5. Wilson KC, Chotirmall SH, Bai C, Rello J. COVID-19:  interim guidance on management pending empirical evidence. April 3, 2020 (https://www .thoracic .org/ covid/covid - 19 - guidance .pdf).6. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 March 20 (Epub ahead of print).7. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of opti-mized dosing design of hydroxychloro-quine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020 March 9 (Epub ahead of print).8. Brown SM, Duggal A, Hou PC, et al. Nonlinear imputation of PaO2/FIO2 from SpO2/FIO2 among mechanically ventilat-ed patients in the ICU: a prospective, ob-servational study. Crit Care Med 2017; 45: 1317-24.9. Brown SM, Grissom CK, Moss M, et al. Nonlinear imputation of Pao2/Fio2 from Spo2/Fio2 among patients with acute re-spiratory distress syndrome. Chest 2016; 150: 307-13.10. Robins JM. Marginal structural mod-els. 1998 (https://cdn1 .sph .harvard .edu/ wp - content/ uploads/ sites/ 343/ 2013/ 03/ msm - web .pdf).11. Rubin DB. Multiple imputation for nonresponse in surveys. New York:  John Wiley, 1987.12. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloro-quine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open 2020; 3(4): e208857.13. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clini-cal trial. MedRxiv. 2020 (https://www  .medrxiv .org/ content/ 10 .1101/ 2020 .03 .22 .20040758v3) (preprint).14. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of pa-tients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci) 2020 (http://www .zjujournals .com/ med/ EN/ 10 .3785/ j .issn .1008 - 9292 .2020 .03 .03).Copyright © 2020 Massachusetts Medical Society.";11 mai 2020 
0;therapeutique;TRAITEMENT ANTICOAGULANT POUR LA PREVENTION DU RISQUE THROMBOTIQUE CHEZ UN PATIENT HOSPITALISE AVEC COVID-19 ET SURVEILLANCE DE L’HEMOSTASE  PROPOSITIONS DU GIHP ET DU GFHT;Sophie Susen et al;https://www.groupedeveillecovid.fr/blog/2020/05/06/traitement-anticoagulant-prevention-risque-thrombotique-chez-patient-hospitalise-covid-19-surveillance-de-lhemostase-propositions-gihp-gfht/;5;#;6 mai 2020 
0;therapeutique;Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19;Adarsh Bhimraj et al;https://www.groupedeveillecovid.fr/blog/2020/05/03/systematic-review-of-the-efficacy-and-safety-of-antiretroviral-drugs-against-sars-mers-or-covid-19-initial-assessment/;61;Last updated April 21, 2020 at 12:22 PM EDT and posted online at www.idsociety.org/COVID19guidelines. Please check website for most updated version of these guidelines. Version 1.0.4  by ELISA) and a neutralization titer greater than 40 (end point dilution titer)  Duan K, Liu B, Li C, et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv 2020. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 2020  ;3 mai 2020 
0;therapeutique;Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial;Yeming Wang and al;https://www.groupedeveillecovid.fr/blog/2020/04/30/remdesivir-in-adults-with-severe-covid-19-a-randomised-double-blind-placebo-controlled-multicentre-trial/;10;"10 www.thelancet.com   Published online April 29, 2020   https://doi.org/10.1016/S0140-6736(20)31022-9Data sharingAfter approval from the Human Genetic Resources Administration of China, this trial data can be shared with qualifying researchers who submit a proposal with a valuable research question. A contract should be signed. AcknowledgmentsWe thank Gilead Sciences for providing the study drugs and Huyen Cao and Anu Osinusi for advice regarding safe use of remdesivir. We thank Joe Yao and Ella Lin for statistical consultation. We also thank members of the international data safety monitoring board (Jieming Qu [chair], Weichung Joe Shih, Robert Fowler, Rory Collins, and Chen Yao), independent statisticians (Xiaoyan Yan and Bin Shan), academic secretaries (Lingling Gao and Junkai Lai), and eDMC system providers (Tai Xie, Rong Ran, Peng Zhang, and Emily Wang) for their services. Roche Diagnostics (Shanghai) provided instruments and SARS-CoV-2 assay detection; SMO assistance was provided by Shanghai MedKey Med-Tech Development, Clinplus, Hangzhou SIMO, and MEDPISON. This work was supported by the Chinese Academy of Medical Sciences Emergency Project of COVID-19 (2020HY320001); Major Projects of National Science and Technology on New Drug Creation and Development (2020ZX09201012); the National Key Research and Development Program of China (2018YFC1200102); and the Beijing Science and Technology Project (Z19110700660000). TJ is funded by a National Institutes of Health Research (NIHR) Senior Research Fellowship (2015-08-001). PH is funded by the Wellcome Trust and the UK Department for International Development [215091/Z/18/Z], the Bill & Melinda Gates Foundation [OPP1209135], and NIHR [200907].References1 Johns Hopkins University and Medicine. COVID-19 map. Johns Hopkins Coronavirus Resource Centre. https://coronavirus.jhu.edu/map.html (accessed April 25, 2020).2 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; published online Feb 24. DOI:10.1001/jama.2020.2648.3 Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507Œ13.4 Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054Œ62.5 Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle regionŒcase series. N Engl J Med 2020; published online March 30. DOI:10.1056/NEJMoa2004500.6 Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine e˜ectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 2Œ71.7 Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is e˜ective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6: 16.8 Tang W, Cao Zhu, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv 2020; published online April 14. DOI:10.1101/ 2020.04.10.20060558 (preprint).9 Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv 2020; published online April 15. DOI:10.1101/2020.03.17.20037432 (preprint).10 Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020; published online March 27. DOI:10.1001/jama.2020.4783.11 Cao B, Wang Y, Wen D, et al. A trial of lopinavirŒritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; published online March 18. DOI:10.1056/NEJMoa2001282.12 Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit ˚lo-, pneumo-, and paramyxoviruses. Sci Rep 2017; 7: 43395.13 Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9: eaal3653.14 Warren TK, Jordan R, Lo MK, et al. Therapeutic e˛cacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531: 381Œ85.15 Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res 2019; 169: 104541.16 Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic e˛cacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11: 222.17 de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA 2020; 117: 6771Œ76.18 Pizzorno A, Padey B, Julien T, et al. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. bioRxiv 2020; published online April 2. DOI:10.1101/2020.03.31.017889 (preprint).19 Williamson BN, Feldmann F, Schwarz B, et al. Clinical bene˚t of remdesivir in rhesus macaques infected with SARS-CoV-2. bioRxiv 2020; published online April 22. DOI:10.1101/2020.04.15.043166 (preprint).20 Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293Œ303.21 Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; published online April 10. DOI:10.1056/NEJMoa2007016.22 Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020; 382: 929Œ36.23 Whitehead J, Stratton I. Group sequential clinical trials with triangular continuation regions. Biometrics 1983; 39: 227Œ36.24 Gilead Sciences. Investigator™s brochure of remdesivir, 5th edition. Feb 21, 2020.25 Jacobs M, Rodger A, Bell DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 2016; 388: 498Œ503.26 Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018; 9: e00221Œ18.27 Lee N, Allen Chan KC, Hui DS, et al. E˜ects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol 2004; 31: 304Œ09.28 Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 2018; 197: 757Œ67.";30 avril 2020 
0;transfusion;The Obstacle Course of Reperfusion for STEMI in the COVID-19 Pandemics;Marco Roffi, and al;https://www.groupedeveillecovid.fr/blog/2020/04/28/the-obstacle-course-of-reperfusion-for-stemi-in-the-covid-19-pandemics/;7;;28 avril 2020 
0;transfusion;Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how;Pierre Tiberghien and al;https://www.groupedeveillecovid.fr/blog/2020/04/27/collecting-and-evaluating-convalescent-plasma-for-covid-19-treatment-why-and-how-2/;12;"Accepted Article This article is protected by copyright. All rights reserveds                                                                                                                                                                                      36 Ko JH, Müller MA, Seok H, et al. Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity. Diagn Microbiol Infect Dis. 2017;89:106-111.  37 Agence national de sécurité des médicaments et des produits de santé (ANSM) Principes et bonnes pratiques pour les établissements de transfusion sanguine et les dépôts de sang hospitaliers. Décision du 18/7/2018 38 Nurtop E, Villarroel PMS, Pastorino B, et al. Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies. Virol J. 2018;15:192 Erratum in: Virol J. 2019;16:12.  39 Wong HK, Lee CK, Hung IF, et al. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion. 2010;50:1967-71. 40 Hashem AM, Hassan AM, Tolah AM, et al. Amotosalen and ultraviolet A light efficiently inactivate MERS-coronavirus in human platelet concentrates. Transfus Med. 2019;29:434-441 41 Keil SD, Bowen R, Marschner S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. Transfusion. 2016;56:2948-2952.  42 Geisen C, Kann G, Strecker T, et al. Pathogen-reduced Ebola virus convalescent plasma: first steps towards  standardization of manufacturing and quality control including assessment of Ebola-specific neutralizing antibodies. Vox Sang. 2016;110:329335.  43 Dean CL, Hooper JW, Dye JM, et al. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. Transfusion. 2020 Mar 4. 44 Lan L, Xu D, Ye G, et al. Positive RT-PCR Test Results in Patients Recovered From COVID-19. JAMA.2020; 10.1001/jama.2020. 45Baden LR, Rubin EJ, Morrissey S, et al. We Can Do Better - Improving Outcomes in the Midst of an Emergency. N Engl J Med. 2017;377:14821484. 46 Zhao J, Yang Y, Huang HP, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. medRxiv 2020.03.11.20031096 (not peer-reviewed yet) 47 https://europeanbloodalliance.eu/  ";27 avril 2020 
0;transfusion;The impact of the SARS-CoV-2 outbreak on the safety and availability of blood transfusions in Italy;Massimo Franchini and al;https://www.groupedeveillecovid.fr/blog/2020/04/27/the-impact-of-the-sars-cov-2-outbreak-on-the-safety-and-availability-of-blood-transfusions-in-italy/;3;"donateinordertoavoidshortagesinthebloodsupply,thesamedocumentalsoincludedadditionalrecommen-dationsfortheassociationsandfederationsofvoluntaryblooddonors.Theseincludedthemaintenanceofsafeinter-individualdistance(aminimumof1m)inwaitingrooms,acarefulplanningofthescheduleforcallingupdonorsinordertoregulatethevolumeofhumantrafÞcwithincentres,ameticulousdisinfectionofhandsoftheBEandcollectionsitesÕpersonnel,andsimilarlyrigorousprotocolsforthesanitationanddisinfectionofthecollec-tionrooms.TheuseofmasksforbothBEpersonnelanddonorswasnotrequiredfollowingtherecommendationsoftheWHOandNationalHealthAuthorities.Thesemea-sureswereprogressivelyextendedtomostofthecitiesofnorthernItaly(9March2020).FollowingthedeclarationofthegovernmentofthewidespreaddisseminationoftheSARS-CoV-2infectioninItaly,thelastupdateoftheCNSon10March2020extendedthesemeasurestothewholenationalterritoryofItaly.On18March,theCNSdeÞnedspeciÞccriteriaforcollectionofplasmafromconvales-centsubjects.TheCNScontinuestoreinforceitsappealtodonatebloodcomponentsinbothpublichospitalBEsandassoci-atedcollectionsites.Giventhelimitationsonmovementimposedbythegovernment,theCNShasbeenpivotalincommunicatingandmanagingthenecessarydeviationsfromthesemeasuresofdonorsandthehealthcareperson-nelinvolvedinblooddonation,inordertomaintainthesmoothcollectionofblood.IntheÞrstweekofMarch,areductionof10%wholeblooddonationsperweekwasexperiencedbytheItalianBloodSystem(from48000ŒasastandardnumberofblooddonationsperweekinthisperiodŒto43000nationwide),buttheinventorywasmaintainedbyacon-temporaryreductionofelectivesurgeryusingmedium-highamountsofblood.Thestrategicreserveofbloodkeptforemergencieswasnotaccessed.DuringthesecondweekofMarch,afterthecampaignoftheCNSandItaliangovernmentencouragingblooddonation,weobserveda12%increaseinthecollectionofwholeblood(from48000to53600nationwide).InFig.1,thetrendofpositivecasesforSARS-CoV-2infectioninItaly,updatedon20March2020,isreportedwithaconcisechronologyofthemaindocumentsreleasedandthetrendofblooddonationsinthesameperiod.ThesemeasureshavebeenabletoguaranteebloodsafetyandsupplyinItaly.Wehopethatourongoingexperience,asbrießyreportedinthisCommentary,willhelptransfusionmedicinespecialistsfromothercountries,whoarefacingtheeffectofthisepidemiconthebloodsupply.Weproposethatitispossibletomanageatrans-fusionsystemduringthiscriticalperiod,usingpragmatic,prudentandevidence-basedmeasures.Inourcountry,sofar,blooddonation,afteraninitialfall(-10%),hasbeenmaintainedduringSARS-CoV-2emergency,havingbeenrecognizedbythegovernmentasapriorityinordertomaintainbasichealthcareservices.WiththeSARS-CoV-2outbreakspreadinginallEuropeanCountries,werecom-menddeÞningcommonEuropeanguidelinesthatestab-lishscreeningcriteriaforblooddonors.Suchcriterianeedtotakeintoaccountthedifferentepidemiologicalsituationsindifferentcountries,whileestablishingcom-monprinciplesensuringbloodsafetythroughoutEurope.References1SchoemanD,FieldingBC:Coronavirusenvelopeprotein:currentknowledge.VirolJ2019;16:692ChenY,LiuQ,GuoD:Coronaviruses:genomestructure,replication,and-pathogenesis.JMedVirol2020;92:418Œ4233ZumlaA,HuiDS,PerlmanS:MiddleEastrespiratorysyndrome.Lancet2015;386:995Œ10074PeeriNC,ShresthaN,RahmanMS,etal.:TheSARS,MERSandnovelcoronavirus(COVID-19)epidemics,thenewestandbiggestglobalhealththreats:whatlessonshavewelearned?IntJEpidemiol2020.https://doi.org/10.1093/ije/dyaa033[Epubaheadofprint].5BassettiM,VenaA,GiacobbeDR:ThenovelChinesecoronavirus(2019-nCoV)infections:ChallengesforÞghtingthestorm.EurJClinInvest2020;50:e132096WorldHealthOrganization:Coronavirusdisease(COVID-19)outbreak.https://www.who.int/emergencies/diseases/novel-coronavirus-2019[Lastaccessed20-3-2020]7WorldHealthOrganization.Coronavirusdisease2019(COVID-19)SituationReportŒ59.Dataasreportedbynationalauthoritiesby00:00CET19March2020.8ChangL,YanY,WangL:CoronavirusDisease2019:CoronavirusesandbloodSafety.TransfusMedRev2020.[epubaheadofprint]9EuropeanCentreforDiseasePreventionandControl.Outbreakofnovelcoron-avirusdisease2019(COVID-19):increasedtransmissiongloballyŒÞfthupdate;2March2020.Stockholm:ECDC;2020.https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-outbreak-novel-coronavirus-disease-2019-covid-19-increased©2020InternationalSocietyofBloodTransfusionVoxSanguinis(2020)SARS-CoV-2andbloodtransfusionsinItaly3";27 avril 2020 
0;transfusion;Coronavirus Disease 2019: Coronaviruses and Blood Safety;Le Chang and al;https://www.groupedeveillecovid.fr/blog/2020/04/27/coronavirus-disease-2019-coronaviruses-and-blood-safety/;7;"[55]RebullaP.Thelongandwindingroadtopathogenreductionofplatelets,redbloodcellsandwholeblood.BrJHaematol2019;186:655–67http://doi.org/10.1111/bjh.16093.[56]SeltsamA,MullerTH.Updateontheuseofpathogen-reducedhumanplasmaandplate-letconcentrates.BrJHaematol2013;162:442–54http://doi.org/10.1111/bjh.12403.[57]ChineseSocietyofBloodTransfusion.RecommendationsonbloodcollectionandsupplyduringtheepidemicofnovelcoronaviruspneumoniainChina(1stedition)[Chinese],https://www.csbt.org.cn/plus/view.php?aid=16530;2020[accessed2020-2-5].6L.Changetal./TransfusionMedicineReviewsxxx(xxxx)xxxPleasecitethisarticleas:L.Chang,Y.YanandL.Wang,CoronavirusDisease2019:CoronavirusesandBloodSafety,TransfusionMedicineReviews,https://doi.org/10.1016/j.tmrv.2020.02.003";27 avril 2020 
0;telemedecine;Virtually Perfect? Telemedicine for Covid-19;Judd E. Hollander, and Brendan G. Carr;https://www.groupedeveillecovid.fr/blog/2020/03/24/virtually-perfect-telemedicine-for-covid-19/;3;"PERSPECTIVE3Virtually Perfect? Telemedicine for Covid-19n engl j med   nejm.org  that clinicians can continue to care for established (nonexposed) patients by converting scheduled office visits to telemedicine visits. These visits can be conducted with both patient and clinician at home, greatly limiting travel and expo-sure and permitting uninterrupt-ed care of established patients. Online training modules and re-mote training sessions are avail-able for clinicians or patients who require just-in-time training or as-sistance during their first call.The main barriers to main-taining usual care by telemedicine require changes that are unlikely to come from the federal level. Commercial reimbursement, Med-icaid reimbursement, and creden-tialing are the states™ domain. Only 20% of states require pay-ment parity between telemedicine and in-person services.5 Fortunate-ly, both the Centers for Medicare and Medicaid Services and some local commercial payers have modified payment policy in re-sponse to Covid-19. We hope oth-ers will follow suit.Disasters and pandemics pose unique challenges to health care delivery. Though telehealth will not solve them all, it™s well suited for scenarios in which infrastruc-ture remains intact and clinicians are available to see patients. Payment and regulatory struc-tures, state licensing, credential-ing across hospitals, and program implementation all take time to work through, but health systems that have already invested in tele-medicine are well positioned to ensure that patients with Covid-19 receive the care they need. In this instance, it may be a virtually per-fect solution.Disclosure forms provided by the au-thors are available at NEJM.org.From Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia (J.E.H.); and Icahn School of Medicine at Mount Sinai, New York (B.G.C.). This article was published on March 11, 2020, at NEJM.org.1. Duffy S, Lee TH. In-person health care as option B. N Engl J Med 2018; 378: 104-6.2. Lurie N, Carr BG. The role of telehealth in the medical response to disasters. JAMA Intern Med 2018; 178: 745-6 .3. Joshi AU, Randolph FT, Chang AM, et al. Impact of emergency department tele-intake on left without being seen and throughput metrics. Acad Emerg Med 2020; 27: 139-47.4. Langabeer JR II, Gonzalez M, Alqusairi D, et al. Telehealth-enabled emergency med-ical services program reduces ambulance transport to urban emergency departments. West J Emerg Med 2016; 17: 713-20.5. Lacktman NM, Acosta JN, Levine SJ. 50-State survey of telehealth commercial payer statutes. Foley.com/Telemedicine, December 2019 (https://www .foley .com/  - /  media/ files/ insights/ health - care - law - today/ 19mc21486 - 50state - survey - of - telehealth - commercial .pdf).DOI:˜10.1056/NEJMp2003539Copyright © 2020 Massachusetts Medical Society.Virtually Perfect? Telemedicine for Covid-19";24 mars 2020 
0;vih;Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort;null;https://www.groupedeveillecovid.fr/blog/2020/06/08/description-of-covid-19-in-hiv-infected-individuals-a-single-centre-prospective-cohort/;11;"www.thelancet.com/hiv   Published online May 28, 2020   https://doi.org/10.1016/S2352-3018(20)30164-8 1119 Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging 2020; 12: 6049Œ57.20 Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708Œ20.21 Borobia AM, Carcas AJ, Arnalich F, et al. A cohort of patients with COVID-19 in a major teaching hospital in Europe. medRxiv 2020; published online May 6. DOI:10.1101/2020.04.29.20080853 (preprint).22 Agencia española de medicamentos y productos sanitarios. Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2. May 19, 2020. https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid-19/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2/?lang=en (accessed April 22, 2020).23 Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun 2020; 6: 102452.24 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033Œ34.25 Blanco JL, Ambrosioni J, Garcia F, et al. COVID-19 in patients with HIV: clinical case series. Lancet HIV 2020; 7: e314Œ16.26 Choy K-T, Wong AY-L, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res 2020; 178: 104786.27 De Meyer S, Bojkova D, Cinatl J, et al. Lack of antiviral activity of darunavir against SARS-CoV-2. medRxiv 2020; published online April 8. DOI:10.1101/2020.04.03.20052548 (preprint).28 Sun J, Xiao J, Sun R, et al. Prolonged persistence of SARS-CoV-2 RNA in body ˘uids. Emerg Infect Dis 2020; published online May 8. DOI:10.3201/eid2608.201097.";8 juin 2020 
0;vih;HIV postexposure prophylaxis during COVID-19;We declare no competing interests;https://www.groupedeveillecovid.fr/blog/2020/06/08/hiv-postexposure-prophylaxis-during-covid-19/;1;"www.thelancet.com/hiv   Published online May 25, 2020  https://doi.org/10.1016/S2352-3018(20)30146-6 1to provide access to PEPSE for those who need it, is important. As of the beginning of May, 2020, the UK is more than 1 month into lockdown. If people are having less sex and fewer individuals are in the 4-week window period of the standard fourth-generation HIV test, we now have an opportunity to find people with undiagnosed HIV by encouraging those at high risk of HIV to test now and before they resume their previous sexual frequency. To this end, 56 Dean Street has released a social media campaign to encourage testing. We declare no competing interests.Muhammad Junejo, Nicolo Girometti, Alan McOwan, *Gary Whitlock, on behalf of the Dean Street Collaborative Groupgary.whitlock@chelwest.nhs.uk56 Dean Street, Chelsea and Westminster Hospital National Health Service Foundation Trust, London W1D 6AQ, UK (MJ, NG, AM, GW)1 Cresswell F, Waters L, Briggs E, et al. UK guideline for the use of HIV post-exposure prophylaxis following sexual exposure, 2015. Int J STD AIDS 2016; 27: 713Œ38.2 UK Government. GUMCAD STI Surveillance System. https://www.gov.uk/guidance/gumcad-sti-surveillance-system (accessed May 20, 2020).3 UK Government. Coronavirus (COVID-19). https://www.gov.uk/coronavirus (accessed May 7, 2020).anal intercourse. The median age of those receiving prescriptions was 32 years (IQR 27Œ39) in the pre-lockdown period and 32 years (26Œ45) for the period in lockdown. There was no di˜erence in the amount of prescriptions given to individuals because of group sex between the two periods. However, HIV exposures were more likely to involve sex facilitated by recreational drug use with methamphetamine, mephedrone, ketamine, or gamma-hydroxybutyrate (known as chemsex) and sex facilitated by the injection of these substances (known as slamsex) in lockdown than before lockdown. The most obvious explanation for this decline in prescriptions of PEPSE is that individuals are engaging in less condomless sex during lockdown. However, these values might re˚ect people™s reluctance to travel during this period, which would mean that individuals are not accessing the PEPSE they require.If our ˛rst explanation is correct, we expect that there would be fewer HIV transmissions during lockdown. If our second explanation is correct, there would be more HIV transmissions. In either case, we feel that promoting HIV testing in those at risk, and continuing HIV postexposure prophylaxis during COVID-1956 Dean Street, a sexual health clinic in Soho (London, UK) provides free-of-charge HIV postexposure prophylaxis (PEPSE) by face-to-face assessment, in accordance with UK guidance.1 In 2018, 56 Dean Street accounted for a quarter of the 12 000 PEPSE prescriptions given nationally.2 On March 23, 2020, the UK Govern-ment introduced lockdown measures to reduce the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), advo-cating for home isolation and physical distancing of 2 m when individuals have to leave their homes, such as for medical needs.3 During this period of lockdown, although 56 Dean Street has lim-ited some face-to-face services, the assessment and provision of PEPSE as a walk-in service has been maintained. Weekly prescriptions of PEPSE at 56 Dean Street decreased from a peak of 54 (from Feb 17Œ23, 2020) to four (from March 30ŒApril 5, 2020) during lockdown (figure). We did a case-note review of recipients of PEPSE in two 4 week periods (appendix). A 4 week period before lockdown (Jan 20, 2020, to Feb 16, 2020) was chosen as a comparison because this period was immediately before the SARS-CoV-2 outbreak began in the UK but was close enough to the date of the lockdown to minimise potential seasonal variability. Compared with this 4 week period before lockdown, there were more than 80% fewer PEPSE prescriptions in the ˛rst 4 weeks of the lockdown, from March 23, 2020, to April 19, 2020 (161 vs 28 prescriptions). In both periods, the majority of prescriptions were given to men and most PEPSE was given for unprotected, receptive Figure: Weekly prescriptions for HIV PEPSE at 56 Dean Street, London, UK, in 2020PEPSE=postexposure prophylaxis following sexual exposure.Jan 13Œ19Jan 20Œ26Jan 27ŒFeb 2Feb 3Œ9Feb 10Œ16Feb 17Œ23Feb 24ŒMarch 1March 2Œ8March 9Œ15March 16Œ22March 23Œ29March 30ŒApril 5April 6Œ12April 13Œ190102030405060PEPSE prescriptionsWeekLancet HIV 2020Published Online May 25, 2020 https://doi.org/10.1016/S2352-3018(20)30146-6For more on the social media campaign, see https://www.testnowstophiv.comSee Online for appendix";8 juin 2020 
0;vih;COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients;Härter G et al;https://www.groupedeveillecovid.fr/blog/2020/05/15/covid-19-in-people-living-with-human-immunodeficiency-virus-a-case-series-of-33-patients/;6;" G.˜Härter et al. 2. Guan WJ, Ni ZY, Hu Y, et˚al. Clinical characteristics of coro-navirus disease 2019 in China. N Engl J Med. 2020. https ://doi.org/10.1056/NEJMo a2002 032. 3. Liang W, Guan W, Chen R, et˚al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335Œ7. 4. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibil-ity to severe COVID-19 and establishment of a host risk score: ˜ndings of 487 cases outside Wuhan. Crit Care. 2020;24:108. 5. Zhou F, Yu T, Du R, et˚al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054Œ62. https ://doi.org/10.1016/S0140 -6736(20)30566 -3(Epub 2020 Mar 11). 6. Blanco JL, Ambrosioni J, Garcia F, Martínez E, Soriano A, Mallo-las J, Miro JM. COVID-19 in HIV investigators. COVID-19 in patients with HIV: clinical case series. Lancet HIV. 2020. https ://doi.org/10.1016/S2352 -3018(20)30111 -9(Epub ahead of print). 7. He ZC, Dong Q, Zhuang H, Song S, Peng G, Dwyer DE. Eˇects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis. 2005;9:323Œ30. 8. Chen G, Wu D, Guo W, et˚al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest. 2020;2020:137244. 9. Qin C, Zhou L, Hu Z, et˚al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020. https ://doi.org/10.1093/cid/ciaa2 48. 10. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. https ://doi.org/10.1001/jama.2020.2648. 11. Peters PJ, Skarbinski J, Louie JK, et˚al. HIV-infected hospi-talized patients with 2009 pandemic inˆuenza A (pH1N1)ŠUnited States, spring and summer 2009. Clin Infect Dis. 2011;52(1):S183ŒS188188. 12. Lyn˜eld R, Davey R, Dwyer DE, et˚al. Outcomes of inˆuenza A (H1N1) pdm09 virus infection: results from two interna-tional cohort studies. PLoS ONE. 2014;9:e101785. https ://doi.org/10.1371/journ al.pone.01017 85. 13. Wong AT, Tsang OT, Wong MY, et˚al. Coronavirus infection in an AIDS patient. AIDS. 2004;18:829Œ30. 14. Zhu F, Cao Y, Xu S, Zhou M. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China. J Med Virol. 2020. https ://doi.org/10.1002/jmv.25732 . 15. EACS and BHIVA statement on risk of COVID-19 for people living with HIV (PLWH). https ://www.eacso ciety .org/home/covid -19-and-hiv.html 16. Robert-Koch Institute, Berlin, Germany. Corona virus disease 2019. Daily situation report. Accessed 25 Apr 2020. https ://www.rki.de/DE/Conte nt/InfAZ /N/Neuar tiges _Coron aviru s/Situa tions beric hte/2020-04-25-en.pdf?__blob=publi catio nFile  17. Richardson S, Hirsch JS, Narasimhan M, et˚al. Presenting char-acteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020. https ://doi.org/10.1001/jama.2020.6775. 18. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama Japan. Euro Surveill. 2020. https ://doi.org/10.2807/1560-7917.ES.2020.25.10.20001 80. 19. Gudbjartsson DF, Helgason A, Jonsson H, et˚al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020. https ://doi.org/10.1056/NEJMo a2006 100. 20. Stecher M, Schommers P, Schmidt D, et˚al. Antiretroviral treat-ment indications and adherence to the GermanŒAustrian treatment initiation guidelines in the German ClinSurv HIV cohort between 1999 and 2016. Infection. 2019;47:247Œ55. 21. Machnowska P, Meixenberger K, Schmidt D, et˚al. Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter study cohort. PLoS ONE. 2019;14(1):e0209605. https ://doi.org/10.1371/journ al.pone.02096 05. 22. Lim J, Jeon S, Shin HY, et˚al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35:e79. 23. Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical character-istics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14:64Œ8. 24. Wu J, Li W, Shi X, et˚al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020. https ://doi.org/10.1111/joim.13063 . 25. Park SY, Lee JS, Son JS, et˚al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. J Hosp Infect. 2019;101:42Œ6. 26. Cao B, Wang Y, Wen D, et˚al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020. https ://doi.org/10.1056/NEJMo a2001 282. 27. US Department of Health and Human Services. Interim guidance for COVID-19 and persons with HIV. https ://aidsi nfo.nih.gov/guide lines /html/8/covid -19-and-perso ns-with-hiv--inter im-guida nce-/554/inter im-guida nce-for-covid -19-and-perso ns-with-hiv. 28. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharma-cologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. https ://doi.org/10.1001/jama.2020.6019. 29. El˜ky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci. 2020;25:117592. 30. Randomized clinical trial for the prevention of SARS-CoV-2 infection (COVID-19) in healthcare personnel (EPICOS). https ://clini caltr ials.gov/ct2/show/NCT04 33492 8?cond=Rando mized +clini cal+trial +for+the+preve ntion +of+SARS-CoV-2+infec tion+%28COV ID-19%29+in+healt hcare +perso nnel&draw=2&rank=1";15 mai 2020 
0;vih;Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment;Enver Akalin and al;https://www.groupedeveillecovid.fr/blog/2020/04/27/systematic-review-of-the-efficacy-and-safety-of-antiretroviral-drugs-against-sars-mers-or-covid-19-initial-assessment-2/;3;"n engl j med   nejm.org 3VariableValueC-reactive proteinMedian (range) Š mg/dl7.9 (0.5Œ48.7)Patients with level >5 mg/dl Š no./total no. (%)13/28 (46)ProcalcitoninMedian (range) Š ng/ml0.2 (0.1Œ5.1)Patients with level >0.2 ng/ml Š no./total no. (%)12/28 (43)Lactate dehydrogenaseMedian (range) Š U/liter336 (158Œ309)Patients with level >1.5 times upper limit of normal range Š no./total no. (%)10/28 (36)Creatine kinaseMedian (range) Š U/liter145 (48Œ815)Patients with level >200 U/liter Š no./total no. (%)9/28 (32)Outcomes˜at˜a˜median˜of˜21˜days˜(range,˜14Œ28)˜Š˜no./total˜no.˜(%)Death10/36 (28)Intubation11/28 (39)Death after intubation7/11 (64)Renal replacement therapy6/28 (21)Remained hospitalized12/28 (43)Discharged from hospital10/28 (36)Table˜1.˜(Continued)the reported 1% to 5% mortality among patients with Covid-19 in the general population who have undergone testing in the United States and the reported 8 to 15% mortality among patients with Covid-19 who are older than 70 years of age.Enver Akalin, M.D. Yorg Azzi, M.D. Rachel Bartash, M.D. Harish Seethamraju, M.D. Michael Parides, Ph.D. Vagish Hemmige, M.D. Michael Ross, M.D. Stefanie Forest, M.D., Ph.D. Yitz D. Goldstein, M.D. Maria Ajaimy, M.D. Luz Liriano-Ward, M.D. Cindy Pynadath, M.D. Pablo Loarte-Campos, M.D. Purna B. Nandigam, M.D. Jay Graham, M.D. Marie Le, M.D. Juan Rocca, M.D. Milan Kinkhabwala, M.D.Montefiore Medical Center Bronx, NY eakalin@montefiore.orgDrs. Akalin and Azzi contributed equally to this letter.Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.This letter was published on April 24, 2020 at NEJM.org.1. Alberici F, Delbarba E, Manenti C, et al. A single center ob-servational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. Kidney Int 2020 April 9 (Epub ahead of print).2. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Phar-macologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020 April 13 (Epub ahead of print).3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.4. Diao B, Wang C, Tan Y, et al. Reduction and functional ex-haustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv. February 20, 2020 (https://www .medrxiv .org/ content/ 10 .1101/ 2020 .02 .18 .20024364v1).DOI:˜10.1056/NEJMc2011117Correspondence Copyright © 2020 Massachusetts Medical Society.Correspondence";27 avril 2020 
0;vih;Darunavir does not prevent SARS-CoV-2 infection in HIV patients;Agostino Riva and al;https://www.groupedeveillecovid.fr/blog/2020/04/27/darunavir-does-not-prevent-sars-cov-2-infection-in-hiv-patients/;2;"'""(M)O)*)P)M)˜˛ˇ*)K)P)O˛ˇO)K˛ˇQ)D)M˛ˇP)M)N)N˛ˇO)N)˜)/)M)˜)*)P)K)Q)S)P)6)˘,5)@)/)O)P)S˛ˇR)M)M)P)M)M)P)D)M˛ˇO)*),,˘,5)'˘(K)I)"",)'8(&""""˙˝ˆ)'5(/)/)J)˜)*)*)M)J)M)5,)'0(P)R)M)/)*)N)*)*)R)˜)M˛ˇ˜)P)˜)J)M)P))'3(P)˜)M)/)P)M)/)N)P)J)N)M)/)6)P)˘5)ˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇˇ˜ !ˇˇ˜ !ˇˇˇY˜ !)K638ˇ";27 avril 2020 
0;vih;COVID-19 in patients with HIV: clinical case series;JL Blanco;https://www.groupedeveillecovid.fr/blog/2020/04/21/covid-19-in-patients-with-hiv-clinical-case-series/;3;"www.thelancet.com/hiv   Published online April 15, 2020  https://doi.org/10.1016/S2352-3018(20)30111-9 3given remdesivir (only available through clinical trials, with restricted access at the time these patients were evaluated). We administered concomitant antibacterials in all three patients who had pneumonia (patients 2, 4, and 5), and corticosteroids in two patients (patients 4 and 5) and tocilizumab in one (patient 2). We have discharged four patients (80%); one remains in hospital in the intensive care unit (patient 2).Our preliminary experience high-lights several issues. First, patients with HIV accounted for almost 1% of patients with COVID-19 who required admission to hospital in Barcelona. We only observed the infection in people younger than 50 years, who identi˜ed as MSM, and who have a COVID-19 clinical pictures resembling the general population. None of these ˜ve patients has died, although we admitted two to intensive care, where one remains. More studies of COVID-19 in patients with HIV are needed in the older MSM population, drug users, and heterosexual men and women in middle-income and lower-income settings. Second, two patients who were MSM were sex workers, one reporting participating in a chemsex party 6 days before admission to hospital. During this pandemic, implementing health edu-cation programmes is very important to explain that such activities as these could cause clusters of SARS-CoV-2 transmission. Third, we adapted ART in all patients to a regimen based on protease inhibitors: three patients were given lopinavir-boosted rito-navir and two were given darunavir-boosted cobici stat. In the past month, a clinical trial4 found that lopinavir-boosted ritonavir was ine˛ective as a monotherapy against severe pneu -monia asso ciated with COVID-19 in China. Therefore, investigation of the e˙cacy of this treatment in patients with COVID-19 in combined the-rapy in earlier stages of the disease is needed. Additionally, Janssen reported on March 18, 2020, that darunavir was ine˛ective against SARS-CoV-2 due to low a˙nity to coronavirus protease. Fourth, we did not give our patients remdesivir, the most active in-vitro and in-vivo antiviral drug against coronavirus to date,5 and is currently only available through clinical trials or for compassionate use. This drug has no pharmacokinetic interactions with any medication including ART drugs. Finally, in advanced patients (ie, late presenters), we must ensure di˛erential diagnosis and initial antimicrobial treatment to address pulmonary opportunistic infections (eg, Pneumocystis jirovecii, as seen in patient 5) presenting with similar clinical and radiological symptoms. This pandemic is a chall enge a˛ecting everyone. By generating information such as we present here, the management and prognosis of patients co-infected with HIV and SARS-CoV-2 might be improved.JLB and JA contributed equally. JMM has received consulting honoraria or research grants from AbbVie, Angelini, Contrafect, Cubist, Genentech, Gilead Sciences, Jansen, Medtronic, MSD, Novartis, P˜zer, and ViiV Healthcare, and has received a personal 80:20 research grant from Institut d™Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, during 2017Œ21. All other authors declare no competing interests.Jose L Blanco, Juan Ambrosioni, Felipe Garcia, Esteban Martínez, Alex Soriano, Josep Mallolas, *Jose M Miro, on behalf the COVID-˜˚ in HIV Investigatorsƒjmmiro@ub.eduƒThe COVID-19 in HIV Investigators are listed in the appendix (p 1).Infectious Diseases Service, Hospital Clinic, Institut d™Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Villarroel, 170. 08036 Barcelona, Spain1 Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; published online Feb 28. DOI:10.1056/NEJMoa2002032. 2 Zhu F, Cao Y, Xu S, Zhou M. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China. J Med Virol 2020; published online March 11. DOI:10.1002/jmv.25732.3 UNAIDS. UNAIDS Data 2019. Geneva: Joint United Nations Programme on HIV/AIDS, 2020. https://www.unaids.org/sites/default/˜les/media_asset/2019-UNAIDS-data_en.pdfn (accessed April 8, 2020).4 Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; published online March 18. DOI:10.1056/NEJMoa2001282.5 Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic e˙cacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11: 222.For more on COVID-19 drug interactions see www.covid19-druginteractions.orgFor report from Janssen on darunavir-based treatments for SARS-CoV-2 see https://www.janssen.com/uk/sars-cov-2-treatmentSee Online for appendix";21 avril 2020 
0;virologie;Virological assessment of hospitalized patients with COVID-2019;Roman Wölfel and al;https://www.groupedeveillecovid.fr/blog/2020/04/08/virological-assessment-of-hospitalized-patients-with-covid-2019/;17;3nature research  |  reporting summaryOctober 2018Clinical dataPolicy information about clinical studiesAll manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.Clinical trial registrationN.A.Study protocolNo study protocol emergency admissions of patients with new disease. Data collectionData collection at treating hospital, and two laboratories as identifed in affiliations list. OutcomesLaboratory and clinical status. No explicit outcome measure.;8 avril 2020 
0;virologie;Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China;Qiurong Ruan et al;https://www.groupedeveillecovid.fr/blog/2020/03/25/clinical-predictors-of-mortality-due-to-covid-19-based-on-an-analysis-of-data-of-150-patients-from-wuhan-china/;3;and Xingjie Hao for collecting cases or scienti˜c support. And we gratefully acknowledge all the health care workers on the front line and all the patients involved in the study.Authors contributionJXS, QRR and KY contributed to the conception and design of the study, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. KY, WXW and LYJ contributed to the acquisition of data. KY, WXW, LYJ and JXS contributed to the analysis and interpretation of the data. KY and WXW contributed to the statistical analyses. All authors participated in manuscript writing, revision and approval for ˜nal submission. Drs. QRR and KY contributed equally and shared ˜rst authorship.FundingThis work was supported by the Emergency Project for the Prevention and Control of the Novel Coronavirus (SARS-CoV-2) Outbreak in Hubei Province, China, as well as the National Natural Science Foundation of China (81703174 and 81602722). The funding source had no role in the design and conduct of the study, the analysis and interpretation of the data, or in the writing of the manuscript.Compliance with ethical standardsConflicts of interestAll authors declare no competing interests.Ethical approvalThis study was approved by the Ethics Commission of Jin Yin-tan Hospital (KY-2020-14.01) and the Ethics Commission of Tongji Hospital (TJ-C20200125).Publisher™s NoteSpringer Nature remains neutral with regard to jurisdictional claims in pub-lished maps and institutional a˚liations.Accepted: 24 February 2020References 1. Mahase E (2020) Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ 368:m641. https ://doi.org/10.1136/bmj.m641 2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, T Yu, Zhang X, Zhang L (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. https ://doi.org/10.1016/s0140 -6736(20)30211 -7 3. Wang D, Li S, Jiang J, Yan J, Zhao C, Wang Y, Ma Y, Zeng H, Guo X, Wang H, Tang J, Zuo H, Lin L, Cui G, Section of Precision Medicine Group of Chinese Society of Cardiology, Editorial Board of Chinese Journal of Car-diology, Working Group of Adult Fulminant Myocarditis (2019) Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis. Sci China Life Sci 62(2):187Œ202. https ://doi.org/10.1007/s1142 7-018-9385-3;25 mars 2020 
0;virologie-reponse-immunitaire;Factors associated with prolonged viral RNA shedding in patients with COVID-19;Xu K et al;https://www.groupedeveillecovid.fr/blog/2020/04/14/factors-associated-with-prolonged-viral-rna-shedding-in-patients-with-covid-19/;27;Accepted Manuscript  27 Figure 2  Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciaa351/5818308 by guest on 12 April 2020;14 avril 2020 
0;virologie-reponse-immunitaire;COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism;Wenzhong Liu et al;https://www.groupedeveillecovid.fr/blog/2020/04/10/covid-19-attacks-the-1-beta-chain-of-hemoglobin-and-captures-the-porphyrin-to-inhibit-human-heme-metabolism/;30;download fileview on ChemRxivcovid19-202000328-EN-1.pdf (2.47 MiB);10 avril 2020 
0;virologie-reponse-immunitaire;Réponse immunitaire innée et SARS-CoV;Dr Thomas LAVAUX;https://www.groupedeveillecovid.fr/blog/2020/04/06/reponse-immunitaire-innee-sars-cov/;48;Il faudra des travaux protocoles thérapeutiques bien conduit pour pouvoir valider ces hypothèsesRéponse IFN excessive par défaut de rétrocontrôle peut expliquer la gravité de la maladie chez les sujets âgésPrendre en compte le caractère biphasique de la pathologie dans la stratégie thérapeutiqueConclusion48;6 avril 2020 
0;virologie-reponse-immunitaire;Réponse immunitaire innée et SARS-CoV;Dr Thomas LAVAUX;https://www.groupedeveillecovid.fr/blog/2020/04/06/reponse-immunitaire-innee-sars-cov/;48;Il faudra des travaux protocoles thérapeutiques bien conduit pour pouvoir valider ces hypothèsesRéponse IFN excessive par défaut de rétrocontrôle peut expliquer la gravité de la maladie chez les sujets âgésPrendre en compte le caractère biphasique de la pathologie dans la stratégie thérapeutiqueConclusion48;6 avril 2020 
0;virologie-reponse-immunitaire;Stability of SARS-CoV-2 in different environmental conditions;Alex W H Chin and al;https://www.groupedeveillecovid.fr/blog/2020/04/04/stability-of-sars-cov-2-in-different-environmental-conditions/;1;"www.thelancet.com/microbe   Published online April 2, 2020   https://doi.org/10.1016/S2666-5247(20)30003-3 1temperature (22°C). Additionally, we also found that SARS-CoV-2 is extremely stable in a wide range of pH values at room temperature (pH 3Œ10; appendix p 1). Overall, SARS-CoV-2 can be highly stable in a favourable environment,4 but it is also susceptible to standard disinfection methods. This work was supported by National Institute of Allergy and Infectious Diseases, National Institutes of Health (contract HHSN272201400006C). LLMP was supported by the Croucher Foundation. We declare no competing interests. Alex W H Chin, Julie T S Chu, Mahen R A Perera, Kenrie P Y Hui, Hui-Ling Yen, Michael C W Chan, Malik Peiris, *Leo L M Poonllmpoon@hku.hkSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China. 1 Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 2020; published online Feb 24. https://doi.org/10·1016/S1473Œ3099(20)30113Œ4.2 Ye G, Lin H, Chen L, et al. Environmental contamination of the SARS-CoV-2 in healthcare premises: an urgent call for protection for healthcare workers. medRxiv 2020; published online March 16. DOI:10·1101/2020·03·11·20034546 (preprint).3 Chu DKW, Pan Y, Cheng SMS, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 2020; published online Jan 31. DOI:10·1093/clinchem/hvaa029.4 van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; published online March 17. DOI:10·1056/NEJMc2004973.desired time-points were immediately soaked with 200 µL of virus transport medium for 30 mins to elute the virus.  Therefore, this recovery of virus does not necessarily re˜ect the potential to pick up the virus from casual contact. No infectious virus could be recovered from printing and tissue papers after a 3-hour incubation, whereas no infectious virus could be detected from treated wood and cloth on day 2. By contrast, SARS-CoV-2 was more stable on smooth surfaces. No infectious virus could be detected from treated smooth surfaces on day 4 (glass and banknote) or day 7 (stainless steel and plastic). Strikingly, a detectable level of infectious virus could still be present on the outer layer of a surgical mask on day 7 (~0·1% of the original inoculum). Interestingly, a biphasic decay of infectious SARS-CoV-2 could be found in samples recovered from these smooth surfaces (appendix pp 2Œ7). 39 representative non-infectious samples tested positive by RT-PCR3 (data not shown), showing that non-infectious viruses could still be recovered by the eluents. We also tested the virucidal e˚ects of disinfectants by adding 15 µL of SARS-CoV-2 culture (~7·8 log unit of TCID50 per mL) to 135 µL of various disinfectants at working concentration (appendix p 1). With the exception of a 5-min incubation with hand soap, no infectious virus could be detected after a 5-min incubation at room Stability of SARS-CoV-2 in di˜erent environmental conditionsWe previously reported the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in di˚erent clinical samples.1 This virus can be detected on di˚erent surfaces in a contaminated site.2 Here, we report the stability of SARS-CoV-2 in di˚erent environmental conditions. We first measured the stability of SARS-CoV-2 at di˚erent temperatures. SARS-CoV-2 in virus transport medium (˛nal concentration ~6·8 log unit of 50% tissue culture infectious dose [TCID50] per mL) was incubated for up to 14 days and then tested for its infectivity (appendix p 1). The virus is highly stable at 4°C, but sensitive to heat. At 4°C, there was only around a 0·7 log-unit reduction of infectious titre on day 14. With the incubation temperature increased to 70°C, the time for virus inactivation was reduced to 5 mins.We further investigated the stability of this virus on different surfaces. Briefly, a 5 µL droplet of virus culture (~7·8 log unit of TCID50 per mL) was pipetted on a surface (appendix p 1; ~cm˝ per piece) and left at room temperature (22°C) with a relative humidity of around 65%. The inoculated objects retrieved at See Online for appendixLancet Microbe 2020Published Online April 2, 2020 https://doi.org/10.1016/ S2666-5247(20)30003-3";4 avril 2020 
0;virologie-reponse-immunitaire;Stability of SARS-CoV-2 in different environmental conditions;Alex W H Chin and al;https://www.groupedeveillecovid.fr/blog/2020/04/04/stability-of-sars-cov-2-in-different-environmental-conditions/;8;;4 avril 2020 
0;virologie-reponse-immunitaire;Stability of SARS-CoV-2 in different environmental conditions;Alex W H Chin and al;https://www.groupedeveillecovid.fr/blog/2020/04/04/stability-of-sars-cov-2-in-different-environmental-conditions/;1;"www.thelancet.com/microbe   Published online April 2, 2020   https://doi.org/10.1016/S2666-5247(20)30003-3 1temperature (22°C). Additionally, we also found that SARS-CoV-2 is extremely stable in a wide range of pH values at room temperature (pH 3Œ10; appendix p 1). Overall, SARS-CoV-2 can be highly stable in a favourable environment,4 but it is also susceptible to standard disinfection methods. This work was supported by National Institute of Allergy and Infectious Diseases, National Institutes of Health (contract HHSN272201400006C). LLMP was supported by the Croucher Foundation. We declare no competing interests. Alex W H Chin, Julie T S Chu, Mahen R A Perera, Kenrie P Y Hui, Hui-Ling Yen, Michael C W Chan, Malik Peiris, *Leo L M Poonllmpoon@hku.hkSchool of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China. 1 Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 2020; published online Feb 24. https://doi.org/10·1016/S1473Œ3099(20)30113Œ4.2 Ye G, Lin H, Chen L, et al. Environmental contamination of the SARS-CoV-2 in healthcare premises: an urgent call for protection for healthcare workers. medRxiv 2020; published online March 16. DOI:10·1101/2020·03·11·20034546 (preprint).3 Chu DKW, Pan Y, Cheng SMS, et al. Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. Clin Chem 2020; published online Jan 31. DOI:10·1093/clinchem/hvaa029.4 van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; published online March 17. DOI:10·1056/NEJMc2004973.desired time-points were immediately soaked with 200 µL of virus transport medium for 30 mins to elute the virus.  Therefore, this recovery of virus does not necessarily re˜ect the potential to pick up the virus from casual contact. No infectious virus could be recovered from printing and tissue papers after a 3-hour incubation, whereas no infectious virus could be detected from treated wood and cloth on day 2. By contrast, SARS-CoV-2 was more stable on smooth surfaces. No infectious virus could be detected from treated smooth surfaces on day 4 (glass and banknote) or day 7 (stainless steel and plastic). Strikingly, a detectable level of infectious virus could still be present on the outer layer of a surgical mask on day 7 (~0·1% of the original inoculum). Interestingly, a biphasic decay of infectious SARS-CoV-2 could be found in samples recovered from these smooth surfaces (appendix pp 2Œ7). 39 representative non-infectious samples tested positive by RT-PCR3 (data not shown), showing that non-infectious viruses could still be recovered by the eluents. We also tested the virucidal e˚ects of disinfectants by adding 15 µL of SARS-CoV-2 culture (~7·8 log unit of TCID50 per mL) to 135 µL of various disinfectants at working concentration (appendix p 1). With the exception of a 5-min incubation with hand soap, no infectious virus could be detected after a 5-min incubation at room Stability of SARS-CoV-2 in di˜erent environmental conditionsWe previously reported the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in di˚erent clinical samples.1 This virus can be detected on di˚erent surfaces in a contaminated site.2 Here, we report the stability of SARS-CoV-2 in di˚erent environmental conditions. We first measured the stability of SARS-CoV-2 at di˚erent temperatures. SARS-CoV-2 in virus transport medium (˛nal concentration ~6·8 log unit of 50% tissue culture infectious dose [TCID50] per mL) was incubated for up to 14 days and then tested for its infectivity (appendix p 1). The virus is highly stable at 4°C, but sensitive to heat. At 4°C, there was only around a 0·7 log-unit reduction of infectious titre on day 14. With the incubation temperature increased to 70°C, the time for virus inactivation was reduced to 5 mins.We further investigated the stability of this virus on different surfaces. Briefly, a 5 µL droplet of virus culture (~7·8 log unit of TCID50 per mL) was pipetted on a surface (appendix p 1; ~cm˝ per piece) and left at room temperature (22°C) with a relative humidity of around 65%. The inoculated objects retrieved at See Online for appendixLancet Microbe 2020Published Online April 2, 2020 https://doi.org/10.1016/ S2666-5247(20)30003-3";4 avril 2020 
0;virologie-reponse-immunitaire;Viral dynamics in mild and severe cases of COVID-19;Liu Y et al;https://www.groupedeveillecovid.fr/blog/2020/03/25/viral-dynamics-in-mild-and-severe-cases-of-covid-19/;2;"2 www.thelancet.com/infection   Published online March 19, 2020   https://doi.org/10.1016/S1473-3099(20)30232-24 Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; published online Feb 24. https://doi.org/10.1016/S2213-2600(20)30079-5.5 WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. 2020. https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117 (accessed March 13, 2020).6 Chu CM, Poon LL, Cheng VC, et al. Initial viral load and the outcomes of SARS. CMAJ 2004; 171: 1349Œ52.Department of Clinical Microbiology (YL), Department of Infectious Disease (T-XX), Department of Blood Transfusion (AL), Department of Orthopedic Surgery (J-ML), and Department of Respiration (WZ), The First A˙liated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China; and School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China (L-MY, MP, LLMP)1 Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 2020; published online Feb 24. https://doi.org/10.1016/S1473-3099(20)30113-4.2 Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; published online Jan 30. DOI:10.1056/NEJMc2001737.3 Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; published online Feb 28. DOI:10.1056/NEJMoa2002032.patients with severe COVID-19 tend to have a high viral load and a long virus-shedding period. This finding suggests that the viral load of SARS-CoV-2 might be a useful marker for assessing disease severity and prognosis.We declare no competing interests. This work was supported by the Health and Medical Research Fund (Hong Kong) and Emergency Science and Technology Project for COVID-19 of Jiangxi province (202011-2).Yang Liu, Li-Meng Yan, Lagen Wan, Tian-Xin Xiang, Aiping Le, Jia-Ming Liu, Malik Peiris, *Leo L M Poon, *Wei Zhangllmpoon@hku.hk; zhangweiliuxin@163.com";25 mars 2020 
0;virologie-reponse-immunitaire;COVID-19: consider cytokine storm syndromes and immunosuppression;Puja Mehta, Daniel F McAuley, Michael Brown, Emilie Sanchez, Rachel S Tattersall, Jessica J Manson, et al;https://www.groupedeveillecovid.fr/blog/2020/03/20/covid-19-consider-cytokine-storm-syndromes-and-immunosuppression/;2;"2 www.thelancet.com   Published online March 13, 2020   https://doi.org/10.1016/S0140-6736(20)30628-02 Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; published online March 3. DOI:10.1007/s00134-020-05991-x.3 Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet 2014; 383: 1503Œ16.4 Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like syndrome: a distinct entity leading to early death in sepsis. Front Immunol 2019; 10: 55.5 Seguin A, Galicier L, Boutboul D, Lemiale V, Azoulay E. Pulmonary involvement in patients with hemophagocytic lymphohistiocytosis. Chest 2016; 149: 1294Œ301.6 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497Œ506.7 Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020; 395: 473Œ75.8 Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase iii trial. Crit Care Med 2016; 44: 275Œ81.9 Chinese Clinical Trial Registry. A multicenter, randomized controlled trial for the eˇcacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). Feb 13, 2020. http://www.chictr.org.cn/showprojen.aspx?proj=49409 (accessed March 6, 2020).10 Richardson P, Griˇn I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395: e30Œ31.11 Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol 2014; 66: 2613Œ20.COVID-19 pneumonia and elevated IL-6 in China (ChiCTR2000029765).9 Janus kinase (JAK) inhibition could a˘ect both in˚ammation and cellular viral entry in COVID-19.10All patients with severe COVID-19 should be screened for hyperinflam-mation using laboratory trends (eg, increasing ferritin, decreasing platelet counts, or erythrocyte sedimentation rate) and the HScore11 (table) to identify the subgroup of patients for whom immunosuppression could improve mortality. Therapeutic options include steroids, intravenous immuno globulin, selective cytokine blockade (eg, anakinra or tocilizumab) and JAK inhibition.PM is a clinical training fellow within the Experimental Medicine Initiative to Explore New Therapies network and receives project funding unrelated to this Correspondence. PM also receives co-funding by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. DFM chairs the NIHR and Medical Research Council funding committee for COVID-19 for therapeutics and vaccines. DFM reports personal fees from consultancy for ARDS for GlaxoSmithKline, Boehringer Ingelheim, and Bayer; in addition, his institution has received funds from grants from the UK NIHR, Wellcome Trust, Innovate UK, and others, all unrelated to this Correspondence. DFM also has a patent issued to his institution for a treatment for ARDS. DFM is a Director of Research for the Intensive Care Society and NIHR Eˇcacy and Mechanism Evaluation Programme Director. All other authors declare no competing interests.Puja Mehta, Daniel F McAuley, Michael Brown, Emilie Sanchez, Rachel S Tattersall, *Jessica J Manson, on behalf of the HLH Across Speciality Collaboration, UKjessica.manson@nhs.netCentre for In˚ammation and Tissue Repair, UCL Respiratory, Division of Medicine, University College London, London, UK (PM); Department of Rheumatology (JJM), Hospital for Tropical Diseases (MB), and Department of Clinical Virology (ES), University College London Hospital, London NW1 2PG, UK; Wellcome-Wolfson Institute for Experimental Medicine, Queen™s University Belfast, Belfast, UK (DFM); Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK (DFM); Department of Rheumatology, Sheˇeld Teaching Hospitals NHS Foundation Trust, Sheˇeld, UK (RST); and Sheˇeld Children™s Hospital NHS Foundation Trust, Sheˇeld, UK (RST)1 WHO. Coronavirus disease 2019 (COVID-19)situation report Œ 52. March 12, 2020. https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_2 (accessed March 13, 2020).";20 mars 2020 
0;epidemiologie-et-sante-publique;Prevalence of Asymptomatic SARS-CoV-2 Infection;Daniel P. Oran, AM, and Eric J. Topol, MD ;https://www.groupedeveillecovid.fr/blog/2020/07/31/prevalence-of-asymptomatic-sars-cov-2-infection/;7;CurrentAuthorAddresses:Mr.OranandDr.Topol:ScrippsResearchTranslationalInstitute,3344NorthTorreyPinesCourt,3rdFloor,LaJolla,CA92037.AuthorContributions:Conceptionanddesign:D.P.Oran,E.J.Topol.Analysisandinterpretationofthedata:D.P.Oran,E.J.Topol.Draftingofthearticle:D.P.Oran,E.J.Topol.Criticalrevisionofthearticleforimportantintellectualcon-tent:E.J.Topol.Finalapprovalofthearticle:D.P.Oran,E.J.Topol.Statisticalexpertise:E.J.Topol.Administrative,technical,orlogisticsupport:E.J.Topol.Collectionandassemblyofdata:D.P.Oran,E.J.Topol.Annals.orgAnnalsofInternalMedicine;31 juillet 2020 
0;epidemiologie-et-sante-publique;Covid-19: US states are not reporting vital data, says former CDC chief;null;https://www.groupedeveillecovid.fr/blog/2020/07/31/covid-19-us-states-are-not-reporting-vital-data-says-former-cdc-chief/;1;"Covid-19:USstatesarenotreportingvitaldata,saysformerCDCchiefOwenDyerMostUSstatesaremissingkeyindicatorsinthedatatheypublishaboutthecourseofthecovid-19pandemic,saysareportpresentedbyTomFrieden,formerdirectoroftheCentersforDiseaseControlandPrevention(CDC).ThereportbyResolvetoSaveLives,aNewYorkbasednon-profitgroupledbyFrieden,examinedthecovid-19dashboardsofall50statesandtheDistrictofColumbia.1Indicatorscriticaltounderstandingthepandemicscoursewereoftenmissing,itfound.Notasinglestatecurrentlyreportstheaverageturnaroundtimeofapolymerasechainreaction(PCR)test,aspressreportsaboundoftestsinmanyregionstakingaweekormoretocomeback,adelaythatrenderstestingnearlyuselessincontrollingthediseasesspread.Thetestpositivityrategoesunreportedby25%ofstates.ResolvetoSaveLives,whichispartoftheglobalhealthorganisationVitalStrategies,listed15indicatorsthatareroutinelyusedinothercountriesreportingandexaminedtheperformanceofeachUSstateoneachindicator.Theseindicatorsincludesyndromicreportingofinfluenza-likeillness,reportedby10states,andcovid-likeillness,reportedby18states.Thesetwoareconsideredleadingindicators,allowingafasterresponsethanthetrailingindicatorsofhospitaladmissionsanddeaths.Reportingtendstobemostlackinginareaswheretheresponsehasalsobeenmostlacking.Statereportingoncontacttracingisabysmal,thereportsaid.Onlyeightstatesreportdataonthesourceofexposureforcases,whichisdeterminedduringcaseinterviews.Sourcedataisroutinelyreportedincountriesthatarerespondingeffectivelytocovid-19;infectionsfromunknownsourcessignalundetectedcommunitytransmission.TheDistrictofColumbiapublishedsuchcontacttracingdataforthefirsttimethisweek,reportingthatjust2.8%ofnewcaseshadbeenlinkedtocasesthatwerealreadyknown.Thedistrictstargetwas60%.Thedatathatarewidelyreportednotablytestnumbers,cases,anddeathsareoftenrenderedlessusefulbylackofclarity.Halfofstatesfailtodistinguishbetweenactiveandrecoveredcasesorbetweenprobableandconfirmedcases.Allbutthreestatesreporttrendsindailytestnumbers,butfewmakethevitaldistinctionbetweenPCRtestsforactiveinfectionandantibodytestsforpreviousinfection.Onlysevenstatesprovideinformationabouthealthworkerinfectionsontheirdashboards.AfigureisprovidedbytheCDC,whichcurrentlyreports106180infectionsand552deathsamonghealthcarepersonnel,buttheagencyacknowledgesinanaccompanyingnotethathealthcarepersonnelstatuswasonlyavailablefor634428peopleaboutoneinfiveofthoseknowntotheCDC.2Alackofstandarddefinitionsmakesitimpossibletocompilenationaldatareliably,Friedentoldanewsbriefingpresentingthereport.Despitegoodworkbymanystatesandatsunamiofdatapoints,hesaid,becauseofthelackofnationalleadership,wedonthavecommonstandards,definitions,targets,oraccountability.TheUSisflyingblind,hesaid,questioningthecurrentobsessionwithhighertestnumbers.Ifresultsaretakingseveraldays,ifpositivecasesarerarelyisolated,andifcontactsarealmostneverwarned,hesaid,thenwereallyhavedoneverylittlegood.ThecurrentnumberofcasesintheUnitedStatesexceedsthecombinedtotalinallofEurope,Africa,andAsia,saidFrieden.Heexplained,With4%oftheworldspopulation,wehaveonequarterofcovidreporteddeaths.Andduringthe45minutesofthisbriefing,morethan20peoplewilldiefromcovidintheUSandthousandsmorewillbecomeinfected.1ResolvetoSaveLives.TrackingCOVID-19intheUnitedStates.21Jul2020.https://preventepidemics.org/wp-content/uploads/2020/07/Tracking-COVID-19-in-the-United-States-Report.pdf.2CentersforDiseaseControlandPrevention.CasesintheUS.Updated26Jul2020.https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html.ThisarticleismadefreelyavailableforuseinaccordancewithBMJ'swebsitetermsandconditionsforthedurationofthecovid-19pandemicoruntilotherwisedeterminedbyBMJ.Youmayuse,downloadandprintthearticleforanylawful,non-commercialpurpose(includingtextanddatamining)providedthatallcopyrightnoticesandtrademarksareretained.1thebmj|BMJ2020;370:m2993 | doi: 10.1136/bmj.m2993NEWSMontrealCitethisas:BMJ2020;370:m2993http://dx.doi.org/10.1136/bmj.m2993Published:27July2020 on 29 July 2020 by guest. Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.m2993 on 27 July 2020. Downloaded from ";31 juillet 2020 
0;epidemiologie-et-sante-publique;"The COVID-19 pandemic: diverse contexts; different epidemics—how and why?";BMJ Global Health 2020;https://www.groupedeveillecovid.fr/blog/2020/07/30/the-covid-19-pandemic-diverse-contexts-different-epidemics-how-and-why/;16;"16BMJ Global Health 103 Khafaie MA, Rahim F. Cross- Country comparison of case fatality rates of COVID-19/SARS- COV-2. Osong Public Health Res Perspect 2020;11:74Œ80. 104 Cyranoski D. Mystery deepens over animal source of coronavirus. Nature 2020;579:18Œ19. 105 Asadi S, Wexler AS, Cappa CD, et˜al. Aerosol emission and superemission during human speech increase with voice loudness. Sci Rep 2019;9:2348. 106 Wei WE, Li Z, Chiew CJ, et˜al. Presymptomatic transmission of SARS- CoV-2 Š Singapore, January 23ŒMarch 16, 2020. MMWR Morb Mortal Wkly Rep 2020;69:411Œ5. 107 van Doremalen N, Bushmaker T, Morris DH, et˜al. Aerosol and surface stability of SARS- CoV-2 as compared with SARS- CoV-1. N Engl J Med 2020;382:1564Œ7. 108 Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential FecalŒOral transmission. Gastroenterology 2020;158:30281- X:pii: S0016Œ1519. Mar 3. 109 Xu Y, Li X, Zhu B, et˜al. Characteristics of pediatric SARS- CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med 2020;26:502Œ5. 110 Medema G, Heijnen L, Elsinga G, et˜al. Presence of SARS- Coronavirus-2 in sewage. medRxiv 2020. 111 Ahmed W, Angel N, Edson J, et˜al. First con˜rmed detection of SARS- CoV-2 in untreated wastewater in Australia: a proof of concept for the wastewater surveillance of COVID-19 in the community. Sci Total Environ 2020;728:138764. 112 Lodder W, de Roda Husman AM. SARS- CoV-2 in wastewater: potential health risk, but also data source. Lancet Gastroenterol Hepatol 2020;5:533Œ4. 113 Cheng H- Y, Jian S- W, Liu D- P, et˜al. High transmissibility of COVID-19 near symptom onset. medRxiv 2020. 114 Ferretti L, Wymant C, Kendall M, et˜al. Quantifying SARS- CoV-2 transmission suggests epidemic control with digital contact tracing. Science 2020;368:eabb6936. 115 He X, Lau EHY, Wu P, et˜al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020;26:672Œ5. 116 Araujo MB, Naimi B. Spread of SARS- CoV-2 coronavirus likely to be constrained by climate. medRxiv 2020. 117 Sajadi MM, Habibzadeh P, Vintzileos A, et˜al. Temperature, humidity and latitude analysis to predict potential spread and seasonality for COVID-19, 2020. Available: https:// ssrn. com/ abstract= 3550308 [Accessed 15 Apr 2020]. 118 Luo W, Majumder MS, Liu D, et˜al. The role of absolute humidity on transmission rates of the COVID-19 outbreak. medRxiv 2020. 119 Martelletti L, Martelletti P. Air pollution and the novel Covid-19 disease: a putative disease risk factor. SN Compr Clin Med 2020:1Œ5. 120 Guo L, Ren L, Yang S, et˜al. Pro˜ling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 2020;24. 121 Bao L, Deng W, Gao H, et˜al. Reinfection could not occur in SARS- CoV-2 infected rhesus macaques. bioRxiv 2020. 122 Yuan J, Kou S, Liang Y, et˜al. Pcr assays turned positive in 25 discharged COVID-19 patients. Clin Infect Dis 2020. 123 Lan L, Xu D, Ye G, et˜al. Positive RT- PCR test results in patients recovered from COVID-19. JAMA 2020;323:1502. 124 Bobrovitz N, Arora RK, Yan T, et˜al. Lessons from a rapid systematic review of early SARS- CoV-2 serosurveys. medRxiv 2020. 125 Okba NMA, Müller MA, Li W, et˜al. Severe acute respiratory syndrome coronavirus 2- speci˜c antibody responses in coronavirus disease patients. Emerg Infect Dis 2020;26:1478Œ88. 126 Gorse GJ, Patel GB, Vitale JN, et˜al. Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum. CVI 2010;17:1875Œ80. 127 Theel ES, Slev P, Wheeler S, et˜al. The role of antibody testing for SARS- CoV-2: is there one? J Clin Microbiol 2020:00797Œ20. 128 World Health Organization. ""Immunity passports"" in the context of COVID-19, 2020. Available: https://www. who. int/ news- room/ commentaries/ detail/ immunity- passports- in- the- context- of- covid- 19 [Accessed 30 May 2020]. 129 Britton T, Trapman P, Ball FG. The disease- induced herd immunity level for Covid-19 is substantially lower than the classical herd immunity level. medRxiv 2020. 130 Gomes MGM, Corder RM, King JG, et˜al. Individual variation in susceptibility or exposure to SARS- CoV-2 lowers the herd immunity threshold. medRxiv 2020. doi:10.1101/2020.04.27.20081893. [Epub ahead of print: 02 May 2020]. 131 Kwok KO, Lai F, Wei WI, et˜al. Herd immunity Œ estimating the level required to halt the COVID-19 epidemics in affected countries. Journal of Infection 2020;80:e32Œ3. 132 Rambaut A. Phylogenetic analysis of nCoV-2019 genomes, 2020. Available: http:// virological. org/ t/ phylodynamic- analysis- 176- genomes- 6- mar- 2020/ 356 [Accessed 15 Apr 2020]. 133 Bar- On YM, Flamholz A, Phillips R, et˜al. SARS- CoV-2 (COVID-19) by the numbers. eLife 2020;9:e57309. 134 Wang C, Liu Z, Chen Z, et˜al. The establishment of reference sequence for SARS- CoV-2 and variation analysis. J Med Virol 2020;92:667Œ74. 135 Achenbach J. The coronavirus isn™t mutating quickly, suggesting a vaccine would offer lasting protection. The Washington Post 2020 25 March, 2020. Available: https://www. washingtonpost. com/ health/ the- coronavirus- isnt- mutating- quickly- suggesting- a- vaccine- would- offer- lasting- protection/ 2020/ 03/ 24/ 406522d6- 6dfd- 11ea- b148- e4ce3fbd85b5_ story. html [Accessed 15 May 2020]. 136  Nextstrain. com. Genomic epidemiology of novel coronavirus, 2020. Available: https:// nextstrain. org/ ncov? r= location [Accessed 30 May 2020]. 137 Larremore DB, Bubar KM, Grad YH. Implications of test characteristics and population seroprevalence on ‚immune passport™ strategies, 2020. Available: http:// nrs. harvard. edu/ urn- 3: HUL. InstRepos: 42664007 [Accessed 30 May 2020]. 138 Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020;109:1088Œ95. 139 Viner RM, Mytton OT, Bonell C, et˜al. Susceptibility to and transmission of COVID-19 amongst children and adolescents compared with adults: a systematic review and meta- analysis. medRxiv 2020. 140 Bai Y, Yao L, Wei T, et˜al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 2020;323:1406Œ7. 141 Rothe C, Schunk M, Sothmann P, et˜al. Transmission of 2019- nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020;382:970Œ1. on July 29, 2020 by guest. Protected by copyright.http://gh.bmj.com/BMJ Glob Health: first published as 10.1136/bmjgh-2020-003098 on 27 July 2020. Downloaded from ";30 juillet 2020 
0;epidemiologie-et-sante-publique;Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe;Seth Flaxman, Swapnil Mishra, Axel Gandy, H. Juliette T. Unwin, Thomas A. Mellan, Helen Coupland, Charles Whittaker, Harrison Zhu, Tresnia Berah, Jeffrey W. Eaton, Mélodie Monod, Imperial College COVID-19 Response Team, Azra C. Ghani, Christl A. Donnelly, Steven M. Riley, Michaela A. C. Vollmer, Neil M. Ferguson, Lucy C. Okell & Samir Bhatt;https://www.groupedeveillecovid.fr/blog/2020/06/09/estimating-the-effects-of-non-pharmaceutical-interventions-on-covid-19-in-europe/;18;"2nature research  |  reporting summaryApril 2020Field-specific reportingPlease select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.Life sciencesBehavioural & social sciences Ecological, evolutionary & environmental sciencesFor a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdfLife sciences study designAll studies must disclose on these points even when the disclosure is negative.Sample sizeNo samples were collected; data on the count of COVID-19-related deaths over time in 11 European countries was used.Data exclusionsNo data was excluded.Replicationn/aRandomizationn/aBlindingn/aReporting for specific materials, systems and methodsWe require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Materials & experimental systemsn/aInvolved in the studyAntibodiesEukaryotic cell linesPalaeontology and archaeologyAnimals and other organismsHuman research participantsClinical dataDual use research of concernMethodsn/aInvolved in the studyChIP-seqFlow cytometryMRI-based neuroimaging";9 juin 2020 
0;epidemiologie-et-sante-publique;Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis;Derek K Chu, Elie A Akl, Stephanie Duda, Karla Solo, Sally Yaacoub, Holger J Schünemann;https://www.groupedeveillecovid.fr/blog/2020/06/05/physical-distancing-face-masks-and-eye-protection-to-prevent-person-to-person-transmission-of-sars-cov-2-and-covid-19-a-systematic-review-and-meta-analysis/;15;"www.thelancet.com   Published online June 1, 2020   https://doi.org/10.1016/S0140-6736(20)31142-9 1574 Wu J, Xu F, Zhou W, et al. Risk factors for SARS among persons without known contact with SARS patients, Beijing, China. Emerg Infect Dis 2004; 10: 210Œ16.75 Yin WW, Gao LD, Lin WS, et al. E˜ectiveness of personal protective measures in prevention of nosocomial transmission of severe acute respiratory syndrome. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25: 18Œ22.76 Yu ITS, Wong TW, Chiu YL, Lee N, Li Y. Temporal-spatial analysis of severe acute respiratory syndrome among hospital inpatients. Clin Infect Dis 2005; 40: 1237Œ43.77 Yu IT, Xie ZH, Tsoi KK, et al. Why did outbreaks of severe acute respiratory syndrome occur in some hospital wards but not in others? Clin Infect Dis 2007; 44: 1017Œ25.78 Verbeek JH, Rajamaki B, Ijaz S, et al. Personal protective equipment for preventing highly infectious diseases due to exposure to contaminated body ˚uids in healthcare sta˜. Cochrane Database Syst Rev 2019; 7: CD011621.79 MacIntyre CR, Wang Q, Seale H, et al. A randomized clinical trial of three options for N95 respirators and medical masks in health workers. Am J Respir Crit Care Med 2013; 187: 960Œ66.80 Campbell A. Chapter eight: it™s not about the mask: SARS Commission ˛nal report, volume 3. December, 2006. http://www.archives.gov.on.ca/en/e_records/sars/report/v3-pdf/Vol3Chp8.pdf (accessed May 12, 2020).81 Webster P. Ontario issues ˛nal SARS Commission report. Lancet 2007; 369: 264.82 Rimmer A. COVID-19: experts question guidance to reuse PPE. BMJ 2020; 369: m1577. 83 Mackenzie D. Reuse of N95 masks. Engineering 2020; published online April 13. DOI:10.1016/j.eng.2020.04.003.84 Greenhalgh T, Schmid MB, Czypionka T, Bassler D, Gruer L. Face masks for the public during the covid-19 crisis. BMJ 2020; 369: m1435.85 Bahl P, Doolan C, de Silva C, Chughtai AA, Bourouiba L, MacIntyre CR. Airborne or droplet precautions for health workers treating coronavirus disease 2019? J Infect Dis 2020; published online April 16. DOI:10.1093/infdis/jiaa189.86 Schünemann HJ, Khabsa J, Solo K, et al. Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19: a living systematic review of multiple streams of evidence. Ann Intern Med 2020; published online May 22. DOI:10.7326/M20-2306.87 Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and e˝cacy of face masks. Nat Med 2020; 26: 676Œ80.";5 juin 2020 
0;epidemiologie-et-sante-publique;AVIS relatif à l’utilisation de l’hydroxychloroquine dans le Covid-19 24 mai 2020;null;https://www.groupedeveillecovid.fr/blog/2020/06/02/avis-relatif-a-lutilisation-de-lhydroxychloroquine-covid-19-24-mai-2020/;28;Avis relatif à l™utilisation de l™hydroxychloroquine dans le Covid-19 24 mai 2020  Haut Conseil de la santé publique 28/28 Cet avis doit être diffusé dans sa totalité, sans ajout ni modification  Raison de l™exclusion Référence Schémas non comparatifs Gautret JC et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Medicine & Infectious Disease. https://doi.org/10.1016/j.tmaid.2020.101663  Geleris Y et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England journal of medicine. 10.1056/NEJMoa2012410  Carlucci PM et al. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. medRxiv. 10.1101/2020.05.02.20080036 Autre schéma inadapté Vouri TN et al. An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic. Research in Social and Administrative Pharmacy. https://doi.org/10.1016/j.sapharm.2020.04.031 Séries de cas de petite taille Gautret JC et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. https://dx.doi.org/10.1016/j.ijantimicag.2020.105949  Mallat F et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. medRxiv. 10.1101/2020.04.27.20082180   van den Broek JE et al. Chloroquine-induced QTc prolongation in COVID-19 patients. Netherlands Heart Journal. 10.1007/s12471-020-01429-7   i Lane  et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. MedRxiv https://doi.org/10.1101/2020.04.08.20054551 ii Gerard A Therapies 2020 : ﬁOff-labelﬂ use of hydroxychloroquine, azithromycin, lopinavir-ritonavirand chloroquine in COVID-19: a survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers  Le 24 mai 2020 Haut Conseil de la santé publique 14 avenue Duquesne 75350 Paris 07 SP www.hcsp.fr ;2 juin 2020 
0;epidemiologie-et-sante-publique;Covid-19 and alcohol—a dangerous cocktail;Ilora Finlay and al;https://www.groupedeveillecovid.fr/blog/2020/06/02/covid-19-and-alcohol-a-dangerous-cocktail/;2;"Competing interests: We have read and understood BMJ policy on declaration ofinterests and declare the following interests: IG declares a single lecture fee andtravel expenses from Kiowa Kirin.Provenance and peer review: Not commissioned; not externally peer reviewed.1Eley J. Record month for UK supermarkets as consumers spend extra £1.9bn. FinancialTimes 2020. Mar 31. https://www.ft.com/content/cf153651-09f3-4cf5-a012-e4f823b648be2Institute of Alcohol Studies. Alcohol, domestic abuse and sexual assault. 2014. http://www.ias.org.uk/uploads/IAS%20report%20Alcohol%20domestic%20abuse%20and%20sexual%20assault.pdf3Gilchrist L, Ireland L, Forsyth A, Laxton T, Godwin J. Roles of alcohol in intimate partnerabuse. 2014. https://alcoholchange.org.uk/publication/roles-of-alcohol-in-intimate-partner-abuse4Home Office. Domestic homicide reviews. 2016. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/575232/HO-Domestic-Homicide-Review-Analysis-161206.pdf5Home Office. Impact assessment: a minimum unit price for alcohol. 2012. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/157763/ia-minimum-unit-pricing.pdf6WilliamsR, AithalG, AlexanderGJ, etal . Unacceptable failures: the final report of theLancet Commission into liver disease in the UK. Lancet 2020;395:226-39.10.1016/S0140-6736(19)32908-3 317916907Public Health England. Alcohol and drug prevention, treatment and recovery: why invest?2018. https://www.gov.uk/government/publications/alcohol-and-drug-prevention-treatment-and-recovery-why-invest/alcohol-and-drug-prevention-treatment-and-recovery-why-investPublished by the BMJ Publishing Group Limited. For permission to use (where not alreadygranted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissionsFor personal use only: See rights and reprints http://www.bmj.com/permissionsSubscribe:http://www.bmj.com/subscribeBMJ 2020;369:m1987 doi: 10.1136/bmj.m1987 (Published 20 May 2020)Page 2 of 2EDITORIALS on 26 May 2020 at Universite Louis Pasteur Strasbourg. Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.m1987 on 20 May 2020. Downloaded from ";2 juin 2020 
0;epidemiologie-et-sante-publique;OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients.;Elizabeth Williamson and al;https://www.groupedeveillecovid.fr/blog/2020/06/02/opensafely-factors-associated-with-covid-19-related-hospital-death-in-the-linked-electronic-health-records-of-17-million-adult-nhs-patients/;22; 21 Respiratory disease ex asthma 1.78 (1.67-1.90) 1.97 (1.77-2.18) 1.74 (1.62-1.86) 1.79 (1.66-1.93)      Asthma (vs none)*2     With no recent OCS use 1.11 (1.02-1.20) 1.14 (1.01-1.29) 1.10 (1.02-1.20) 1.03 (0.94-1.13) With recent OCS use 1.25 (1.08-1.44) 1.39 (1.12-1.73) 1.22 (1.05-1.42) 1.24 (1.06-1.46)      Chronic heart disease 1.27 (1.20-1.35) 1.33 (1.22-1.46) 1.27 (1.19-1.35) 1.27 (1.19-1.36)      Diabetes (vs none)*3     Controlled  (HbA1c<58 mmol/mol) 1.50 (1.40-1.60) 1.48 (1.33-1.65) 1.47 (1.37-1.57) 1.47 (1.36-1.59) Uncontrolled  (HbA1c>=58 mmol/mol) 2.36 (2.18-2.56) 2.57 (2.27-2.91) 2.30 (2.12-2.50) 2.23 (2.03-2.45) No recent HbA1c measure 1.87 (1.63-2.16) 1.68 (1.33-2.12) 1.85 (1.60-2.15) 1.91 (1.63-2.24)      Cancer (non-haematological, vs none)     Diagnosed < 1 year ago 1.56 (1.29-1.89) 1.51 (1.10-2.05) 1.52 (1.24-1.86) 1.68 (1.36-2.09) Diagnosed 1-4.9 years ago 1.19 (1.04-1.35) 1.36 (1.13-1.65) 1.20 (1.05-1.37) 1.21 (1.04-1.40)  0.97 (0.88-1.06) 0.92 (0.79-1.06) 0.96 (0.87-1.05) 1.02 (0.92-1.13)      Haematological malignancy (vs none)     Diagnosed < 1 year ago 3.52 (2.41-5.14) 2.60 (1.30-5.22) 3.77 (2.58-5.50) 3.30 (2.10-5.18) Diagnosed 1-4.9 years ago 3.12 (2.50-3.89) 3.67 (2.66-5.06) 3.03 (2.40-3.83) 3.42 (2.67-4.38)  1.88 (1.55-2.29) 1.64 (1.18-2.28) 1.90 (1.55-2.33) 1.84 (1.46-2.32)      Liver disease 1.61 (1.33-1.95) 1.86 (1.40-2.47) 1.59 (1.30-1.93) 1.61 (1.30-2.00)      Stroke/dementia 1.79 (1.67-1.93) 1.61 (1.43-1.81) 1.78 (1.65-1.92) 1.75 (1.61-1.90)      Other neurological 2.46 (2.19-2.76) 2.28 (1.88-2.76) 2.38 (2.10-2.69) 2.41 (2.11-2.76)      Kidney disease 1.72 (1.62-1.83) 1.75 (1.58-1.92) 1.71 (1.60-1.82) 1.76 (1.64-1.89)      Organ transplant 4.27 (3.20-5.70) 2.62 (1.51-4.57) 4.44 (3.31-5.96) 4.59 (3.36-6.27)      Spleen diseases 1.41 (0.93-2.12) 1.87 (1.06-3.30) 1.25 (0.79-1.96) 1.43 (0.90-2.27)      Rheumatoid/Lupus/ Psoriasis 1.23 (1.12-1.35) 1.31 (1.14-1.51) 1.20 (1.09-1.32) 1.17 (1.05-1.30)      Other immunosuppressive condition 1.69 (1.21-2.34) 2.01 (1.25-3.25) 1.52 (1.06-2.19) 1.66 (1.16-2.39) FOOTNOTES: Models adjusted for age using a 4-knot cubic spline age spline, except for estimation of age group effects. *Ethnicity effect estimated from a model restricted to those with recorded ethnicity. *2OCS = oral corticosteroids. Recent OCS use defined as in the year before baseline. *3HbA1c classification based on latest   . CC-BY 4.0 International licenseIt is made available under a  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted May 7, 2020. .https://doi.org/10.1101/2020.05.06.20092999doi: medRxiv preprint ;2 juin 2020 
0;epidemiologie-et-sante-publique;Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study;Christopher M Petrilli and al;https://www.groupedeveillecovid.fr/blog/2020/05/26/factors-associated-with-hospital-admission-and-critical-illness-among-5279-people-with-coronavirus-disease-2019-in-new-york-city-prospective-cohort-study/;15;RESEARCH Fox J, Monette G. Generalized collinearity diagnostics. J Am Stat Assoc˜ Imdad MU, Aslam M. mctest: multicollinearity diagnostic measures versps://CRAN.R-project.org/package=mctest. Venables WN, Ripley BD. Modern Applied Statistics.˜˝th ed. Springer,  Venzon DJ, Moolgavkar SH. A method for computing prle-likelihood based cence intervals. Appl Stat˜ Fine JP, Grey RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc˜ Grey RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat˜doi:˜˘.˜˚˜˝/ao Sfumato P. Goodness-of for time-to-event data. ˚˘˚˘. https://www.rdocumentation.org/packages/gsions/˜.˘.˙. Melby C, Gu J, Rojanasakul M. Mapping New York City hospital beds as coronavirus cases surge. ˚˘˚˘ https://www.bloomberg.com/graphics/˚˘˚˘-new-york-coronavirus-outbreak-how-many-hospital-beds/. World Health Organization. Hospital beds (per ˜˘ ˘˘˘ population). ˚˘˚˘ https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hospital-beds-(per-˜˘-˘˘˘-population). Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med˜NEJMoa˘˙˘˛˛˛ Bell JG, Pham T, et al, LUNG SAFE Investigators, ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in ˙˘ countries. JAMA˜jam Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock[published Online FirsLancet˜ Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment the risk of SARS-CoV-˚ infection?Lancet Respir Med˜˚ˆ˘˘(˚˘)˛˘˜ˆˇ-˛ Simonsen L, Fukuda K, Schonberger LB, Cox NJ. The impact of influenza epidemics on hospitalizations. J Infect Dis˜ Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United StateClin Infect Dis˜id/cis˚˜˜ Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med˜a˘˚˜˛˛˛ Danzi GB, Laleazzi G, Gherbesi E. Acute pulmonary embolism and COmonia: a random association?Eur Heart J˜˚˘˚˘:ehrheartj/ehaa˚˙˝ Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COt ofve cases. Transl Res˜˙˚˝˝(˚˘)˛˘˘ˇ˘-˘. doi:˜˘.˜˘˜ˆ/j.trsl Schmidt FM, Weschenfelder J, Sander C, et al. Inflammatory cytokines in general and central obesity and modulatin of physical activity. PLoS One˜ournal Caër C, Rouault C, Le Roy T, et al. Immune cell-derived cytokines contribute to obesity-related inflammbrogenesis and metabolic deregulation in human adipose tissue. Sci Rep  Geovanini GR, Libby P. Atherosclerosis and inflammation: overview and updates. Clin Sci (Lond)˜C Jacobs D, Blackburn H, Higgins M, et al. Report of the conference on low blood cholesterol: mortality associations. Circulation˜CWeb appendix: Supplementary material on 26 May 2020 at Universite Louis Pasteur Strasbourg. Protected by copyright.http://www.bmj.com/BMJ: first published as 10.1136/bmj.m1966 on 22 May 2020. Downloaded from ;26 mai 2020 
0;epidemiologie-et-sante-publique;Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study;“COVID-19 : when should quarantine be enforced“;https://www.groupedeveillecovid.fr/blog/2020/05/23/individual-quarantine-versus-active-monitoring-of-contacts-for-the-mitigation-of-covid-19-a-modelling-study/;2;"2 www.thelancet.com/infection   Published online May 20, 2020   https://doi.org/10.1016/S1473-3099(20)30428-Xthe early stages of a pandemic might reduce how much longer those intrusive measures have to be applied, and to how many people. Additionally, bene˛ts for other fundamental rights are accrued as the pandemic unfolds, such as saving both lives and livelihoods.9We declare no competing interests.*Chris T Bauch, Madhur Anandcbauch@uwaterloo.caDepartment of Applied Mathematics, University of Waterloo, Waterloo, ON N2L 3G1, Canada (CTB); and School of Environmental Sciences, University of Guelph, Guelph, ON, Canada (MA)1  Peak CM, Kahn R, Grad YH, et al. Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study. Lancet Infect Dis 2020; published online May 20. https://doi.org/10.1016/S1473-3099(20)30361-3.2 Du Z, Xu X, Wu Y, Wang L, Cowling BJ, Meyers LA. The serial interval of COVID-19 from publicly reported con˛rmed cases. medRxiv 2020; published online Jan 1. DOI:10.1101/2020.02.19.20025452 (preprint).3 Ferretti L, Wymant C, Kendall M, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science 2020; published online March 31. DOI:10.1126/science.abb6936.4 COVID-19 National Emergency Response Center, Epidemiology & Case Management Team, Korea Centers for Disease Control & Prevention. Contact transmission of COVID-19 in South Korea: novel investigation techniques for tracing contacts. Osong Public Health Res Perspect 2020; 11: 60Œ63.5 Bauch CT, Galvani AP. Social factors in epidemiology. Science 2013; 342: 47Œ49.6 Bonds MH, Keenan DC, Rohani P, Sachs JD. Poverty trap formed by the ecology of infectious diseases. Proc Biol Sci 2010; 277: 1185Œ92.7 Innes C, Anand M, Bauch CT. The impact of humanŒenvironment interactions on the stability of forest-grassland mosaic ecosystems. Sci Rep 2013; 3: 2689.8 Kaplan EH, Craft DL, Wein LM. Emergency response to a smallpox attack: the case for mass vaccination. Proc Natl Acad Sci USA 2002; 99: 10935Œ40.9 United Nations. The Universal Declaration of Human Rights. https://www.un.org/en/universal-declaration-human-rights/ (accessed April 22, 2020).";23 mai 2020 
0;epidemiologie-et-sante-publique;Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study;“COVID-19 : when should quarantine be enforced“;https://www.groupedeveillecovid.fr/blog/2020/05/23/individual-quarantine-versus-active-monitoring-of-contacts-for-the-mitigation-of-covid-19-a-modelling-study/;9;"www.thelancet.com/infection   Published online May 20, 2020    https://doi.org/10.1016/S1473-3099(20)30361-3 9can also result in unintended consequences that can exacerbate transmission of SARS-CoV-2, such as avoi-dance of contact tracers and inaccurate recall, a reduction in health-care worker support and availability of supplies, and a rise in other infectious diseases more broadly.24 The impact of travel restrictions on human mobility, a necessary ˜rst step in the causal chain to outbreak  reduction in movement, recorded by mobile phone call detail records, was documented in Sierra Leone during the national lockdowns implemented in response to the 2014Œ16 epidemic of Ebola virus disease.25The con˛icting conclusions from our two scenarios, driven largely by the di˚erences in the extent of pre-symptomatic transmission, highlight the urgent need for more data to clarify key epidemiological parameters of COVID-19, particularly the serial interval and the extent of presymptomatic transmission, to inform response e˚orts. These highly in˛uential parameters warrant further study to improve data-driven policy making.ContributorsCMP analysed the data, CMP and RK wrote the ˜rst draft of the manuscript, and all authors participated in the writing, reviewing, and editing of the manuscript. All authors contributed to the study design.Declaration of interestsWe declare no competing interests.AcknowledgmentsThis work was supported in part by the US National Institute of General Medical Sciences (award number U54GM088558). The content is solely the responsibility of the authors and does not necessarily represent the ational Institute of General Medical Sciences, the National Institutes of Health, or other contributing agencies.References1 Centers for Disease Control and Prevention. Social distancing. May 6, 2020. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/social-distancing.html (accessed May 14, 2020).2 Qin A, Myers SL, Yu E. China tightens Wuhan lockdown in ‚wartime™ battle with coronavirus. The New York Times. Feb 6, 2020. https://www.nytimes.com/2020/02/06/world/asia/coronavirus-china-wuhan-quarantine.html (accessed Feb 12, 2020).3 McCarthy IO, Wojno AE, Joseph HA, Teesdale S. Check and Report Ebola (CARE) Hotline: the user perspective of an innovative tool for postarrival monitoring of Ebola in the United States. JMIR Public Health Surveill 2017; 3: e89.4 Fraser C, Riley S, Anderson RM, Ferguson NM. Factors that make an infectious disease outbreak controllable. Proc Natl Acad Sci USA 2004; 101: 6146Œ51.5 Peak CM, Childs LM, Grad YH, Buckee CO. Comparing nonpharmaceutical interventions for containing emerging epidemics. Proc Natl Acad Sci USA 2017; 114: 4023Œ28.6 Hellewell J, Abbott S, Gimma A, et al. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. Lancet Glob Health 2020; 8: e488Œ96.7 Ferretti L, Wymant C, Kendall M, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science 2020; published online March 31. DOI:10.1126/science.abb6936.8 Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; published online Feb 7. DOI:10.1001/jama.2020·1585.9 Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 2020; 382: 970Œ71.10 Kupferschmidt K. Study claiming new coronavirus can be transmitted by people without symptoms was ˛awed. Science. Feb 3, 2020. https://www.sciencemag.org/news/2020/02/paper-non-symptomatic-patient-transmitting-coronavirus-wrong# (accessed Feb 8, 2020).11 Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (2019-nCoV) infections. medRxiv 2020; published online Feb 17. DOI:10.1101/2020.02.03.20019497 (preprint).12 Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382: 1199Œ207.13 Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill 2020; 25.14 European Centre for Disease Prevention and Control. Contact tracing: public health management of persons, including healthcare workers, having had contact with COVID-19 cases in the European Union. Feb 25, 2020. https://www.ecdc.europa.eu/sites/default/˜les/documents/covid-19-public-health-management-contact-novel-coronavirus-cases-EU.pdf (accessed March 25, 2020).15 Chinese Center for Disease Control and Prevention. COVID-19 prevention and control guidelines. http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7/˜les/4132bf035bc242478a6eaf157eb0d979.pdf (accessed March 25, 2020).16 Hsieh Y-H, King C-C, Chen CWS, et al. Quarantine for SARS, Taiwan. Emerg Infect Dis 2005; 11: 278Œ82.17 US Centers for Disease Control and Prevention. CDC issues federal quarantine order to repatriated U.S. citizens at March Air Reserve Base. Jan 31, 2020. https://www.cdc.gov/media/releases/2020/s0131-federal-quarantine-march-air-reserve-base.html (accessed Feb 10, 2020).18 Ng Y, Li Z, Chua YX, et al. Evaluation of the e˚ectiveness of surveillance and containment measures for the ˜rst 100 patients with COVID-19 in Singapore Š January 2ŒFebruary 29, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 307Œ11.19 Gostin LO, Bayer R, Fairchild AL. Ethical and legal challenges posed by severe acute respiratory syndrome: implications for the control of severe infectious disease threats. JAMA 2003; 290: 3229Œ37.20 Adalja AA, Toner E, Inglesby TV. Priorities for the US health community responding to COVID-19. JAMA 2020; published online March 3. DOI:10.1001/jama.2020.3413.21 World Health Organization. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-˜nal-report.pdf (accessed March 1, 2020).22 Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20Œ28 January 2020. Euro Surveill 2020; 25.23 Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; published online Feb 28. DOI:10.1056/NEJMoa2002032.24 Tindale L, Coombe M, Stockdale JE, et al. Transmission interval estimates suggest pre-symptomatic spread of COVID-19. medRxiv 2020; published online March 6. DOI:10.1101/2020.03.03.20029983 (preprint).25 Peak CM, Wesolowski A, Zu Erbach-Schoenberg E, et al. Population mobility reductions associated with travel restrictions during the Ebola epidemic in Sierra Leone: use of mobile phone data. Int J Epidemiol 2018; 47: 1562Œ70.";23 mai 2020 
